Cancer Research and Treatment

Original Articles

Lung and Thoracic cancer

The Profile of Gut Microbiota in Carcinogenesis Driven by Mutant EGFR in Non–Small Cell Lung Cancer: Da-Som Kim, Eun Hye Kim, Ji Yong Kim, Dong Ha Kim, Yun Jung Choi, Jaeyi Jeong, Young Hoon Sung, Dong-Cheol Woo, Chong Jai Kim, Jae Cheol Lee, Miyong Yun, Jin-Yong Jeong, Jin Kyung Rho; Cancer Res Treat. 2026;58(1):115-127. Published online March 4, 2025; DOI: https://doi.org/10.4143/crt.2024.1177

Purpose
Accumulating evidence has clarified that gut dysbiosis is involved in lung cancer development and progression. Although the relationship between tumors and gut microbiota has been extensively studied using clinical samples, no studies have examined the association between mutant epidermal growth factor receptor (EGFR)–induced lung carcinogenesis and dysbiosis in gut microbiota. Therefore, we investigated the gut microbiota profiles in stool samples from human lung-specific conditional EGFR-mutant transgenic mice during lung tumor carcinogenesis.
Materials and Methods
Stool samples were collected before tamoxifen treatment (V1) and at each time point following mutant EGFR expression in lung tissue (V2) and lung tumor appearance (V3). Fecal 16S rRNA taxonomy was analyzed to assess microbial diversity, composition, and dynamic changes at each time point.
Results
We found that microbiota richness and diversity were significantly elevated when tumors developed and grew in the lung. Phylogenetic analysis of the microbial community revealed that Lachnospiraceae, Ruminococcaceae, Porphyromonadaceae, Rhodospirillaceae, Odoribacteraceae, and Desulfovibrionaceae showed a significant increase at the V3 stage compared to the V1 stage at the family level. In contrast, Lactobacillaceae, Bacteroidaceae, Muribaculaceae, Coriobacteriaceae, and Rikenellaceae significantly decreased at the V3 stage compared to the V1 stage. Furthermore, Lactobacillus species, also known as short chain fatty acid-producing bacteria, were relatively abundant at the V1 stage but were depleted with the occurrence of lung tumors at the V3 stage.
Conclusion
Changes in gut microbiota, such as Lactobacillus species, may be a predictive factor for the emergence and progression of tumors in an animal model of lung adenocarcinoma induced by mutant EGFR.

Citations

Citations to this article as recorded by

Gut microbiota and metabolites: emerging prospects in the treatment of non-small cell lung cancer
Jing-Mian Jiao, Chen-Guang Liu, Dan Zang, Jun Chen
Frontiers in Immunology.2025;[Epub] CrossRef
Study on the Impact of Changes in Intestinal Microbiota Structure of Lung Cancer Patients on the Efficacy of Immune Checkpoint Inhibitors
静鲁
Advances in Clinical Medicine.2025; 15(11): 744. CrossRef

2,273 View
136 Download
1 Web of Science
2 Crossref

Gastrointestinal cancer

Clinical Characteristics of and Treatment Pattern for EGFR-Amplified Colorectal Cancer: Seong-Eun Kim, Hyehyun Jeong, Sun Young Kim, Jeong Eun Kim, Yong Sang Hong, Deokhoon Kim, Jihun Kim, Ji Sung Lee, Tae Won Kim; Cancer Res Treat. 2025;57(4):1104-1114. Published online January 10, 2025; DOI: https://doi.org/10.4143/crt.2024.569

Abstract PDF Supplementary Material PubReader ePub: Purpose
This study aimed to compare clinicopathologic features and clinical outcomes of metastatic colorectal cancer (mCRC) based on epidermal growth factor receptor (EGFR) amplification status.
Materials and Methods
Patients with mCRC who underwent next-generation sequencing using a targeted 244-gene panel from 2016 to 2021 were identified and screened for EGFR copy numbers. Cases with at least five copies were reviewed for tumor purity adjustment, and those with an adjusted copy number of ≥ 6 were defined as EGFR-amplified (EGFR amp+). Their clinical characteristics were compared with those without EGFR amplification (EGFR amp–).
Results
Among 2,421 patients, 35 (1.4%) were EGFR amp+. Clinical characteristics did not significantly differ according to EGFR amplification status, but EGFR amp+ cases had fewer instances of peritoneal seeding (8.6% vs. 21.8%). Overall survival (OS) tended to be better in EGFR amp+ patients compared with EGFR amp– patients (median OS [mOS], 76 vs. 37 months; p=0.145). Among 572 patients who received anti-EGFR antibody–based chemotherapy (anti-EGFR CTx) during disease course, mOS tended to be better in 16 EGFR amp+ patients (79 months) compared with 556 EGFR amp– patients (39 months, p=0.048). Seven out of 35 EGFR amp+ patients were treated with front-line anti-EGFR CTx, and their progression-free survival did not differ from that of EGFR amp– patients treated with front-line anti-EGFR CTx (20 vs. 14 months, p=0.344).
Conclusion
This study may suggest a favorable predictive impact of EGFR amplification in patients treated with anti-EGFR CTx. However, the benefit of front-line anti-EGFR antibody treatment in this group was not notable.

2,898 View
106 Download

Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for More Than 1 Year: Youngun Kim, Jung Sun Kim, Beodeul Kang, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Yun Beom Sang, Sanghoon Jung, Chansik An, Chan Kim, Hong Jae Chon; Cancer Res Treat. 2024;56(4):1231-1239. Published online May 27, 2024; DOI: https://doi.org/10.4143/crt.2024.237

Abstract PDF Supplementary Material PubReader ePub

Purpose
Since 2020, atezolizumab plus bevacizumab (Ate/Bev) has been the standard first-line therapy for unresectable hepatocellular carcinoma (HCC), but long-term treatment studies are limited. This study evaluated the clinical characteristics and effects of Ate/Bev for over 1 year.
Materials and Methods
This study included patients with unresectable HCC treated with first-line Ate/Bev between May 2020 and April 2022. Those receiving Ate/Bev for 1 year or more were classified as the long-term treatment group.
Results
Of 246 patients, 69 (28.0%) were in the long-term treatment group, which comprised more proportions of intrahepatic tumor burden < 25%, Eastern Cooperative Oncology Group 0, and a lower proportion of portal vein tumor thrombosis than the short-term treatment group. The long-term treatment group had a higher incidence of atezolizumab-related thyroid dysfunction (31.9% vs. 10.7%, p < 0.001; median time to onset [mTTO], 2.8 months), dermatologic toxicity (29.0% vs. 14.7%, p=0.017; mTTO, 3.3 months), bevacizumab-related hypertension (44.9% vs. 22.0%, p=0.001; mTTO, 4.2 months), and proteinuria (69.6% vs. 38.4%, p < 0.001; mTTO, 6.8 months), compared to the short-term treatment group. Regarding liver function in the long-term treatment group, patients initially classified as Child-Pugh class A decreased from 87.0% to 75.4%, and albumin-bilirubin grade 1 decreased from 68.1% to 50.7% after 1 year of treatment.
Conclusion
The Ate/Bev long-term treatment group had a lower intrahepatic tumor burden, less portal vein tumor thrombosis, and better performance status and liver function at baseline. Atezolizumab-related immunological adverse events emerged relatively early in treatment compared to the bevacizumab-related. Additionally, some patients demonstrated liver function deterioration during long-term Ate/Bev treatment.

Citations

Citations to this article as recorded by

Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study
Jung Sun Kim, Jeffrey Wong, San‐Chi Chen, David Tai, Hannah Yang, Youngun Kim, Beodeul Kang, Ilhwan Kim, Hyeyeong Kim, Chansik An, Su Jin Jang, Masatoshi Kudo, Ho Yeong Lim, Chan Kim, Thomas Yau, Hong Jae Chon
Liver International.2026;[Epub] CrossRef
Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features
Won Suk Lee, Seonjeong Woo, Sung Hwan Lee, Gae Hoon Jo, Ilhwan Kim, Hyeyeong Kim, Chansik An, Sanghoon Jung, Gwangil Kim, Haeyoun Kang, Beodeul Kang, Jung Sun Kim, Ho Yeong Lim, Incheon Kang, Hannah Yang, So Jung Kong, Dahyeon Son, Dong Jun Shin, Woo Youn
Clinical and Molecular Hepatology.2026; 32(1): 258. CrossRef
A case of long-term therapy of hepatocellular carcinoma with atezolizumab and bevacizumab combination
K. V. Menshikov, A. V. Sultanbaev, Sh. H. Musin, V. A. Valishin, I. A. Men′shikova, V. S. Chalov, N. I. Sultanbaeva, Sh. N. Galimov
Meditsinskiy sovet = Medical Council.2025; (10): 49. CrossRef
Current Insights into the Long-Term Management of HCC with Immunotherapy-Based Regimens
Sukbae Kim
Convergence Hepatology.2025; 1(1): 14. CrossRef
The Low Platelet Count at the Start of Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Deteriorated Liver Function at the Time of Disease Progression Thereafter: A Multicenter Analysis
Ryo Sato, Takanori Suzuki, Kentaro Matsuura, Daisuke Kato, Katsumi Hayashi, Kohei Okayama, Fumihiro Okumura, Satoshi Sobue, Atsunori Kusakabe, Izumi Hasegawa, Kiyoto Narita, Tsutomu Mizoshita, Yoshihide Kimura, Hiromu Kondo, Hisayo Kojima, Kazuki Hayashi,
Hepatology Research.2025;[Epub] CrossRef
Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
Sohyun Hwang, Dong Jun Shin, Beodeul Kang, Haeyoun Kang, Sung Hwan Lee, Jung Sun Kim, Je-Gun Joung, Suyog Jain, Steven Olsen, Lars Becker, Richard S. Finn, Josep M. Llovet, Gwangil Kim, Chan Kim, Hong Jae Chon
Liver Cancer.2025; : 1. CrossRef
Current perspectives and future strategies for the systemic treatment of hepatocellular carcinoma: a narrative review
Hong Jae Chon
Journal of the Korean Medical Association.2025; 68(12): 809. CrossRef

4,144 View
189 Download
5 Web of Science
7 Crossref

Varlitinib and Paclitaxel for EGFR/HER2 Co-expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13): Dong-Hoe Koo, Minkyu Jung, Yeul Hong Kim, Hei-Cheul Jeung, Dae Young Zang, Woo Kyun Bae, Hyunki Kim, Hyo Song Kim, Choong-kun Lee, Woo Sun Kwon, Hyun Cheol Chung, Sun Young Rha; Cancer Res Treat. 2024;56(4):1136-1145. Published online April 29, 2024; DOI: https://doi.org/10.4143/crt.2023.1324

Abstract PDF Supplementary Material PubReader ePub

Purpose
Varlitinib is a pan-human epidermal growth factor receptor (HER) inhibitor targeting epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and HER4. We present a phase Ib/II study of a combination of varlitinib and weekly paclitaxel as a second-line treatment for patients with EGFR/HER2 co-expressing advanced gastric cancer (AGC).
Materials and Methods
Patients whose tumors with EGFR and HER2 overexpression by immunohistochemistry (≥ 1+) were enrolled. Varlitinib and paclitaxel were investigated every 4 weeks. After determining the recommended phase II dose (RP2D) in phase Ib, a phase II study was conducted to evaluate the antitumor activity.
Results
RP2D was treated with a combination of varlitinib (300 mg twice daily) and paclitaxel. Among 27 patients treated with RP2D, the median progression-free survival and overall survival (OS) were 3.3 months (95% confidence interval [CI], 1.7 to 4.9) and 7.9 months (95% CI, 5.0 to 10.8), respectively, with a median follow-up of 15.7 months. Among 16 patients with measurable disease, the objective response rate (ORR) and disease control rate were 31% and 88%, respectively. Patients with strong HER2 expression (n=8) had a higher ORR and longer OS, whereas those with strong EGFR expression (n=3) had poorer outcomes. The most common adverse events (AEs) of any grade were neutropenia (52%), diarrhea (27%), aspartate aminotransferase/alanine transaminase elevation (22%), and nausea (19%). No treatment-related deaths or unexpected AEs resulting from treatment cessation were observed in patients with RP2D.
Conclusion
A combination of varlitinib and paclitaxel displayed manageable toxicity and modest antitumor activity in patients with EGFR/HER2 co-expressing AGC who progressed after first-line chemotherapy.

Citations

Citations to this article as recorded by

Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights
Yu Aoki, Izuma Nakayama, Kohei Shitara
Current Oncology Reports.2025; 27(1): 15. CrossRef
Pharmacotherapy for previously treated gastric cancer patients: current options and future developments
Seiya Sato, Izuma Nakayama, Kohei Shitara
Expert Review of Clinical Pharmacology.2025; 18(8): 607. CrossRef
Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy
Sixiang Zheng, Ruixian Chen, Lele Zhang, Lun Tan, Lintao Li, Fangyi Long, Ting Wang
European Journal of Medicinal Chemistry.2024; 276: 116702. CrossRef

4,898 View
184 Download
3 Web of Science
3 Crossref

Head and Neck cancer

Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials: Youjin Kim, Bhumsuk Keam, Eun Joo Kang, Jin-Soo Kim, Hye Ryun Kim, Keun-Wook Lee, Jung Hye Kwon, Kyoung Eun Lee, Yaewon Yang, Yoon Hee Choi, Min Kyoung Kim, Jun Ho Ji, Tak Yun, Moon Young Choi, Ki Hyeong Lee, Sung-Bae Kim, Myung-Ju Ahn; Cancer Res Treat. 2024;56(4):1068-1076. Published online April 15, 2024; DOI: https://doi.org/10.4143/crt.2024.008

Abstract PDF Supplementary Material PubReader ePub: Purpose
In this study, we evaluated 66 patients diagnosed with adenoid cystic carcinoma (ACC) enrolled in two Korean Cancer Study Group trials to investigate the response and progression patterns in recurrent and/or metastatic ACC treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs).
Materials and Methods
We evaluated 66 patients diagnosed with ACC who were enrolled in the Korean Cancer Study Group trials. The tumor measurements, clinical data, treatment outcomes, and progression patterns of therapy were analyzed.
Results
In the 66 patients (53 receiving axitinib and 13 receiving nintedanib), the disease control rate was 61%, and three patients achieved partial response. The median follow-up, median progression-free survival (PFS), overall survival, and 6-month PFS rate were 27.6%, 12.4%, and 18.1% months and 62.1%, respectively. Among 42 patients who experienced progression, 27 (64.3%) showed target lesion progression. Bone metastasis was an independent poor prognostic factor.
Conclusion
Overall, most patients demonstrated stable disease with prolonged PFS; however, prominent target lesion progression occurred in some patients. Thus, PFS may capture VEGFR-TKI efficacy better than the objective response rate.

3,611 View
168 Download

Lung and Thoracic cancer

Tumor Microenvironment Modulation by Neoadjuvant Erlotinib Therapy and Its Clinical Impact on Operable EGFR-Mutant Non–Small Cell Lung Cancer: Beung-Chul Ahn, Charny Park, Moon Soo Kim, Jong Mog Lee, Jin Ho Choi, Hyae Young Kim, Geon Kook Lee, Namhee Yu, Youngjoo Lee, Ji-Youn Han; Cancer Res Treat. 2024;56(1):70-80. Published online June 21, 2023; DOI: https://doi.org/10.4143/crt.2023.482

Abstract PDF Supplementary Material PubReader ePub

Purpose
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have greatly improved survival in EGFR-mutant (EGFRm) non–small cell lung cancer (NSCLC); however, their effects on the tumor microenvironment (TME) are unknown. We assessed the changes induced by neoadjuvant erlotinib therapy (NE) in the TME of operable EGFRm NSCLC.
Materials and Methods
This was a single-arm phase II trial for neoadjuvant/adjuvant erlotinib therapy in patients with stage II/IIIA EGFRm NSCLC (EGFR exon 19 deletion or L858R mutations). Patients received up to 2 cycles of NE (150 mg/day) for 4 weeks, followed by surgery and adjuvant erlotinib or vinorelbine plus cisplatin therapy depending on observed NE response. TME changes were assessed based on gene expression analysis and mutation profiling.
Results
A total of 26 patients were enrolled; the median age was 61, 69% were female, 88% were stage IIIA, and 62% had L858R mutation. Among 25 patients who received NE, the objective response rate was 72% (95% confidence interval [CI], 52.4 to 85.7). The median disease-free and overall survival (OS) were 17.9 (95% CI, 10.5 to 25.4) and 84.7 months (95% CI, 49.7 to 119.8), respectively. Gene set enrichment analysis in resected tissues revealed upregulation of interleukin, complement, cytokine, transforming growth factor β, and hedgehog pathways. Patients with upregulated pathogen defense, interleukins, and T-cell function pathways at baseline exhibited partial response to NE and longer OS. Patients with upregulated cell cycle pathways at baseline exhibited stable/progressive disease after NE and shorter OS.
Conclusion
NE modulated the TME in EGFRm NSCLC. Upregulation of immune-related pathways was associated with better outcomes.

Citations

Citations to this article as recorded by

TGF‑β at the Crossroads: Orchestrating the Bone Metastatic Microenvironment and Shaping Therapeutic Frontiers
Khalid S. Mohammad, Fatimah Hussain Bu Izran
Frontiers in Bioscience-Landmark.2025;[Epub] CrossRef
Dual Inhibition of SYK and EGFR Overcomes Chemoresistance by Inhibiting CDC6 and Blocking DNA Replication
Jayaprakash Mandal, Tiffany Nicole Jones, Juliane Marie Liberto, Stephanie Gaillard, Tian-Li Wang, Ie-Ming Shih
Cancer Research.2024; 84(22): 3881. CrossRef

5,999 View
281 Download
2 Web of Science
2 Crossref

General

Identification of Genes Involved in EGF-induced Apoptosis Using CRISPR/Cas9 Knockout Screening: Implications for Novel Therapeutic Targets in EGFR-Overexpressing Cancers: Jae Sik Kim, Joo Ho Lee, Sang-Rok Jeon, Yongsub Kim, Seung Hyuck Jeon, Hong-Gyun Wu; Cancer Res Treat. 2023;55(3):737-745. Published online January 4, 2023; DOI: https://doi.org/10.4143/crt.2022.1414

Abstract PDF Supplementary Material PubReader ePub

Purpose
Exogenous epidermal growth factor (EGF) causes apoptosis in EGF receptor (EGFR)–overexpressing cell lines. The apoptosis-inducing factors could be a therapeutic target. We aimed to determine the mechanism of EGF-induced apoptosis using a genome-wide clustered regularly interspaced short palindromic repeats (CRISPR)-based knockout screen.
Materials and Methods
Two-vector system of the human genome-scale CRISPR knockout library v2 was used to target 19,050 genes using 123,411 single guide RNAs (sgRNAs). Recombinant human EGF (100 nM) or distilled water four times was administered to the experimental and control groups, respectively. The read counts of each sgRNA obtained from next-generation sequencing were analyzed using the edgeR algorithm. We used another EGFR-overexpressing cell line (A549) and short hairpin RNAs (shRNAs) targeting five EGF-resistance genes for validation. DUSP1 expression in A431, A549, and HEK293FT cells was calculated using reverse transcription–quantitative polymerase chain reaction.
Results
We found 77 enriched and 189 depleted genes in the experimental group using the CRISPR-based knockout screen and identified the top five EGF-resistance genes: DDX20, LHFP, REPS1, DUSP1, and KRTAP10-12. Transfecting shRNAs targeting these genes into A549 cells significantly increased the surviving fractions after EGF treatment, compared with those observed in the control shRNA-transfected cells. The expression ratio of DUSP1 (inhibits ERK signaling) increased in A431 and A549 cells after EGF treatment. However, DUSP1 expression remained unchanged in HEK293FT cells after EGF treatment.
Conclusion
The CRISPR-based knockout screen revealed 266 genes possibly responsible for EGF-induced apoptosis. DUSP1 might be a critical component of EGF-induced apoptosis and a novel target for EGFR-overexpressing cancers.

Citations

Citations to this article as recorded by

Comprehensive strategies for constructing efficient CRISPR/Cas based cancer therapy: Target gene selection, sgRNA optimization, delivery methods and evaluation
Sathishbabu Paranthaman, Chinnappa A. Uthaiah, Shadab Md, Huda Mohammed Alkreathy
Advances in Colloid and Interface Science.2025; 341: 103497. CrossRef
RIPK4-p53 interaction drives aflatoxin B1-induced renal mitochondrial apoptosis via Ser15 phosphorylation: A CRISPR-Cas9 mechanistic study
Yuhan Ma, Qin Zhao, Jianlin Yuan, Dan Wang, Xizhu Chen, Yang Yu, Jinfeng Li, Miao Yu, Jian Yuan, Jianan Lou, Senyan Du, Yiping Wen, Yiping Wang, Rui Wu, Qi-Gui Yan, Xiaobo Huang, Yi Zheng, Fei Zhao, San-Jie Cao
International Journal of Biological Macromolecules.2025; 330: 148130. CrossRef
Profiling the Complexity of Resistance Factors in Cancer Cells Towards Berberine and Its Derivatives
Nadire Özenver, Nadeen T. Ali, Rümeysa Yücer, Xiao Lei, Gerhard Bringmann, Thomas Efferth, Mona Dawood
Pharmaceuticals.2025; 19(1): 27. CrossRef
Uncovering the bookshelves of CRISPR-based libraries: Advances and applications in cancer studies
Nathalia Quintero-Ruiz, Wesley de Lima Oliveira, Marcos Vinicius Esteca, Daniela Campos Granato, Fernando Moreira Simabuco
Critical Reviews in Oncology/Hematology.2024; 196: 104287. CrossRef
CRISPR-Cas and CRISPR-based screening system for precise gene editing and targeted cancer therapy
Mingming Qin, Chunhao Deng, Liewei Wen, Guoqun Luo, Ya Meng
Journal of Translational Medicine.2024;[Epub] CrossRef

8,170 View
288 Download
5 Web of Science
5 Crossref

Breast cancer

Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based Regimens: Helen P. Kourea, Foteinos-Ioannis Dimitrakopoulos, Georgia-Angeliki Koliou, Anna Batistatou, Kyriaki Papadopoulou, Mattheos Bobos, Anthoula Asimaki-Vlachopoulou, Sofia Chrisafi, Kitty Pavlakis, Kyriakos Chatzopoulos, Eleni Galani, George Pentheroudakis, Dimitrios Pectasides, Dimitrios Bafaloukos, Eleni Res, Pavlos Papakostas, Angelos Koutras, Vassiliki Kotoula, George Fountzilas; Cancer Res Treat. 2022;54(4):1053-1064. Published online November 17, 2021; DOI: https://doi.org/10.4143/crt.2021.748

Abstract PDF Supplementary Material PubReader ePub

Purpose
Angiogenesis is a crucial phenomenon in the development and progression of breast cancer (BC), but the clinical significance of angiogenesis-related proteins in metastatic BC remains unknown. This study investigates the prognostic value of vascular endothelial growth factor receptors 1, 2, 3 (VEGFR1, VEGFR2, VEGFR3) as well as vascular endothelial growth factors A and C (VEGFA and VEGFC) in metastatic BC patients treated with trastuzumab-based regimens.
Materials and Methods
Two hundred female patients were included. Protein and mRNA expression of the studied angiogenesis-related factors were evaluated by immunohistochemistry and quantitative polymerase chain reaction, respectively.
Results
High expression of VEGFA, VEGFC, VEGFR1, VEGFR2, and VEGFR3 in the tumor cells was observed in 43.5%, 24.2%, 36%, 29.5%, and 43%, respectively. Stromal elements expressed high levels of VEGFA, VEGFC, VEGFR1, VEGFR2, and VEGFR3 in 78.9%, 93.3%, 90.7%, 90.2%, and 74.8% of tumors with available data. High tumor cell expression of VEGFR1 was a favorable prognosticator for survival among patients with human epidermal growth factor receptor 2 (HER2)–positive tumors (hazard ratio [HR], 0.55; p=0.013). A trend towards longer progression-free survival was detected univariately for patients with HER2-negative tumors and high expression of VEGFR2 (HR, 0.60; p=0.059).
Conclusion
VEGFR1 and VEGFR2 seem to have significant prognostic value in BC patients with metastatic disease treated with trastuzumab-based regimens.

Citations

Citations to this article as recorded by

Multi-parametric MRI radiomics predicts different HER2 expression in breast cancer
Siqi Zhao, Fan Wei, Yuanfei Li, Yueqi Wu, Moyun Zhang, Shuo Wang, Xinyue Yin, Zhitian Guo, Jie Yang, Xue Gao, Haonan Guan, Hui Liu, Lina Zhang
Cancer Imaging.2025;[Epub] CrossRef
Synergistic anticancer effects of Chrysin and trastuzumab in HER2-Positive breast cancer cells
Sevda Jafari, Alireza Ostadrahimi, Afsaneh Farjami, Soheila Montazersaheb
Scientific Reports.2025;[Epub] CrossRef
Apatinib beyond first progression is associated with prolonged overall survival in patients with advanced breast cancer: Results from an observational study
Jing Wang, Jinghao Jia, Jingjing Liu, Xuemin Yao, Zhiyong Yuan
Experimental and Therapeutic Medicine.2024;[Epub] CrossRef

7,248 View
113 Download
5 Web of Science
3 Crossref

Lung and Thoracic cancer

miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer Cells by Targeting USP37: Mi Seong Kim, So Hui Kim, Sei Hoon Yang, Min Seuk Kim; Cancer Res Treat. 2022;54(2):445-457. Published online August 3, 2021; DOI: https://doi.org/10.4143/crt.2021.622

Abstract PDF PubReader ePub

Purpose
With the identification of epidermal growth factor receptor (EGFR) mutations in non–small cell lung cancer (NSCLC) cells, EGFR–tyrosine kinase inhibitors (TKIs) are being used widely as the first-line of treatment in NSCLC. These inhibitors block auto-phosphorylation of activated EGFR by competing with ATP binding and mediate EGFR degradation independent of exogenous epidermal growth factor, which is associated with the mutation variants of EGFR. However, the precise mechanisms underlying the TKI-mediated EGFR degradation are still unclear.
Materials and Methods
To examine the physiological roles of miR-4487 and ubiquitin-specific peptidase 37 (USP37) in gefitinib-mediated EGFR degradation in NSCLC cells, multiple NSCLC cell lines were applied. The level of EGFR expression, apoptosis marker and autophagic flux were determined by western blot. Expression level of miR-4487 and cell cycle arrest was analyzed by TaqMan assay and flow cytometry respectively.
Results
We found that gefitinib mediates EGFR degradation under normal culture conditions, and is dependent on autophagic flux and the mutation variants of EGFR. Gefitinib reduced expression levels of USP37, which mediated EGFR degradation similar to gefitinib. Our results also showed a gefitinib-mediated increase in endogenous miR-4487 level and presented evidence for the direct targeting of USP37 by miR-4487, resulting in the sequential enhancement of ubiquitination, autophagy, and EGFR degradation. Thus, the depletion of USP37 and overexpression of miR-4487 led to an increase in gefitinib-mediated apoptotic cell death.
Conclusion
These data suggest that miR-4487 is a potential target for treating NSCLC, and miR-4487/USP37-regulated EGFR degradation is a determinant for developing gefitinib resistance.

Citations

Citations to this article as recorded by

Identification of Raptor and GLI1 as USP37 substrates highlight its context-specific function in medulloblastoma cells
Ashutosh Singh, Donghang Cheng, Amanda R. Haltom, Yanwen Yang, Tara Dobson, Rashieda Hatcher, Veena Rajaram, Vidya Gopalakrishnan
Oncogene.2026; 45(4): 521. CrossRef
The ubiquitination–autophagy axis in cancer therapy resistance: mechanistic insights and therapeutic opportunities
Hengrui Zhang, Hanxi Yan, Yulin Liu, Anqi Zeng, Linjiang Song
Frontiers in Pharmacology.2026;[Epub] CrossRef
Epigenetic code underlying EGFR-TKI resistance in non-small cell lung cancer: Elucidation of mechanisms and perspectives on therapeutic strategies
XiaoYu Yao, Chundi Gao, Changgang Sun, Zhe-Sheng Chen, Jing Zhuang
Drug Discovery Today.2025; 30(3): 104321. CrossRef
Deubiquitination of epidermal growth factor receptor by ubiquitin-specific peptidase 54 enhances drug sensitivity to gefitinib in gefitinib-resistant non-small cell lung cancer cells
Mi Seong Kim, Min Seuk Kim, Chien-Feng Li
PLOS ONE.2025; 20(4): e0320668. CrossRef
MicroRNAs as Sensitizers of Tyrosine Kinase Inhibitor Resistance in Cancer: Small Molecule Partnerships
Alma D. Campos-Parra, David Sánchez-Marín, Víctor Acevedo-Sánchez
Pharmaceuticals.2025; 18(4): 492. CrossRef
Mechanistic Insights and Therapeutic Potentials of Ubiquitin‐Proteasome System in Non‐Small Cell Lung Cancer
Guangyao Zhou, Jiaxiong Tan, Pengpeng Zhang, Zhaokai Zhou, Lianmin Zhang, Zhenfa Zhang
Cell Proliferation.2025;[Epub] CrossRef
Exploring the potential function of high expression of ANAPC1 in regulating ubiquitination in hepatocellular carcinoma
Yu-Xing Tang, Wei-Zi Wu, Sheng-Sheng Zhou, Da-Tong Zeng, Guang-Cai Zheng, Rong-Quan He, Di-Yuan Qin, Wan-Ying Huang, Ji-Tian Chen, Yi-Wu Dang, Yu-Lu Tang, Bang-Teng Chi, Yan-Ting Zhan, Gang Chen
World Journal of Gastrointestinal Oncology.2025;[Epub] CrossRef
Autophagy-associated ncRNAs in lung cancer: From drug resistance to therapeutic targets
Ming Yu, Hanqing Li, Yin Wu, Ping Liu, Quangang Xu, Yi Zhang
International Journal of Biological Macromolecules.2025; 319: 145477. CrossRef
Bioinformatics based exploration of the anti-liver fibrosis mechanism of Pien Tze Huang via EGFR/JAK1/STAT3 pathway
Xiaoting Hong, Yonghua Ye, Chunfeng Lin, Miaolan Zheng, Fan Lin, Qing Xiong, Wei Xu, Huang Li, Yuqin Zhang, Haiyin Zheng
Frontiers in Immunology.2025;[Epub] CrossRef
The significance of the crosstalk between ubiquitination or deubiquitination and ncRNAs in non-small cell lung cancer
Yiyang Sun, Ping He, Li Li, Xue Ding
Frontiers in Oncology.2023;[Epub] CrossRef
Lung adenocarcinoma cell-derived exosomes promote M2 macrophage polarization through transmission of miR-3153 to activate the JNK signaling pathway
L Xu, L Wang, R Yang, T Li, X Zhu
Human Molecular Genetics.2023; 32(13): 2162. CrossRef
The potential role of miRNAs in the pathogenesis of salivary gland cancer – A Focus on signaling pathways interplay
Ahmed I. Abulsoud, Shereen Saeid Elshaer, Ahmed A. El-Husseiny, Doaa Fathi, Nourhan M. Abdelmaksoud, Sherif S. Abdel Mageed, Aya Salman, Mohamed Bakr Zaki, Hesham A. El-Mahdy, Ahmed Ismail, Elsayed G.E. Elsakka, Mai A. Abd-Elmawla, Hussein M. El-Husseiny,
Pathology - Research and Practice.2023; 247: 154584. CrossRef

9,498 View
207 Download
13 Web of Science
12 Crossref

Endocrine cancer

Expression of Estrogen and Progesterone Receptors in Papillary Thyroid Carcinoma in Korea: Hwa Young Ahn, Ra-Yeong Song, Hye Shin Ahn, Hee Sung Kim; Cancer Res Treat. 2021;53(4):1204-1212. Published online February 10, 2021; DOI: https://doi.org/10.4143/crt.2020.1201

Abstract PDF PubReader ePub

Purpose
The aim of this study was to examine the rate of expression of estrogen receptor α (ERα) and β1 (ERβ1), progesterone receptor (PR), and rate of overexpression of epidermal growth factor receptor (EGFR) in a relatively large cohort of patients with papillary thyroid carcinoma (PTC). We also aimed to examine whether each receptor influenced clinicopathological characteristics and prognosis of PTC.
Materials and Methods
We made a microarray of paraffin-embedded PTC surgical tissues from 436 patients. We compared the results of the immunohistochemical staining for each hormone receptor with clinicopathological characteristics.
Results
The positive expression rate of hormonal receptors was 40.4% for ERα, 83.7% for ERβ1, and 71.3% for PR in patients with PTC. Overexpression of EGFR was shown in 19.3% of patients with PTC. The age was lower (44.6±12.1 years vs. 47.1±12.5 years, p=0.040) and tumor smaller (0.96±0.69 cm vs. 1.13±0.82 cm, p=0.020) in the ERα positive group, which also showed higher PR positivity (80.7% vs. 65.0%, p < 0.001) and overexpression of EGFR (27.3% vs. 13.8%, p < 0.001). However, neither the positivity of hormone receptors nor overexpression of EGFR affected the recurrence of PTC.
Conclusion
In conclusion, most (94.6%) patients with PTC were found to exhibit positive expression for ERs or PR. We also found that neither the positive expression of hormone receptors nor overexpression of EGFR were associated with the recurrence of PTC.

Citations

Citations to this article as recorded by

Research progress on estrogen and estrogen receptors in the occurrence and progression of autoimmune thyroid diseases
Jiewen Xie, Jie Wang, Xuejiao Cui
Autoimmunity Reviews.2025; 24(6): 103803. CrossRef
Multi-disease transcriptomic analysis of sex hormone genes reveals a novel prognostic model for thyroid cancer with breast cancer correlations
Lixue Qiao, Hao Li, Keyu Yin, Runsheng Ma, Yifei Zhang, Yue Guo, Detao Yin
Frontiers in Oncology.2025;[Epub] CrossRef
Estrogen Receptors as Key Factors in Carcinogenesis
Oliwia Gruszka, Magdalena Jurzak, Ilona Anna Bednarek
Biomedicines.2025; 13(11): 2620. CrossRef
Expression Pattern of Oestrogen Receptor in Follicular Thyroid Cancers: A 23 Years Retrospective Multicentre Study in Jos Metropolis, North-Central, Nigeria
Samuel Kelechi Richard, Barka Vandi Kwaghe, Nwadiokwu John Ifeanyi, Abdulrazaq Ajanaku Jimoh
Nigerian Postgraduate Medical Journal.2025; 32(4): 315. CrossRef
Struma Ovarii during Pregnancy
Gabriela Dumachița-Șargu, Răzvan Socolov, Teodora Ana Balan, Dumitru Gafițanu, Mona Akad, Raluca Anca Balan
Diagnostics.2024; 14(11): 1172. CrossRef
Serum sex hormones correlate with pathological features of papillary thyroid cancer
Fa-Zhan Xu, Lu-Lu Zheng, Ke-Hao Chen, Ru Wang, Dan-Dan Yi, Chao-Yu Jiang, Zhi-Jian Liu, Xian-Biao SHI, Jian-Feng Sang
Endocrine.2023; 84(1): 148. CrossRef
Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors
Florian Viehweger, Lisa-Marie Tinger, David Dum, Natalia Gorbokon, Anne Menz, Ria Uhlig, Franziska Büscheck, Andreas M. Luebke, Claudia Hube-Magg, Andrea Hinsch, Doris Höflmayer, Christoph Fraune, Patrick Lebok, Sören Weidemann, Maximilian Lennartz, Frank
Analytical Cellular Pathology.2022; 2022: 1. CrossRef
Case report: Lymph node metastases of breast cancer and thyroid cancer encountered in axilla
Rihan Li, Qingfu Zhang, Dongdong Feng, Feng Jin, Siyuan Han, Xinmiao Yu
Frontiers in Oncology.2022;[Epub] CrossRef

8,052 View
140 Download
10 Web of Science
8 Crossref

Gastrointestinal cancer

Hepatitis B Virus Core Protein Mediates the Upregulation of C5α Receptor 1 via NF-κB Pathway to Facilitate the Growth and Migration of Hepatoma Cells: Fanyun Kong, Yukai Tao, Dongchen Yuan, Ning Zhang, Qi Li, Tong Yu, Xiaoying Yang, Delong Kong, Xiaohui Ding, Xiangye Liu, Hongjuan You, Kuiyang Zheng, Renxian Tang; Cancer Res Treat. 2021;53(2):506-527. Published online November 16, 2020; DOI: https://doi.org/10.4143/crt.2020.397

Abstract PDF PubReader ePub

Purpose
C5α receptor 1 (C5ΑR1) is associated with the development of various human cancers. However, whether it is involved in the development of hepatitis B virus (HBV)–related hepatocellular carcinoma (HCC) is poorly understood. We explored the expression, biological role, and associated mechanisms of C5AR1 in HBV-related hepatoma cells.
Materials and Methods
The expression of C5ΑR1 mediated by HBV and HBV core protein (HBc) was detected in hepatoma cells. The function of nuclear factor кB (NF-κB) pathway in HBc-induced C5AR1 expression was assessed. The roles of C5ΑR1 in the activation of intracellular signal pathways, the upregulation of inflammatory cytokines, and the growth and migration of hepatoma cells mediated by HBc, were investigated. The effect of C5α in the development of HCC mediated by C5AR1 was also measured.
Results
C5ΑR1 expression was increased in HBV-positive hepatoma cells. Dependent on HBc, HBV enhanced the expression of C5ΑR1 at the mRNA and protein levels. Besides, HBc could promote C5ΑR1 expression via the NF-κB pathway. Based on the C5ΑR1, HBc facilitated the activation of JNK and ERK pathways and the expression and secretion of interleukin-6 in hepatoma cells. Furthermore, C5ΑR1 was responsible for enhancing the growth and migration of hepatoma cells mediated by HBc. Except these, C5α could promote the malignant development of HBc-positive HCC via C5AR1.
Conclusion
We provide new insight into the mechanisms of hepatocarcinogenesis mediated by HBc. C5ΑR1 has a significant role in the functional abnormality of hepatoma cells mediated by HBc, and might be utilized as a potential therapeutic target for HBV-related HCC.

Citations

Citations to this article as recorded by

Phenazine biosynthesis-like domain-containing protein (PBLD) and Cedrelone promote antiviral immune response by activating NF-ĸB
Peili Hou, Hongchao Zhu, Fengyun Chu, Yan Gao, Xiaonan Sun, Fuzhen Zhang, Xiaomeng Wang, Yueyue Feng, Xingyu Li, Yu Liu, Jun Wang, Xiaoyun Wang, Daniel Chang He, Hongmei Wang, Hongbin He
Nature Communications.2025;[Epub] CrossRef
HBV core protein enhances WDR46 stabilization to upregulate NUSAP1 and promote HCC progression
Fanyun Kong, Ensi Bao, Yujie Zhong, Yuxin Wang, Ruyu Liu, Huanyang Zhang, Lu Yang, Rong Jiang, Xuanke Liu, Chen Li, Xiangye Liu, Xiucheng Pan, Kuiyang Zheng, Hongjuan You, Renxian Tang
Hepatology Communications.2025;[Epub] CrossRef
Transcriptional regulation of tumor suppressor gene RASSF1A by HBx
Yanhong Kang, Wei Li, Junfeng Wei, Lin Yang, Yi Kang
Molecular and Cellular Probes.2025; 82: 102034. CrossRef
Hepatitis B virus core protein promotes liver cancer progression by stabilizing CANX and suppressing IRF7 transcription
Hong-juan You, Huan-yang Zhang, Yu-jie Zhong, Ru-yu Liu, Lu Yang, Rong Jiang, Yu-xin Wang, En-si Bao, Xiang-ye Liu, Chen Li, Xiu-cheng Pan, Xu-feng Huang, Kui-yang Zheng, Ren-xian Tang, Fan-yun Kong
Acta Pharmacologica Sinica.2025; 46(11): 3036. CrossRef
Effects of interleukin‑6 genetic variation on hepatitis B virus infection and susceptibility to hepatocellular carcinoma: A systematic review and meta‑analysis
Bibin Antony, Karthikeyan Murugesan, Anjuna Radhakrishnan, Yupa Min, Gowtham Subbaraj
World Academy of Sciences Journal.2025; 7(4): 1. CrossRef
Understanding the role of C5a/C5aR1-mediated complement activation pathway in tumor progression and therapy resistance
Lemei Zheng, Jianxia Wei, Mengna Li, Changning Xue, Qingqing Wei, Zubing Wu, Xiaolong Li, Ting Zeng, Huizhen Xin, Wei Xiong, Hongyu Deng, Ming Zhou
Science China Life Sciences.2025;[Epub] CrossRef
Bioinformatics analysis reveals C5AR1’s impact on thyroid cancer development via immune infiltration
Yueyao Sun, Lei Xu, Xiaowen Ma, Haobo Wang, Zihao Li, Ji Feng, Tongtong Ji, Qi Wang, Bo Liu, Fangjian Shang
Scientific Reports.2025;[Epub] CrossRef
Hepatitis B virus core protein stabilizes RANGAP1 to upregulate KDM2A and facilitate hepatocarcinogenesis
Hong-Juan You, Li-Hong Ma, Xing Wang, Yu-Xin Wang, Huan-Yang Zhang, En-Si Bao, Yu-Jie Zhong, Xiang-Ye Liu, De-Long Kong, Kui-Yang Zheng, Fan-Yun Kong, Ren-Xian Tang
Cellular Oncology.2024; 47(2): 639. CrossRef
Colchicine-mediated selective autophagic degradation of HBV core proteins inhibits HBV replication and HBV-related hepatocellular carcinoma progression
Hui Zhang, Xiameng Su, Leirong Gu, Ming Tan, Yuting Liu, Kexin Xu, Jihua Ren, Juan Chen, Zhihong Li, Shengtao Cheng
Cell Death Discovery.2024;[Epub] CrossRef
Hepatitis B virus X protein increases LASP1 SUMOylation to stabilize HER2 and facilitate hepatocarcinogenesis
Hongjuan You, Dongchen Yuan, Qi Li, Ning Zhang, Delong Kong, Tong Yu, Xiangye Liu, Xiaomei Liu, Rui Zhou, Fanyun Kong, Kuiyang Zheng, Renxian Tang
International Journal of Biological Macromolecules.2023; 226: 996. CrossRef
PLK3 promotes the proneural–mesenchymal transition in glioblastoma via transcriptional regulation of C5AR1
Shuo Yu, Lin Lv, Yang Li, Qian Ning, Tingting Liu, Tinghua Hu
Molecular Biology Reports.2023; 50(10): 8249. CrossRef
The role of UXT in tumors and prospects for its application in hepatocellular carcinoma
Zhengwang Wang, Shaojian Mo, Pengzhe Han, Lu Liu, Ziang Liu, Xifeng Fu, Yanzhang Tian
Future Oncology.2022; 18(29): 3335. CrossRef
C5aR1 promotes the progression of colorectal cancer by EMT and activating Wnt/β-catenin pathway
Duo Xu, Meirong Li, Longyan Ran, Xiaochen Li, Xingwang Sun, Tao Yin
Clinical and Translational Oncology.2022; 25(2): 440. CrossRef
The Complement System: A Potential Therapeutic Target in Liver Cancer
Meng Yuan, Li Liu, Chenlin Wang, Yan Zhang, Jiandong Zhang
Life.2022; 12(10): 1532. CrossRef
A Pleiotropic Role of the Hepatitis B Virus Core Protein in Hepatocarcinogenesis
Caroline Lefeuvre, Hélène Le Guillou-Guillemette, Alexandra Ducancelle
International Journal of Molecular Sciences.2021; 22(24): 13651. CrossRef

6,371 View
143 Download
15 Crossref

FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition: Yanwei Ye, Jie Li, Dongbao Jiang, Jingjing Li, Chuangfeng Xiao, Yingze Li, Chao Han, Chunlin Zhao; Cancer Res Treat. 2020;52(4):1162-1177. Published online May 25, 2020; DOI: https://doi.org/10.4143/crt.2020.138

Abstract PDF PubReader ePub

Purpose
Fibroblast growth factor receptor 4 (FGFR4) plays a critical role in cancer progression involving in tumor proliferation, invasion, and metastasis. This study clarified the role of FGFR4-Arg388 variant in gastric cancer (GC), and more importantly highlighted the possibility of this single nucleotide polymorphism (SNP) as potential therapeutic targets.
Materials and Methods
FGFR4 polymorphism was characterized in advanced GC patients to perform statistical analysis. FGFR4-dependent signal pathways involving cell proliferation, invasion, migration, and resistance to oxaliplatin (OXA) in accordance with the SNP were also assessed in transfected GC cell lines.
Results
Among 102 GC patients, the FGFR4-Arg388 patients showed significantly higher tumor stage (p=0.047) and worse overall survival (p=0.033) than the Gly388 patients. Immunohistochemical results showed that FGFR4-Arg388 patients were more likely to have higher vimentin (p=0.025) and p-STAT3 (p=0.009) expression compared with FGFR4-Gly388 patients. In transfected GC cells, the overexpression of FGFR4-Arg388 variant increased proliferation and invasion of GC cells, increasing resistance of GC cells to OXA compared with cells overexpressing the Gly388 allele.
Conclusion
The exploration mechanism may be through FGFR4-Arg388/STAT3/epithelial to mesenchymal transition axis regulating pivotal oncogenic properties of GC cells. The FGFR4-Arg388 variant may be a biomarker and a candidate target for adjuvant treatment of GC.

Citations

Citations to this article as recorded by

Exosomes Mediate the Production of Oxaliplatin Resistance and Affect Biological Behaviors of Colon Cancer Cell Lines
Yanwei Ye, Yingze Li, Chu Wu, Yiming Shan, Jie Li, Dongbao Jiang, Jingjing Li, Chao Han, Dongdong Liu, Chunlin Zhao
Current Cancer Drug Targets.2025; 25(4): 386. CrossRef
FGFR4 p.Gly388Arg polymorphism in PBMCs of LAM patients: findings of a pilot study
Sinem Koc-Gunel, Amy L. Ryan, Melanie Winter, Thomas O. F. Wagner
Frontiers in Medicine.2025;[Epub] CrossRef
Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers
Tsuyoshi Takashima, Daiki Taniyama, Naoya Sakamoto, Maika Yasumoto, Ryuichi Asai, Takuya Hattori, Ririno Honma, Pham Quoc Thang, Shoichi Ukai, Ryota Maruyama, Kenji Harada, Kazuya Kuraoka, Kazuaki Tanabe, Atsuo T. Sasaki, Hideki Ohdan, Eiichi Morii, Junko
British Journal of Cancer.2021; 125(1): 65. CrossRef
FGFR4 Gly388Arg Polymorphism Reveals a Poor Prognosis, Especially in Asian Cancer Patients: A Meta-Analysis
Jung Han Kim, Soo Young Jeong, Hyun Joo Jang, Sung Taek Park, Hyeong Su Kim
Frontiers in Oncology.2021;[Epub] CrossRef
FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance
Jakub Szymczyk, Katarzyna Sluzalska, Izabela Materla, Lukasz Opalinski, Jacek Otlewski, Malgorzata Zakrzewska
Cancers.2021; 13(22): 5796. CrossRef

8,060 View
154 Download
7 Web of Science
5 Crossref

Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing: Eunhyang Park, Hyo Sup Shim; Cancer Res Treat. 2020;52(2):543-551. Published online November 8, 2019; DOI: https://doi.org/10.4143/crt.2019.305

Abstract PDF Supplementary Material PubReader ePub

Purpose
Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1) are ‘must-test’ biomarkers in the molecular diagnostics of advanced-stage lung cancer patients. Although single-gene assays are currently considered the gold standard for these genes, next-generation sequencing (NGS) tests are being introduced to clinical practices. We compared the results of current diagnostics and aimed to suggest timely effective guidance for their clinical use.
Materials and Methods
Patients with lung cancer who received both conventional single-gene assays and subsequent targeted NGS testing were enrolled, and the results of their tests were compared.
Results
A total of 241 patients were enrolled, and the EGFR real-time polymerase chain reaction, ALK fluorescence in situ hybridization (FISH), and ROS1 FISH assays exhibited 92.9%, 99.6%, and 99.5% concordance with the NGS tests, respectively. The discordant cases were mostly false-negatives of the single-gene assays, probably due to technical limitation. Of 158 cases previously designated as wild-type, EGFR, ALK, and ROS1 alterations were identified in 10.1%, 1.9%, and 1.3%, respectively, and other targetable alterations were identified in 36.1% of the cases. Of patients with additionally identified actionable alterations, 32.6% (31/95) received matched therapy with a clinical benefit of 48.4% (15/31).
Conclusion
Even though the conventional and NGS methods were concordant in the majority of cases, NGS testing still revealed a considerable number of additional EGFR, ALK, and ROS1 alterations, as well as other targetable alterations, in Korean advanced-stage lung cancer patients. Given the high frequency of EGFR and other targetable mutations identified in the present study, NGS testing is highly recommended in the diagnosis of Korean lung cancer patients.

Citations

Citations to this article as recorded by

Next-Generation Sequencing (NGS) in non-small cell lung carcinoma: A real-world experience in the public health system of Galicia (Northwest Spain)
Ihab Abdulkader-Nallib, José Manuel Cameselle-Teijeiro, Iván Lesende-Rodríguez, Raquel Pérez-Becerra, José Ramón Antúnez-López, Jorge García-González, Luis León-Mateos, María Sánchez-Ares, Federico Pio Fabrizio
PLOS One.2025; 20(7): e0326336. CrossRef
Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma
Jae Seok Lee, Eun Kyung Kim, Kyung A Kim, Hyo Sup Shim
Cancer Research and Treatment.2024; 56(1): 104. CrossRef
Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysis
Jiamin Lu, Yuqian Feng, Kaibo Guo, Leitao Sun, Shanming Ruan, Kai Zhang
Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef
Cost-effectiveness of next-generation sequencing for advanced EGFR/ALK-negative non-small cell lung cancer
Dong-Won Kang, Sun-Kyeong Park, Sokbom Kang, Eui-Kyung Lee
Lung Cancer.2024; 197: 107970. CrossRef
Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system
Ching-Yao Yang, Jin-Yuan Shih, Wei-Yu Liao, Chao-Chi Ho, Chia-Lin Hsu, Tzu-Hsiu Tsai, Shang-Gin Wu, Yen-Ting Lin, Wei-Hsun Hsu, Suyog Jain, Steve Olsen, James Chih-Hsin Yang, Chong-Jen Yu, Pan-Chyr Yang
European Journal of Cancer.2023; 193: 113310. CrossRef
Clinicopathological Characteristics of NRG1 Fusion–Positive Solid Tumors in Korean Patients
Yoon Jin Cha, Chung Lee, Bio Joo, Kyung A Kim, Choong-kun Lee, Hyo Sup Shim
Cancer Research and Treatment.2023; 55(4): 1087. CrossRef
Differences in genomic profile of high-grade urothelial carcinoma according to tumor location
Cheol Keun Park, Nam Hoon Cho
Urologic Oncology: Seminars and Original Investigations.2022; 40(3): 109.e1. CrossRef
Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations
Yoon Ji Choi, Jung Yoon Choi, Ju Won Kim, Ah Reum Lim, Youngwoo Lee, Won Jin Chang, Soohyeon Lee, Jae Sook Sung, Hee-Joon Chung, Jong Won Lee, Eun Joo Kang, Jung Sun Kim, Taekyu Lim, Hye Sook Kim, Yu Jung Kim, Mi Sun Ahn, Young Saing Kim, Ji Hyun Park, Se
Cancer Research and Treatment.2022; 54(1): 30. CrossRef
Increased Radiosensitivity of Solid Tumors Harboring ATM and BRCA1/2 Mutations
Kyung Hwan Kim, Han Sang Kim, Seung-seob Kim, Hyo Sup Shim, Andrew Jihoon Yang, Jason Joon Bock Lee, Hong In Yoon, Joong Bae Ahn, Jee Suk Chang
Cancer Research and Treatment.2022; 54(1): 54. CrossRef
Utility of Single-Gene Testing in Cancer Specimens
Mehenaz Hanbazazh, Diana Morlote, Alexander C. Mackinnon, Shuko Harada
Clinics in Laboratory Medicine.2022; 42(3): 385. CrossRef
Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
Jeonghyo Lee, Yeon Bi Han, Hyun Jung Kwon, Song Kook Lee, Hyojin Kim, Jin-Haeng Chung
Journal of Pathology and Translational Medicine.2022; 56(5): 249. CrossRef
Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy
Jii Bum Lee, Hyung Soon Park, Su Jin Choi, Seong Gu Heo, Ho Jung An, Hye Ryun Kim, Min Hee Hong, Sun Min Lim, Kyle Chang, Katie Quinn, Justin Odegaard, Byoung Yong Shim, Byoung Chul Cho
Therapeutic Advances in Medical Oncology.2022;[Epub] CrossRef
Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation
Jisheng Li, Liping Zhu, Justin Stebbing, Ling Peng
Journal of Cancer Research and Therapeutics.2022; 18(5): 1436. CrossRef
Lung cancer pathogenesis and poor response to therapy were dependent on driver oncogenic mutations
Xin Sun, Kai Li, Rui Zhao, Ye Sun, Jie Xu, Zi-Yang Peng, Run-Dong Song, Hong Ren, Shou-Ching Tang
Life Sciences.2021; 265: 118797. CrossRef
Patient-Specific Multi-Omics Models and the Application in Personalized Combination Therapy
August John, Bo Qin, Krishna R Kalari, Liewei Wang, Jia Yu
Future Oncology.2020; 16(23): 1737. CrossRef
Genetic Markers in Lung Cancer Diagnosis: A Review
Katarzyna Wadowska, Iwona Bil-Lula, Łukasz Trembecki, Mariola Śliwińska-Mossoń
International Journal of Molecular Sciences.2020; 21(13): 4569. CrossRef

10,518 View
280 Download
17 Web of Science
16 Crossref

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies: Myung-Ju Ahn, Ji-Youn Han, Dong-Wan Kim, Byoung Chul Cho, Jin-Hyoung Kang, Sang-We Kim, James Chih-Hsin Yang, Tetsuya Mitsudomi, Jong Seok Lee; Cancer Res Treat. 2020;52(1):284-291. Published online July 23, 2019; DOI: https://doi.org/10.4143/crt.2019.200

Abstract PDF PubReader ePub

Purpose
Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR sensitizing mutation and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system (CNS) metastases. We present results of a subgroup analysis of Korean patients from the pooled data of two global phase II trials: AURA extension (NCT01802632) and AURA2 (NCT02094261).
Materials and Methods
Enrolled patients had EGFR T790M-positive NSCLC and disease progression during or after EGFR-TKI therapy. Patients received osimertinib 80 mg orally once daily until disease progression. The primary endpoint was objective response rate (ORR).
Results
In total, 66 Korean patients received osimertinib treatment with a median treatment duration of 19 months. In the evaluable-for-response population (n=62), ORR was 74% (95% confidence interval [CI], 61.5 to 84.5) and median duration of response was 9.8 months (95% CI, 7.1 to 16.8). In the full analysis set (n=66), median progression-free survival was 10.9 months (95% CI, 8.3 to 15.0; data cutoff November 1, 2016), and median overall survival was 29.2 months (95% CI, 24.8 to 35.7; data cutoff May 1, 2018). Eight patients with CNS metastases were evaluable for response, none of whom showed CNS progression. The most common adverse events were rash (53%), cough (33%), paronychia, diarrhea, and decreased appetite (each 32%).
Conclusion
Efficacy and safety profiles of osimertinib in this subgroup are consistent with the global phase II pooled population, which supports osimertinib as a recommended treatment for Korean patients with T790M positive NSCLC.

Citations

Citations to this article as recorded by

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer
S.-H. Lee, J. Menis, T.M. Kim, H.R. Kim, C. Zhou, S.A. Kurniawati, K. Prabhash, H. Hayashi, D.D.-W. Lee, M.S. Imasa, Y.L. Teh, J.C.-H. Yang, T. Reungwetwattana, V. Sriuranpong, C.-E. Wu, Y. Ang, M. Sabando, M. Thiagarajan, H. Mizugaki, V. Noronha, M. Yuli
ESMO Open.2024; 9(12): 103996. CrossRef
The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review
Valerio Nardone, Caterina Romeo, Emma D’Ippolito, Pierpaolo Pastina, Maria D’Apolito, Luigi Pirtoli, Michele Caraglia, Luciano Mutti, Giovanna Bianco, Antonella Consuelo Falzea, Rocco Giannicola, Antonio Giordano, Pierosandro Tagliaferri, Claudia Vincigue
La radiologia medica.2023; 128(3): 316. CrossRef
The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China
Mingjun Rui, Zijing Wang, Zhengyang Fei, Yao Wu, Yingcheng Wang, Lei Sun, Ye Shang, Hongchao Li
Frontiers in Pharmacology.2022;[Epub] CrossRef
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial
Anwen Xiong, Shengxiang Ren, Huaimin Liu, Liyun Miao, Lei Wang, Jianhua Chen, Wei Li, Runpu Li, Xiang Wang, Zhiwei Lu, Donglin Wang, Xiaohong Wu, Zhihua Liu, Ligang Xing, Yimin Mao, Chunling Liu, Aiping Zeng, Hongrui Niu, Yingying Du, Yuping Sun, Yueyin P
Journal of Thoracic Oncology.2022; 17(10): 1216. CrossRef
Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma
Agnieszka Rybarczyk-Kasiuchnicz, Rodryg Ramlau, Katarzyna Stencel
International Journal of Molecular Sciences.2021; 22(2): 593. CrossRef

11,665 View
315 Download
6 Web of Science
5 Crossref

Fibroblast Growth Factor Receptor 1 (FGFR1) Amplification Detected by Droplet Digital Polymerase Chain Reaction (ddPCR) Is a Prognostic Factor in Colorectal Cancers: Jeong Mo Bae, Xianyu Wen, Tae-Shin Kim, Yoonjin Kwak, Nam-Yun Cho, Hye Seung Lee, Gyeong Hoon Kang; Cancer Res Treat. 2020;52(1):74-84. Published online May 8, 2019; DOI: https://doi.org/10.4143/crt.2019.062

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to reveal the clinicopathological characteristics and prognostic implications associated with fibroblast growth factor receptor 1 (FGFR1) amplification in colorectal cancers (CRCs).
Materials and Methods
We measured the copy number of FGFR1 by droplet digital polymerase chain reaction (ddPCR), and analyzed the FGFR1 expression by immunohistochemistry, in 764 surgically resected CRCs (SNUH2007 dataset, 384 CRCs; SNUH Folfox dataset, 380 CRCs).
Results
CRCs with ≥ 3.3 copies of the FGFR1 gene were classified as FGFR1 amplified. FGFR1 amplification was found in 10 of the 384 CRCs (2.6%) in the SNUH2007 dataset, and in 28 of the 380 CRCs (7.4%) in the SNUH Folfox dataset. In the SNUH2007 dataset, there was no association between the FGFR1 copy number status and sex, gross appearance, stage, or differentiation. High FGFR1 expression was associated with female sex and KRAS mutation. At the molecular level, FGFR1 amplification was mutually exclusive with BRAF mutation, microsatellite instability, and MLH1 methylation, in both SNUH2007 and SNUH Folfox datasets. Survival analysis revealed that FGFR1 amplification was associated with significantly worse clinical outcome compared with no FGFR1 amplification, in both SNUH2007 and SNUH Folfox datasets. Within the SNUH2007 dataset, CRC patients with high FGFR1 expression had an inferior progression-free survival compared with those with low FGFR1 expression. The FGFR inhibitor, PD173074, repressed the proliferation of a CRC cell line overexpressing FGFR1, but not of cells with FGFR1 amplification.
Conclusion
FGFR1 amplification measured by ddPCR can be a prognostic indicator of poor clinical outcome in patients with CRCs.

Citations

Citations to this article as recorded by

Oncogenic mutations of clinical significance in colorectal cancer
Vivienne Lea, Stephanie Hui-Su Lim, Cheok Soon Lee
Pathology.2025; 57(5): 555. CrossRef
Melanin-Concentrating Hormone (MCH): Role in Mediating Reward-Motivated and Emotional Behavior and the Behavioral Disturbances Produced by Repeated Exposure to Reward Substances
Olga Karatayev, Sarah F. Leibowitz
International Journal of Molecular Sciences.2025; 26(15): 7143. CrossRef
FGFR1-amplified colorectal cancer: a distinct prognostic subtype identified through integrated genomic and immunohistochemical profiling
X. Lyu, R. Cai, B. Han, Y. Liu, Y. Zhang, Z. Wu, Y. Cheng, Z. Lin, G. Qin, X. Xie, J. Zhang, W. Zhan, Y. Deng
ESMO Open.2025; 10(9): 105561. CrossRef
Personalized therapy in metastatic colorectal cancer: biomarker-driven use of biologics
Francesco Sullo, Chiara Gallio, Laura Matteucci, Alessandro Bittoni, Margherita Muratore, Luca Esposito, Bianca Ceredi, Graziana Gallo, Paola Ulivi, Ilario Giovanni Rapposelli, Alessandro Passardi
Expert Opinion on Biological Therapy.2025; 25(9): 947. CrossRef
Clinical application value of MYO1-G methylation in plasma circulating tumor DNA combined with fecal occult blood test for early screening of colorectal cancer
Di Kang, Jing Li, Jingquan Xu, Yangyang Li, Weiliang Song, Zili Zhang
Clinics and Research in Hepatology and Gastroenterology.2025; 49(9): 102690. CrossRef
Decision tree-based machine learning methods for identifying colorectal cancer-associated microRNA signatures and their regulatory networks
Farzaneh Hamidi, Neda Gilani, Anoshirvan Kazemnejad, Younes Aftabi, Maryam Shirforoush-Sattari, Aria Jahanimoghadam
Scientific Reports.2025;[Epub] CrossRef
A panorama of colon cancer in the era of liquid biopsy
Sylvie Devalle, Veronica Aran, Cesar de Souza Bastos Júnior, Vera Lucia Pannain, Paulo Brackmann, Marcelo Leal Gregório, José Eduardo Ferreira Manso, Vivaldo Moura Neto
The Journal of Liquid Biopsy.2024; 4: 100148. CrossRef
Targeting FGFR1 by β,β-dimethylacrylalkannin suppresses the proliferation of colorectal cancer in cellular and xenograft models
Ran Zhao, Fanxiang Yin, Mangaladoss Fredimoses, Jianhua Zhao, Xiaorong Fu, Beibei Xu, Mengrui Liang, Hanyong Chen, Kangdong Liu, Mingjuan Lei, Kyle Vaughn Laster, Zhi Li, Joydeb Kumar Kundu, Zigang Dong, Mee-Hyun Lee
Phytomedicine.2024; 129: 155612. CrossRef
Single-center analysis of a real-world cohort of patients with metastatic urothelial carcinoma evaluated by NGS: molecular landscape and efficacy of targeted therapies
César Gutiérrez Pérez, Enrique Lastra Aras, Patricia Saiz López, Enrique García Toro, Carmen Blanco Abad, Inmaculada Rodríguez Ledesma, María Pumares González, Miriam Vela Domínguez, Noelia Espinosa Cabria, Guillermo Crespo Herrero
Clinical and Translational Oncology.2024; 27(3): 1211. CrossRef
Diphenyl urea‐benzylidene acetohydrazide hybrids as fibroblast growth factor receptor 1 inhibitors and anticancer agents
Heba T. Abdel‐Mohsen, Amira M. Nageeb, Iman A. Y. Ghannam
Drug Development Research.2024;[Epub] CrossRef
Clinical evaluation of a droplet digital PCR assay for detecting POLE mutations and molecular classification of endometrial cancer
Gilhyang Kim, Song Kook Lee, Dong Hoon Suh, Kidong Kim, Jae Hong No, Yong Beom Kim, Hyojin Kim
Journal of Gynecologic Oncology.2022;[Epub] CrossRef
Detection and Quantification of Stagonosporopsis cucurbitacearum in Seeds of Cucurbita maxima Using Droplet Digital Polymerase Chain Reaction
Sergio Murolo, Marwa Moumni, Valeria Mancini, Mohamed Bechir Allagui, Lucia Landi, Gianfranco Romanazzi
Frontiers in Microbiology.2022;[Epub] CrossRef
Fibroblast growth factor 2: Role in prenatal alcohol-induced stimulation of hypothalamic peptide neurons
Guo-Qing Chang, Nushrat Yasmin, Adam D. Collier, Olga Karatayev, Nailya Khalizova, Amanda Onoichenco, Milisia Fam, Avi S. Albeg, Samantha Campbell, Sarah F. Leibowitz
Progress in Neuro-Psychopharmacology and Biological Psychiatry.2022; 116: 110536. CrossRef
Copy Number Alterations as Novel Biomarkers and Therapeutic Targets in Colorectal Cancer
Elaine S. Tan, Todd C. Knepper, Xuefeng Wang, Jennifer B. Permuth, Liang Wang, Jason B. Fleming, Hao Xie
Cancers.2022; 14(9): 2223. CrossRef
Tumor-induced Osteomalacia: A Systematic Review and Individual Patient’s Data Analysis
Domenico Rendina, Veronica Abate, Giuseppe Cacace, Lanfranco D’Elia, Gianpaolo De Filippo, Silvana Del Vecchio, Ferruccio Galletti, Alberto Cuocolo, Pasquale Strazzullo
The Journal of Clinical Endocrinology & Metabolism.2022; 107(8): e3428. CrossRef
Indications of Genomic Abnormalities for Molecular Targeted Therapy in Colorectal Cancer
Koshi Mimori
Nippon Daicho Komonbyo Gakkai Zasshi.2022; 75(10): 449. CrossRef
Onco-ontogeny recapitulates phylogeny – a consideration
P. N. Plowman, C. E. Plowman
Oncogene.2021; 40(8): 1542. CrossRef
Integrating Multi–Omics Data for Gene-Environment Interactions
Yinhao Du, Kun Fan, Xi Lu, Cen Wu
BioTech.2021; 10(1): 3. CrossRef
Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
Guihong Liu, Tao Chen, Zhenyu Ding, Yang Wang, Yuquan Wei, Xiawei Wei
Cell Proliferation.2021;[Epub] CrossRef
Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling
Harriet R. Ferguson, Michael P. Smith, Chiara Francavilla
Cells.2021; 10(5): 1201. CrossRef
Identification of Prognostic Dosage-Sensitive Genes in Colorectal Cancer Based on Multi-Omics
Zhiqiang Chang, Xiuxiu Miao, Wenyuan Zhao
Frontiers in Genetics.2020;[Epub] CrossRef
Gene Expression Signature to Predict Prognosis and Adjuvant Chemosensitivity of Colorectal Cancer Patients

Jianxia Li, Jianwei Zhang, Huabin Hu, Yue Cai, Jiayu Ling, Zehua Wu, Yanhong Deng
Cancer Management and Research.2020; Volume 12: 3301. CrossRef
Identification of Genomic Alterations of Perineural Invasion in Patients with Stage II Colorectal Cancer

Hao Su, Chen Chang, Jiajie Hao, Xin Xu, Mandula Bao, Shou Luo, Chuanduo Zhao, Qian Liu, Xishan Wang, Zhixiang Zhou, Haitao Zhou
OncoTargets and Therapy.2020; Volume 13: 11571. CrossRef
Design, Synthesis and Biological Evaluation: 5-amino-1H-pyrazole-1- carbonyl derivatives as FGFR Inhibitors
Yan Zhang, Niefang Yu
Letters in Drug Design & Discovery.2020; 17(11): 1330. CrossRef

10,655 View
304 Download
24 Web of Science
24 Crossref

Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014: Chang-Min Choi, Ho Cheol Kim, Chi Young Jung, Deog Gon Cho, Jae Hyun Jeon, Jeong Eun Lee, Jin Seok Ahn, Seung Joon Kim, Yeongdae Kim, Yoo-Duk Choi, Yang-Gun Suh, Jung-Eun Kim, Boram Lee, Young-Joo Won, Young-Chul Kim; Cancer Res Treat. 2019;51(4):1400-1410. Published online February 25, 2019; DOI: https://doi.org/10.4143/crt.2018.704

Abstract PDF Supplementary Material PubReader ePub

Purpose
The aim of this study was to investigate epidemiology, clinical characteristics and sex differences of patients with lung cancer using nationwide registry in Korea.
Materials and Methods
The Korean Association for Lung Cancer developed a registry in cooperation with the Korean Central Cancer Registry, and surveyed about 10% of lung cancer cases. For this first survey of cases diagnosed in 2014, cases were selected through a systematic sampling method.
Results
Total 2,621 lung cancer patients were surveyed, and the median patient age was 70 years. During the study period, adenocarcinoma was the most frequent histologic type, the proportion of female patients was 28.4%, and women had a better prognosis (median survival, not reached vs. 13 months; p<0.001) than did men for non-small cell lung cancer. The proportion of never-smokers was 36.4%, and never-smoking was more prevalent in women than in men (87.5 vs. 16.0%, p<0.001). Epidermal growth factor receptor (EGFR) mutations were found in 36.8% of stage IV adenocarcinoma patients, and higher in female compared to male patients (51.2 vs. 26.6%, p<0.001). In addition, patients with EGFR mutation showed better survival (median survival, 18 vs. 8 months; p<0.001) than patients without EGFR mutation in these patients.
Conclusion
This is the first survey to gather unbiased nationwide lung cancer statistics in Korea. More than one-third of lung cancer patients had no smoking history. Female had a high proportion of non-smoker, more adenocarcinoma with EGFR mutation and generally better prognosis than male.

Citations

Citations to this article as recorded by

Prognostic value of electronic health records-based frailty measures for all-cause mortality in older patients with non-small cell lung cancer
Minh-Thao Tu, Thi-Ngoc Tran, Hoejun Kwon, Yoon-Jung Choi, Youngjoo Lee, Hyunsoon Cho
Journal of Geriatric Oncology.2025; 16(1): 102130. CrossRef
Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation
Chang Dong Yeo, Dong Won Park, Seong Hoon Yoon, Eun Young Kim, Jeong Eun Lee, Shin Yup Lee, Chang‐Min Choi, In‐Jae Oh, Do Jin Kim, Jeong Seon Ryu, Jae Cheol Lee, Young‐Chul Kim, Tae Won Jang, Kye Young Lee, Seung Hun Jang, Seung Joon Kim
The Clinical Respiratory Journal.2025;[Epub] CrossRef
Factors Associated with Postoperative Recurrence in Stage I to IIIA Non–Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: Analysis of Korean National Population Data
Kyu Yean Kim, Ho Cheol Kim, Tae Jung Kim, Hong Kwan Kim, Mi Hyung Moon, Kyongmin Sarah Beck, Yang Gun Suh, Chang Hoon Song, Jin Seok Ahn, Jeong Eun Lee, Jae Hyun Jeon, Chi Young Jung, Jeong Su Cho, Yoo Duk Choi, Seung Sik Hwang, Chang Min Choi, Seung Hun
Cancer Research and Treatment.2025; 57(1): 83. CrossRef
Association of Shorter Time to Recurrence and Recurrence-Free Survival with Transthoracic Lung Biopsy in Stage I Lung Cancer
Kum Ju Chae, Hyunsook Hong, Hyungin Park, Soon Ho Yoon
Cancer Research and Treatment.2025; 57(2): 387. CrossRef
A comparison of clinical guidelines, treatment characteristics and outcomes in small cell lung cancer between East Asia and Europe/North America
Chi-Lu Chiang, Ross Andrew Soo, Tony Mok, Pei Jye Voon, Lucksamon Thamlikitkul, Ying Cheng, Hidehito Horinouchi, Byong Chul Cho, Krista Lin Xu, Myung-Ju Ahn
Frontiers in Oncology.2025;[Epub] CrossRef
Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel
Fuyumi Nishihara-Kato, Hisao Imai, Takeshi Tsuda, Satoshi Wasamoto, Yoshiaki Nagai, Takayuki Kishikawa, Yosuke Miura, Akihiro Ono, Yutaka Yamada, Ken Masubuchi, Takashi Osaki, Junichi Nakagawa, Yukihiro Umeda, Hiroyuki Minemura, Yuki Kozu, Hirokazu Tanigu
Oncology.2024; 102(1): 30. CrossRef
Diagnostic challenge and survival analysis of pulmonary oligometastases and primary lung cancer in breast cancer patients
Siyao Mai, Haiqing Liu, Hong Zeng, Ziliang Cheng, Jingwen Huang, Guangzi Shi, Yong Li, Zhuo Wu
Thoracic Cancer.2024; 15(12): 1017. CrossRef
Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study
Jiyun Lee, Hee Kyung Ahn, Sang‐We Kim, Ji‐Youn Han, Sung Sook Lee, Hyung Soon Park, Hyun Woo Lee, Joo‐Hang Kim, Eunhan Cho, Reto Huggenberger, Byoung Chul Cho
Cancer Medicine.2024;[Epub] CrossRef
Sex differences in prognosis factors in patients with lung cancer: A nationwide retrospective cohort study in Korea
Youn Huh, Yeo Ju Sohn, Hae-Rim Kim, Hyejin Chun, Hwa Jung Kim, Ki Young Son, Dong Keon Yon
PLOS ONE.2024; 19(5): e0300389. CrossRef
Glycemic status, insulin resistance, and mortality from lung cancer among individuals with and without diabetes
In Young Cho, Yoosoo Chang, Eunju Sung, Boyoung Park, Jae-Heon Kang, Hocheol Shin, Sarah H. Wild, Christopher D. Byrne, Seungho Ryu
Cancer & Metabolism.2024;[Epub] CrossRef
Mitochondrial Dynamics in Non-Small Cell Lung Cancer
Agata Dutkowska, Daria Domańska-Senderowska, Karolina H. Czarnecka-Chrebelska, Ewa Pikus, Aleksandra Zielińska, Laura Biskup, Agata Kołodziejska, Paulina Madura, Maria Możdżan, Urszula Załuska, Edward Zheng, Eliza Adamczyk, Konrad Kędzia, Szymon Wcisło, M
Cancers.2024; 16(16): 2823. CrossRef
Gender‐specific outcomes of low‐dose computed tomography screening for lung cancer detection: A retrospective study in Chinese never‐smoker population
Huihong Wang, Jicheng Xie, Yahong Chen, Jiang Jin, Meixian Zhang, TaoHsin Tung, Youzu Xu
Cancer Medicine.2024;[Epub] CrossRef
Survival of lung cancer patients according to screening eligibility using Korean Lung Cancer Registry 2014–2016
Sangwon Lee, Eun Hye Park, Bo Yun Jang, Ye Ji Kang, Kyu-Won Jung, Hyo Soung Cha, Kui Son Choi
Scientific Reports.2024;[Epub] CrossRef
Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015
Da Som Jeon, Ho Cheol Kim, Se Hee Kim, Tae-Jung Kim, Hong Kwan Kim, Mi Hyung Moon, Kyongmin Sarah Beck, Yang-Gun Suh, Changhoon Song, Jin Seok Ahn, Jeong Eun Lee, Jeong Uk Lim, Jae Hyun Jeon, Kyu-Won Jung, Chi Young Jung, Jeong Su Cho, Yoo-Duk Choi, Seung
Cancer Research and Treatment.2023; 55(1): 103. CrossRef
Endobronchial ultrasound‐guided re‐biopsy of non–small cell lung cancer with acquired resistance after EGFR tyrosine kinase inhibitor treatment
Kyung Soo Hong, Jinmo Cho, Jong Geol Jang, Min Hye Jang, June Hong Ahn
Thoracic Cancer.2023; 14(4): 363. CrossRef
Stratifying non-small cell lung cancer patients using an inverse of the treatment decision rules: validation using electronic health records with application to an administrative database
Min-Hyung Kim, Sojung Park, Yu Rang Park, Wonjun Ji, Seul-Gi Kim, Minji Choo, Seung-Sik Hwang, Jae Cheol Lee, Hyeong Ryul Kim, Chang-Min Choi
BMC Medical Informatics and Decision Making.2023;[Epub] CrossRef
Regional lymph node recurrence after stereotactic body radiation therapy for lung cancer: Patterns of recurrence, treatment approaches, and clinical outcomes (KROG 21-09)
Tae Hoon Lee, Hyunju Shin, Yong Chan Ahn, Min Kyu Kang, Changhoon Song, Woo Chul Kim, Sung Ho Moon, Jin Hee Kim, Jaeho Cho, Hae Jin Park, Heui Kwan Lee, Byoung Hyuck Kim, Hak Jae Kim
Radiotherapy and Oncology.2023; 183: 109572. CrossRef
A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer
Cheol-Kyu Park, Nakyung Jeon, Hwa-Kyung Park, Hyung-Joo Oh, Young-Chul Kim, Ha-Lim Jeon, Yong-Hyub Kim, Sung-Ja Ahn, In-Jae Oh
Cancers.2023; 15(5): 1606. CrossRef
All-round counterattack to conquer lung cancer
Seung Hun Jang
Journal of the Korean Medical Association.2023; 66(3): 154. CrossRef
Efficacy of Prophylactic Cranial Irradiation According to the Risk of Extracranial Recurrence in Limited-Stage Small Cell Lung Cancer
Tae Hoon Lee, Joo-Hyun Chung, Hong-Gyun Wu, Suzy Kim, Joo Ho Lee, Bhumsuk Keam, Jin-Soo Kim, Ki Hwan Kim, Byoung Hyuck Kim, Hak Jae Kim
Cancer Research and Treatment.2023; 55(3): 875. CrossRef
Lung Cancer Screening in Asia: An Expert Consensus Report
David Chi-Leung Lam, Chong-Kin Liam, Sita Andarini, Samina Park, Daniel S.W. Tan, Navneet Singh, Seung Hun Jang, Varut Vardhanabhuti, Antonio B. Ramos, Tomio Nakayama, Nguyen Viet Nhung, Kazuto Ashizawa, Yeun-Chung Chang, Jamsak Tscheikuna, Cong Cung Van,
Journal of Thoracic Oncology.2023; 18(10): 1303. CrossRef
New insights into the biology and development of lung cancer in never smokers—implications for early detection and treatment
Peiyao Wang, Sophie Sun, Stephen Lam, William W. Lockwood
Journal of Translational Medicine.2023;[Epub] CrossRef
Sublobar Resection versus Stereotactic Body Radiation Therapy for Clinical Stage I Non–Small Cell Lung Cancer: A Study Using Data from the Korean Nationwide Lung Cancer Registry
Jeonghee Yun, Jong Ho Cho, Tae Hee Hong, Kyungmi Yang, Yong Chan Ahn, Hong Kwan Kim
Cancer Research and Treatment.2023; 55(4): 1171. CrossRef
Synthetic Tabular Data Based on Generative Adversarial Networks in Health Care: Generation and Validation Using the Divide-and-Conquer Strategy
Ha Ye Jin Kang, Erdenebileg Batbaatar, Dong-Woo Choi, Kui Son Choi, Minsam Ko, Kwang Sun Ryu
JMIR Medical Informatics.2023; 11: e47859. CrossRef
Long-term Survival According to N Stage Diagnosed by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Non-small Cell Lung Cancer
Bin Hwangbo, Eun Young Park, Bumhee Yang, Geon Kook Lee, Tae Sung Kim, Hyae Young Kim, Moon Soo Kim, Jong Mog Lee
Chest.2022; 161(5): 1382. CrossRef
Survival impact of prophylactic cranial irradiation in small-cell lung cancer in the modern era of magnetic resonance imaging staging
Yu Jin Lim, Changhoon Song, Hak Jae Kim
Radiation Oncology.2022;[Epub] CrossRef
Lung Cancer Screening with Low-Dose Chest Computed Tomography
Yeon Wook Kim
The Korean Journal of Medicine.2022; 97(1): 42. CrossRef
Association between clinical outcomes and local treatment in stage IV non‐small cell lung cancer patients with single extrathoracic metastasis
Jeong Uk Lim, Hye Seon Kang, Ah Young Shin, Chang Dong Yeo, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim
Thoracic Cancer.2022; 13(9): 1349. CrossRef
Analysis of thromboembolic events in patients with non-small cell lung cancer who received adjuvant chemotherapy: single-center real-world data
Tae-Hwan Kim, Yong Won Choi, Hyun Woo Lee, Seok Yun Kang, Heejun Son, Jin-Hyuk Choi, Mi Sun Ahn, Seung-Soo Sheen
Scientific Reports.2022;[Epub] CrossRef
Characteristics and clinical outcomes of patients with nonsmoking small cell lung cancer in Korea
Hye Seon Kang, Jung Uk Lim, Chang Dong Yeo, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim, Ho Cheol Kim, Chang Min Choi, Chi Young Jung, Deog Gon Cho, Jae Hyun Jeon, Jeong Eun Lee, Jin Seok Ahn, Yeongdae Kim, Yoo-Duk Choi, Yang-Gun Suh, Jung-Eun Kim, Youn
BMC Pulmonary Medicine.2022;[Epub] CrossRef
Sex differences in the characteristics and survival of patients with non‐small‐cell lung cancer: A retrospective analytical study based on real‐world clinical data of the Korean population
Da Som Jeon, Jin Woo Kim, Seul Gi Kim, Hyeong Ryul Kim, Si Yeol Song, Jae Cheol Lee, Wonjun Ji, Chang‐Min Choi, Ho Cheol Kim
Thoracic Cancer.2022; 13(18): 2584. CrossRef
Single-cell RNA sequencing analysis to explore immune cell heterogeneity and novel biomarkers for the prognosis of lung adenocarcinoma
Yong Xu, Yao Wang, Leilei Liang, Nan Song
Frontiers in Genetics.2022;[Epub] CrossRef
Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A
Cheol‐Kyu Park, Sung‐Yong Lee, Jae Cheol Lee, Chang‐Min Choi, Shin Yup Lee, Tae‐Won Jang, In‐Jae Oh, Young‐Chul Kim
Thoracic Cancer.2021; 12(4): 444. CrossRef
Active Treatment Improves Overall Survival in Extremely Older Non–Small Cell Lung Cancer Patients: A Multicenter Retrospective Cohort Study
Su Yeon Lee, Yoon-Ki Hong, Wonjun Ji, Jae Cheol Lee, Chang Min Choi
Cancer Research and Treatment.2021; 53(1): 104. CrossRef
A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, In-Jae Oh, Young-Chul Kim
Cancer Research and Treatment.2021; 53(1): 93. CrossRef
Prognostic significance of genetic variants in GLUT1 in stage III non‐small cell lung cancer treated with radiotherapy
Min Kyu Kang, Shin Yup Lee, Jin Eun Choi, Sun Ah Baek, Sook Kyung Do, Jeong Eun Lee, Jongmoo Park, Seung Soo Yoo, Sunha Choi, Kyung Min Shin, Ji Yun Jeong, Jae Yong Park
Thoracic Cancer.2021; 12(6): 874. CrossRef
Awareness and Use of Complementary and Alternative Medicine in Korean Lung Cancer Patients
Joon Young Choi, Wonjun Ji, Chang-Min Choi, Chaeuk Chung, Jae Myoung Noh, Cheol-Kyu Park, In-Jae Oh, Hong In Yoon, Hyeong Ryul Kim, Ho Young Kim, Chang Dong Yeo, Seung Hun Jang
Tuberculosis and Respiratory Diseases.2021; 84(2): 105. CrossRef
Recent Trends of Lung Cancer in Korea
Jae Guk Lee, Ho Cheol Kim, Chang-Min Choi
Tuberculosis and Respiratory Diseases.2021; 84(2): 89. CrossRef
Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
Hayoung Choi, Jae‐Kyeong Lee, Hyung‐Joo Oh, Min‐Seok Kim, Bo Gun Kho, Cheol Kyu Park, In‐Jae Oh, Young‐Chul Kim
Thoracic Cancer.2021; 12(10): 1598. CrossRef
Time‐varying effect of sex on prognosis of lung adenocarcinoma surgical patients in China
Zezhou Wang, Miao Mo, Changming Zhou, Xiaoshuang Feng, Jie Shen, Ting Ye, Yang Zhang, Hong Hu, Haiquan Chen, Ying Zheng
Thoracic Cancer.2021; 12(11): 1699. CrossRef
Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
Journal of Pathology and Translational Medicine.2021; 55(3): 181. CrossRef
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
Fernando Franco, Enric Carcereny, Maria Guirado, Ana L. Ortega, Rafael López-Castro, Delvys Rodríguez-Abreu, Rosario García-Campelo, Edel del Barco, Oscar Juan, Francisco Aparisi, Jose L. González-Larriba, Manuel Domine, Jose M. Trigo, Manuel Cobo, Sara C
PLOS ONE.2021; 16(6): e0251761. CrossRef
Survival Prediction of Lung Cancer Using Small-Size Clinical Data with a Multiple Task Variational Autoencoder
Thanh-Hung Vo, Guee-Sang Lee, Hyung-Jeong Yang, In-Jae Oh, Soo-Hyung Kim, Sae-Ryung Kang
Electronics.2021; 10(12): 1396. CrossRef
Impact of coexistent preserved ratio impaired spirometry on the survival of patients with lung cancer: Analysis of data from the Korean Association for Lung Cancer Registry
I. Re Heo, Ho Cheol Kim, Seung Jun Lee, Jung‐Wan Yoo, Sunmi Ju, Yi Yeong Jeong, Jong Deog Lee, Yu Ji Cho, Jong Hwan Jeong, Manbong Heo, Seung Woo Jung, Tae Hoon Kim
Thoracic Cancer.2021; 12(18): 2478. CrossRef
Lung Cancer in Korea
Sehhoon Park, Chang-Min Choi, Seung-Sik Hwang, Yoon-La Choi, Hyae Young Kim, Young-Chul Kim, Young Tae Kim, Ho Yun Lee, Si Yeol Song, Myung-Ju Ahn
Journal of Thoracic Oncology.2021; 16(12): 1988. CrossRef
Multiple genome pattern analysis and signature gene identification for the Caucasian lung adenocarcinoma patients with different tobacco exposure patterns
Yan-mei Dong, Li-da Qin, Yi-fan Tong, Qi-en He, Ling Wang, Kai Song
PeerJ.2020; 8: e8349. CrossRef
Efficacy of immune checkpoint inhibitors according to PD‐L1 tumor proportion scores in non‐small cell lung cancer
Seongho Park, Yoo‐Duk Choi, Jieun Kim, Bo‐Gun Kho, Cheol‐Kyu Park, In‐Jae Oh, Young‐Chul Kim
Thoracic Cancer.2020; 11(2): 408. CrossRef
Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing
Eunhyang Park, Hyo Sup Shim
Cancer Research and Treatment.2020; 52(2): 543. CrossRef
A New TTZ Feature Extracting Algorithm to Decipher Tobacco Related Mutation Signature Genes for the Personalized Lung Adenocarcinoma Treatment
Qien He, Zhewei Qiu, Yifan Tong, Kai Song
IEEE Access.2020; 8: 89031. CrossRef
Épidémiologie des cancers du poumon en France : les tendances actuelles
E. Giroux Leprieur, A. Vergnenègre, J. Trédaniel
Revue des Maladies Respiratoires Actualités.2020; 12(2): 2S6. CrossRef
Low-dose chest computed tomographic screening and invasive diagnosis of pulmonary nodules for lung cancer in never-smokers
Yeon Wook Kim, Hye-Rin Kang, Byoung Soo Kwon, Sung Yoon Lim, Yeon Joo Lee, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Kyung Won Lee, Jae Ho Lee, Choon-Taek Lee
European Respiratory Journal.2020; 56(5): 2000177. CrossRef
Screening for Lung Cancer Using Low-dose Chest Computed Tomography in Korean Long-term Colorectal Cancer Survivors
Ji Soo Park, Beodeul Kang, Yehyun Park, Soo Jung Park, Jae Hee Cheon, Minkyu Jung, Seung Hoon Beom, Sang Joon Shin, Hyuk Hur, Byung Soh Min, Seung Hyuk Baik, Kang Young Lee, Joong Bae Ahn, Nam Kyu Kim, Tae Il Kim
Journal of Cancer Prevention.2019; 24(1): 48. CrossRef
Épidémiologie des cancers du poumon en France: les tendances actuelles
A. Vergnenègre, J. Trédaniel, L. Bigay-Gamé, O. Bylicki, J-C. Pairon, T. Urban, M. Colonna
Revue des Maladies Respiratoires Actualités.2019; 11(3): 169. CrossRef

14,952 View
562 Download
56 Web of Science
53 Crossref

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13: Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, Ki Hyeong Lee, Keon Uk Park, Ki Hwan Kim, Eun Kyung Cho, Yoon Hee Choi, Hye Ryun Kim, Hoon-Gu Kim, Heui June Ahn, Ha Yeon Lee, Hwan Jung Yun, Jin-Hyoung Kang, Jaeheon Jeong, Moon Young Choi, Sin-Ho Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn; Cancer Res Treat. 2019;51(2):718-726. Published online September 3, 2018; DOI: https://doi.org/10.4143/crt.2018.324

Abstract PDF PubReader ePub

Purpose
The optimal cytotoxic regimens have not been established for patients with non-small cell lung cancer (NSCLC) who develop disease progression on first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).
Materials and Methods
We conducted a multi-center randomized phase II trial to compare the clinical outcomes between pemetrexed plus cisplatin combination therapy followed by maintenance pemetrexed (PC) and pemetrexed monotherapy (P) after failure of first-line EGFR-TKI. The primary objective was progression-free survival (PFS), and secondary objectives included overall response rate (ORR), overall survival (OS), health-related quality of life (HRQOL), and safety and toxicity profiles.
Results
A total of 96 patientswere randomized, and 91 patientswere treated at 14 centers in Korea. The ORR was 34.8% (16/46) for the PC arm and 17.8% (8/45) for the P arm (p=0.066). With 23.4 months of follow-up, the median PFS was 5.4 months in the PC arm and 6.4 months in the P arm (p=0.114). The median OS was 17.9 months and 15.7 months in PC and P arms, respectively (p=0.787). Adverse events ≥ grade 3 were reported in 12 patients (26.1%) in the PC arm and nine patients (20.0%) in the P arm (p=0.491). The overall time trends of HRQOL were not significantly different between the two arms.
Conclusion
The outcomes of pemetrexed therapy in NSCLC patients with disease progression after firstline EGFR-TKI might not be improved by adding cisplatin.

Citations

Citations to this article as recorded by

The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yu
Cancer Research and Treatment.2025; 57(1): 39. CrossRef
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance – The ETOP 15-19 ABC-lung trial
R.A. Soo, K. Vervita, M. Früh, B.C. Cho, M. Majem, D. Rodriguez Abreu, K. Ribi, A. Callejo, T. Moran, M. Domine Gomez, M. Provencio, A. Addeo, J.Y. Han, A.L. Ortega Granados, M. Reck, A. Blasco, R. Garcia Campelo, M.A. Sala González, C. Britschgi, H. Rosc
Lung Cancer.2025; 202: 108454. CrossRef
Real-world treatment outcomes in South Korean patients with epidermal growth factor receptor-mutant non-small cell lung cancer
Young Saing Kim, Eun Young Lee, Hyun Woo Lee, Jin-Hyuk Choi, Tae-Hwan Kim, Yong Won Choi, Mi Sun Ahn
The Korean Journal of Internal Medicine.2025; 40(6): 1029. CrossRef
Osimertinib with Chemotherapy in EGFR -Mutated NSCLC

New England Journal of Medicine.2024; 390(5): 478. CrossRef
Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors
Balazs Halmos, Pragya Rai, Jae Min, Xiaohan Hu, Diana Chirovsky, Mark Shamoun, Bin Zhao
Frontiers in Oncology.2024;[Epub] CrossRef
Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non–small cell carcinoma
Wang Chun Kwok, Tan Fong Cheong, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
Asia-Pacific Journal of Clinical Oncology.2023; 19(1): 87. CrossRef
Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment
Cheng-Yu Chang, Chung-Yu Chen, Shih-Chieh Chang, Ching-Yi Chen, Yi-Chun Lai, Chun-Fu Chang, Yu-Feng Wei
Frontiers in Oncology.2023;[Epub] CrossRef
Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class
Joseph N. Samuel, Christopher M. Booth, Elizabeth Eisenhauer, Michael Brundage, Scott R. Berry, Bishal Gyawali
JAMA Oncology.2022; 8(6): 879. CrossRef
Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)
Ruizhu Sun, Zhansheng Hou, Yankui Zhang, Bo Jiang
Oncology Letters.2022;[Epub] CrossRef
Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid
Wang Chun Kwok, Tan Fong Cheong, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
Lung Cancer.2021; 152: 15. CrossRef
Exploring the role of epidermal growth factor receptor variant III in meningeal tumors
Rashmi Rana, Vaishnavi Rathi, Kirti Chauhan, Kriti Jain, Satnam Singh Chhabra, Rajesh Acharya, Samir Kumar Kalra, Anshul Gupta, Sunila Jain, Nirmal Kumar Ganguly, Dharmendra Kumar Yadav, Timir Tripathi
PLOS ONE.2021; 16(9): e0255133. CrossRef
Risk factors of nephrotoxicity of maintenance pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung
Wang Chun Kwok, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
Lung Cancer.2021; 162: 169. CrossRef
Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife
Current Oncology.2021; 28(6): 4894. CrossRef
Real world experience on maintenance chemotherapy with gemcitabine in second line setting for advanced non-small cell lung carcinoma
Wang Chun Kwok, David Chi Leung Lam, Ka Yan Chiang, James Chung Man Ho, Mary Sau Man Ip, Terence Chi Chun Tam
Journal of Chemotherapy.2020; 32(8): 429. CrossRef

12,079 View
360 Download
16 Web of Science
14 Crossref

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea: Seonggyu Byeon, Youjin Kim, Sung Won Lim, Jang Ho Cho, Sehoon Park, Jiyun Lee, Jong-Mu Sun, Yoon-La Choi, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn; Cancer Res Treat. 2019;51(2):623-631. Published online July 23, 2018; DOI: https://doi.org/10.4143/crt.2018.151

Abstract PDF Supplementary Material PubReader ePub

Purpose
Epidermal growth factor receptor (EGFR) exon 20 insertion mutations account for approximately 4% of all EGFR mutations. Given the rarity of this mutation, its clinical outcomes are not fully established.
Materials and Methods
Between 2009 and 2017, non-small cell lung cancer (NSCLC) patients who showed an exon 20 insertion were retrospectively reviewed for clinical characteristics and outcomes, including responses to chemotherapy (CTx) or targeted therapy.
Results
Of 3,539 NSCLC patients who harbored an activating EGFR mutation, 56 (1.6%) had an exon 20 insertion. Of the advanced NSCLC patients, 27 of 1,479 (1.8%) had an exon 20 insertion. The median overall survival was 29.4 months (95% confidence interval 9.3 to 49.6) for 27 advancedNSCLC patients. The 22 patientswho received systemic CTx achieved a 50.0% response rate and a 77.2% disease control rate, with 4.2 months of progressionfree survival. Six patients received EGFR tyrosine kinase inhibitors (TKIs). Three of the four patients that had only an exon 20 insertion showed progressive disease, while one showed stable disease. The othertwo patients had an exon 20 insertion and another EGFR mutation and achieved a partial response.
Conclusion
The incidence of an exon 20 insertion mutation is rare in Korea and occasionally accompanied by other common EGFR mutations. Although the response to systemic CTx. in these patients is comparable to that of patients with other mutations, the response rate to firstor second-generation EGFR TKIs is quite low. Therefore, the development of a more efficient agent is urgently needed.

Citations

Citations to this article as recorded by

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
Pasi A. Jänne, Bin-Chao Wang, Byoung Chul Cho, Jun Zhao, Juan Li, Maximilian Hochmair, Solange Peters, Benjamin Besse, Nick Pavlakis, Joel W. Neal, Terufumi Kato, Yi-Long Wu, Danny Nguyen, Junjing Lin, Jianchang Lin, Florin Vranceanu, Annette Szumski, Hua
Journal of Clinical Oncology.2025; 43(13): 1553. CrossRef
The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of EGFR exon 20: A retrospective analysis
Ke-Jun Liu, Hong-Rui Li, Quan-Quan Tan, Tao Jiang, Kai-Cheng Peng, Hua-Jun Chen, Qing Zhou, Xu-Chao Zhang, Zheng Zheng, Shi-Yuan Chen, Xue Zheng, Hong-Bo Zheng, Bei-Bei Mao, Long-Long Gong, Xian-Wen Chen, Wendy Wu, Yi-Long Wu, Jun Jia, Jin-Ji Yang
Science Progress.2025;[Epub] CrossRef
Amivantamab versus standard therapies among patients with advanced non-small cell lung cancer and epidermal growth factor receptor exon 20 insertion mutations after platinum-based therapy in China
Lan Shen, Guangyuan Hu, Yan Wang, Jing Zhao, Xin Li, Jianmin Zhuo, Grace Kah Mun Low, Shun Lu
BMC Pulmonary Medicine.2025;[Epub] CrossRef
Current paradigm of EGFR in non-small cell lung cancer: A long way forward
Beatriz Viesser Miyamura, Isa Mambetsariev, Jeremy Fricke, Javier Arias-Romero, Karla Cadman, Sagun Shrestha, Evan Pisick, Danny Nguyen, Jyoti Malhotra, Amanda Reyes, Ravi Salgia
Med.2025; 6(9): 100803. CrossRef
Efficacy of Chemotherapy Combined With Immunotherapy in Advanced Lung Adenocarcinoma Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations: A Retrospective Comparative Study
Ying Zhao, Xiujing Yao, Ruyue Li, Xue Dong, Ying Li, Yintao Li
Cancer Pathogenesis and Therapy.2025;[Epub] CrossRef
Genetic Alteration Profiling in North Macedonian Lung Cancer Patients
Aleksandar Eftimov, Rubens Jovanovic, Slavica Kostadinova Kunovska, Magdalena Bogdanovska Todorovska, Boro Ilievski, Panche Zdravkovski, Selim Komina, Blagica Krstevska, Simonida Crvenkova, Marija Simonovska, Gordana Petrushevska
Genes.2025; 16(10): 1177. CrossRef
Advances in the Diagnosis and Treatment of Advanced Non–Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
Jingwen Liu, Yan Xiang, Tingwen Fang, Lulin Zeng, Ao Sun, Yixiang Lin, Kaihua Lu
Clinical Lung Cancer.2024; 25(2): 100. CrossRef
Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability
Maximilian J. Hochmair, Mojca Unk, Jelena Spasic, Timur Cerić, Assia Konsoulova, Mircea Dediu, Krisztina Bogos, Alinta Hegmane, Kersti Oselin, Marko Stojiljkovic, Tina Roblek, Marko Jakopovic
BMC Proceedings.2024;[Epub] CrossRef
Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia
Masanobu Okahisa, Hibiki Udagawa, Shingo Matsumoto, Terufumi Kato, Hiroshi Yokouchi, Naoki Furuya, Ryota Kanemaru, Ryo Toyozawa, Akihiro Nishiyama, Kadoaki Ohashi, Shingo Miyamoto, Kazumi Nishino, Atsushi Nakamura, Eiji Iwama, Seiji Niho, Hajime Oi, Tetsu
Lung Cancer.2024; 191: 107798. CrossRef
The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation
Xiuyue Man, Xueru Sun, Chen Chen, Yan Xiang, Jing Zhang, Lei Yang
Frontiers in Oncology.2024;[Epub] CrossRef
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
Pınar Gursoy, Ali Murat Tatli, Dilek Erdem, Erdem Goker, Emir Celik, Nebi Serkan Demirci, Abdullah Sakin, Muhammed Mustafa Atci, Ertuğrul Bayram, Tuğba Akın Telli, Burak Bilgin, Ahmet Bilici, Baran Akangunduz, Sevinç Balli, Ahmet Demirkazik, Fatih Selçukb
Journal of Cancer Research and Clinical Oncology.2023; 149(2): 865. CrossRef
Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison
Sai-Hong I. Ou, Huamao M. Lin, Jin-Liern Hong, Yu Yin, Shu Jin, Jianchang Lin, Minal Mehta, Pingkuan Zhang, Danny Nguyen, Joel W. Neal
Lung Cancer.2023; 179: 107186. CrossRef
EGFR and ERBB2 exon 20 insertion/duplication in advanced non–small cell lung cancer: genomic profiling and clinicopathologic features
Ramakrishna R. Sompallae, Bilge Dundar, Natalya V. Guseva, Aaron D. Bossler, Deqin Ma
Frontiers in Oncology.2023;[Epub] CrossRef
Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions
Ying-Ting Liao, Lei-Chi Wang, Ruei-Lin Sun, Yi-Chen Yeh, Hsu-Ching Huang, Chia-I Shen, Yen-Han Tseng, Tsu-Hui Hsiao, Heng-Sheng Chao, Yung-Hung Luo, Yuh-Min Chen, Chi-Lu Chiang
Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10365. CrossRef
EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies
Qianming Bai, Jialei Wang, Xiaoyan Zhou
Cancer Treatment Reviews.2023; 120: 102605. CrossRef
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments
Fenneke Zwierenga, Bianca A.M.H. van Veggel, Anke van den Berg, Harry J.M. Groen, Lili Zhang, Matthew R. Groves, K. Kok, E.F. Smit, T. Jeroen N. Hiltermann, Adrianus J. de Langen, Anthonie J. van der Wekken
Cancer Treatment Reviews.2023; 120: 102628. CrossRef
Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer
Binyang Pan, Jiaqi Liang, Haochun Shi, Kungeng Rao, Weigang Guo, Cheng Zhan
Thoracic Cancer.2023; 14(33): 3247. CrossRef
Aumolertinib-based comprehensive treatment for an uncommon site of EGFR exon 20 insertion mutations with multiple metastases non-small cell lung cancer: a case report
Youjun Deng, Chenglin Yang, Wenyi Liu, Songhua Cai, Xiaotong Guo
Anti-Cancer Drugs.2022; 33(4): 406. CrossRef
Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer
Neeraj Gupta, Philippe B. Pierrillas, Michael J. Hanley, Steven Zhang, Paul M. Diderichsen
CPT: Pharmacometrics & Systems Pharmacology.2022; 11(6): 731. CrossRef
Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
Timothée Olivier, Vinay Prasad
Translational Oncology.2022; 23: 101475. CrossRef
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
Yasir Y. Elamin, Jacqulyne P. Robichaux, Brett W. Carter, Mehmet Altan, Hai Tran, Don L. Gibbons, Simon Heeke, Frank V. Fossella, Vincent K. Lam, Xiuning Le, Marcelo V. Negrao, Monique B. Nilsson, Anisha Patel, R.S.K. Vijayan, Jason B. Cross, Jianjun Zhan
Cancer Cell.2022; 40(7): 754. CrossRef
EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors
Guangjian Yang, Yaning Yang, Jiaqi Hu, Haiyan Xu, Shuyang Zhang, Yan Wang
Frontiers in Pharmacology.2022;[Epub] CrossRef
The mechanism of action of different generations of EGFR-inhibitors in malignant lung tumors. Literature review and data synthesis
Ainur F. Nasretdinov, Konstantin V. Menshikov, Alexander V. Sultanbaev, Shamil I. Musin, Nadezda I. Sultanbaeva, Irina A. Men'shikova
Journal of Modern Oncology.2022; 24(3): 340. CrossRef
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
Maria Garcia Campelo, Caicun Zhou, Suresh Ramalingam, Huamao Lin, Tae Kim, Gregory Riely, Tarek Mekhail, Danny Nguyen, Erin Goodman, Minal Mehta, Sanjay Popat, Pasi Jänne
Journal of Clinical Medicine.2022; 12(1): 112. CrossRef
Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations
Guang-Jian Yang, Jun Li, Hai-Yan Xu, Yang Sun, Liu Liu, Hong-Shuai Li, Lu Yang, Yuan Zhang, Guo-Hui Li, Yan Wang
Lung Cancer.2021; 152: 39. CrossRef
Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review
Heather Burnett, Helena Emich, Chris Carroll, Naomi Stapleton, Parthiv Mahadevia, Tracy Li, Rama Krishna Kancha
PLOS ONE.2021; 16(3): e0247620. CrossRef
Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions
Noura J. Choudhury, Adam J. Schoenfeld, Jessica Flynn, Christina J. Falcon, Hira Rizvi, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Glenn Heller, Helena A. Yu, Marc Ladanyi, Gregory J. Riely
Clinical Cancer Research.2021; 27(10): 2920. CrossRef
EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non–Small Cell Lung Cancer
Jose Luis Leal, Marliese Alexander, Malinda Itchins, Gavin M. Wright, Steven Kao, Brett G.M. Hughes, Nick Pavlakis, Stephen Clarke, Anthony J Gill, Hannah Ainsworth, Benjamin Solomon, Thomas John
Clinical Lung Cancer.2021; 22(6): e859. CrossRef
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
Gregory J. Riely, Joel W. Neal, D. Ross Camidge, Alexander I. Spira, Zofia Piotrowska, Daniel B. Costa, Anne S. Tsao, Jyoti D. Patel, Shirish M. Gadgeel, Lyudmila Bazhenova, Viola W. Zhu, Howard L. West, Tarek Mekhail, Ryan D. Gentzler, Danny Nguyen, Sylv
Cancer Discovery.2021; 11(7): 1688. CrossRef
Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions
Chie Morita, Tatsuya Yoshida, Masayuki Shirasawa, Ken Masuda, Yuji Matsumoto, Yuki Shinno, Shigehiro Yagishita, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Noriko Motoi, Yasushi Yatabe, Yuichiro Ohe
Scientific Reports.2021;[Epub] CrossRef
EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
Samy Chelabi, Xavier Mignard, Karen Leroy, Isabelle Monnet, Solenn Brosseau, Nathalie Theou-Anton, Marie-Ange Massiani, Sylvie Friard, Boris Duchemann, Elizabeth Fabre, Etienne Giroux-Leprieur, Jacques Cadranel, Marie Wislez
Cancers.2021; 13(20): 5132. CrossRef
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim, Sang-We Kim, James Chih-Hsin Yang, Gregory J. Riely, Tarek Mekhail, Danny Nguyen, Maria R. Garcia Campelo, Enriqueta Felip, Sylvie Vincent, Shu Jin, Celina Griffin, Veronica Bunn, Jianchang Lin, Huamao M. Li
JAMA Oncology.2021; 7(12): e214761. CrossRef
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes
Christos Chouaid, Thomas Filleron, Didier Debieuvre, Maurice Pérol, Nicolas Girard, Eric Dansin, Hervé Lena, Radj Gervais, Sophie Cousin, Josiane Otto, Roland Schott, David Planchard, Anne Madroszyk, Courèche Kaderbhai, Pascale DUBRAY-Longeras, Sandrine H
Targeted Oncology.2021; 16(6): 801. CrossRef
External Quality Assurance of Current Technology for the Testing of Cancer-Associated Circulating Free DNA Variants
Sze Yee Chai, Rongxue Peng, Rui Zhang, Li Zhou, Nalishia Pillay, Kwang Hong Tay, Tony Badrick, Jinming Li, Martin P. Horan
Pathology & Oncology Research.2020; 26(3): 1595. CrossRef
Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
B. van Veggel, J.F. Vilacha Madeira R Santos, S.M.S. Hashemi, M.S. Paats, K. Monkhorst, D.A.M. Heideman, M. Groves, T. Radonic, E.F. Smit, E. Schuuring, A.J. van der Wekken, A.J. de Langen
Lung Cancer.2020; 141: 9. CrossRef
EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study
Guangjian Yang, Jun Li, Haiyan Xu, Yaning Yang, Lu Yang, Fei Xu, Bing Xia, Viola W. Zhu, Misako Nagasaka, Yan Yang, Yapin Li, Weini Qiu, Jianming Ying, Sai-Hong Ignatius Ou, Yan Wang
Lung Cancer.2020; 145: 186. CrossRef
Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors
YanRu Qin, Hong Jian, Xiaoling Tong, Xue Wu, Fufeng Wang, Yang W. Shao, Xinmin Zhao
Molecular Oncology.2020; 14(8): 1695. CrossRef
The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
Shang-Gin Wu, Chong-Jen Yu, James Chih-Hsin Yang, Jin-Yuan Shih
Therapeutic Advances in Medical Oncology.2020;[Epub] CrossRef
Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India
Varsha Singh, Aruna Nambirajan, Prabhat Singh Malik, Sanjay Thulkar, Ravindra Mohan Pandey, Kalpana Luthra, Sudheer Arava, Ruma Ray, Anant Mohan, Deepali Jain
Lung Cancer.2020; 149: 53. CrossRef
Effectiveness of Treatments for Advanced Non–Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations
Jenn-Yu Wu, Chong-Jen Yu, Jin-Yuan Shih
Clinical Lung Cancer.2019; 20(6): e620. CrossRef
Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
J. Chantharasamee, N. Poungvarin, P. Danchaivijitr, S. Techawatanawanna
BMC Cancer.2019;[Epub] CrossRef
Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas
Ya Gao, Wies R. Vallentgoed, Pim J. French
Cancers.2018; 10(12): 489. CrossRef

19,634 View
738 Download
48 Web of Science
42 Crossref

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib: Youjin Kim, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jong-Mu Sun; Cancer Res Treat. 2019;51(2):502-509. Published online June 13, 2018; DOI: https://doi.org/10.4143/crt.2018.117

Abstract PDF Supplementary Material PubReader ePub

Purpose
We tried to evaluate whether there are any specific features in treatment outcomes of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), compared with gefitinib or erlotinib.
Materials and Methods
We analyzed patients treated with first-line afatinib, gefitinib, or erlotinib for advanced EGFR-mutant NSCLC at Samsung Medical Center between 2014 and 2016.
Results
In total, 467 patients received first-line afatinib (n=165), gefitinib (n=230), or erlotinib (n=72). Afatinib was used more often in patients with tumors harboring deletion in exon 19 (Del19), whereas the gefitinib group had more elderly, females, and never smokers. The median progression-free survival (PFS) time for afatinib, gefitinib, and erlotinib was 19.1 months, 13.7 months, and 14.0 months, respectively (p=0.001). The superior PFS of afatinib was more remarkable in subgroups of Del19 or uncommon EGFR mutations. Overall toxicity profiles of the three drugs were comparable, though more grade 3 or 4 toxicities were detected in afatinib (7.3%) compared with gefitinib (2.6%) or erlotinib (1.8%). The common grade 3 or 4 toxicities of afatinib included diarrhea (3.0%), paronychia (2.4%), and skin rash (1.8%). Dose modification was more frequently required in patients treated with afatinib (112/165, 68%), compared with gefitinib (5/230, 2%) and erlotinib (4/72, 6%). Interestingly, however, dose reduction in the afatinib group did not impair its efficacy in terms of PFS (dose reduction vs. no reduction group, 23.5 months vs. 12.4 months).
Conclusion
First-line afatinib showed satisfactory efficacy data and manageable toxicity profiles.

Citations

Citations to this article as recorded by

Discovery of novel dual tubulin and MMPs inhibitors for the treatment of lung cancer and overcoming drug resistance
Guimei Li, Meng Wang, Li Luo, Demin Tang, Nan Xu, Rizhen Huang, Yong Yang, Guiping Chen, Zhikun Liu, Hengshan Wang, Xiaochao Huang
European Journal of Medicinal Chemistry.2025; 285: 117249. CrossRef
STAT3 mediates CAF-induced osimertinib resistance via regulating protein secretion in non-small cell lung cancer
Xuchen Fan, Sheng Wu, Honglong Wu, Yingying Huang, Xuhui Tong, Meiling Yu, Zhe Liu
Frontiers in Pharmacology.2025;[Epub] CrossRef
A momentous progress update: epidermal growth factor receptor inhibitors as viable agents for combating cancer
Neha Jangra, Bharti Sharma, Deepak Kumar, Archana Kapoor
RSC Medicinal Chemistry.2025; 16(9): 3893. CrossRef
Tyrosine kinase inhibitors in first-line treatment of advanced NSCLC with epidermal growth factor receptor mutations: Real-world data from Vietnam
KHANH TOAN NGUYEN, THI HUONG PHAM, VAN LAM NGO, VAN TUAN BUI, VAN NHAT NGUYEN, THI PHUONG THAO NGUYEN, THI KHANH HA NGUYEN, THI THUY VAN NGUYEN
Oncology Research.2025; 33(7): 1667. CrossRef
Novel bioactive 2‐phenyl‐4‐aminopyrimidine derivatives as EGFRDel19/T790M/C797S inhibitors for the treatment of non‐small cell lung cancer
Shidi Xu, Zhihui Zhou, Jie He, Jiaojiao Guo, Xiaoling Huang, Yufeng An, Qingshan Pan, Shan Xu, Wufu Zhu
Archiv der Pharmazie.2024;[Epub] CrossRef
Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study
Tae-Hwan Kim, Jin-Hyuk Choi, Mi Sun Ahn, Hyun Woo Lee, Seok Yun Kang, Yong Won Choi, Young Wha Koh, Seung-Soo Sheen
BMC Cancer.2024;[Epub] CrossRef
A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam
Cam Phuong Pham, Thi Thai Hoa Nguyen, Anh Tu Do, Tuan Khoi Nguyen, Thi Anh Thu Hoang, Tuan Anh Le, Dinh Thy Hao Vuong, Dac Nhan Tam Nguyen, Van Khiem Dang, Thi Oanh Nguyen, Van Luan Pham, Minh Hai Nguyen, Thi Huyen Trang Vo, Hung Kien Do, Ha Thanh Vu, Thi
BMC Cancer.2024;[Epub] CrossRef
Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review
Maxime Borgeaud, Kaushal Parikh, Giuseppe Luigi Banna, Floryane Kim, Timothée Olivier, Xiuning Le, Alfredo Addeo
Journal of Thoracic Oncology.2024; 19(7): 973. CrossRef
Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam
Van Luan Pham, Tuan Anh Le, Cam Phuong Pham, Thi Thai Hoa Nguyen, Anh Tu Do, Tuan Khoi Nguyen, Minh Hai Nguyen, Thi Anh Thu Hoang, Dinh Thy Hao Vuong, Dac Nhan Tam Nguyen, Van Khiem Dang, Thi Oanh Nguyen, Thi Huyen Trang Vo, Hung Kien Do, Ha Thanh Vu, Thi
Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
Harnessing molecular hybridization approach to discover novel quinoline EGFR-TK inhibitors for cancer treatment
Noha Ryad, Ayman Abo Elmaaty, Ibrahim M Ibrahim, Ali Hassan Ahmed Maghrabi, Maryam Abdulrahman Yahya Alahdal, Rasha Mohammed Saleem, Islam Zaki, Lina M A Abdel Ghany
Future Medicinal Chemistry.2024; 16(11): 1087. CrossRef
Lung cancer and pregnancy
A. L. Chernyshova, A. A. Chernyakov, Ju. M. Trushjuk, O. S. Dil, A. E. Chernyshova
PULMONOLOGIYA.2024; 34(4): 544. CrossRef
Cytotoxicity and inhibitory potential of CUDC-101 in non-small cell lung cancer cells with rare EGFR L861Q mutation
Chunhong Chu, Huixia Xu, Chenxue Liu, Xiangkai Wei, Lanxin Li, Rui Wang, Wenrui Cui, Guoliang Zhang, Chenyang Liu, Ke Wang, Lei An, Fei He
Current Research in Toxicology.2024; 7: 100194. CrossRef
Design and synthesis of novel 2-(2-(4-bromophenyl)quinolin-4-yl)-1,3,4-oxadiazole derivatives as anticancer and antimicrobial candidates: in vitro and in silico studies
Noha Ryad, Ayman Abo Elmaaty, Samy Selim, Mohammed S. Almuhayawi, Soad K. Al Jaouni, Mohamed S. Abdel-Aziz, Arwa Sultan Alqahtani, Islam Zaki, Lina M. A. Abdel Ghany
RSC Advances.2024; 14(46): 34005. CrossRef
Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea
Cliff Molife, Jae Min Cho, Jennifer Lapthorn, Min Ju Kang, Yulia D’yachkova, Sangmi Kim, Sam Colman, Saerom Kim, Agota Szende, Ji Hyun Park, Hee Kyung Ahn, Min Hee Hong, Kaisa-Leena Taipale, Hye Ryun Kim
Drugs - Real World Outcomes.2023; 10(1): 131. CrossRef
Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer
Pamela Soberanis Pina, Luis Lara-Mejía, Venecia Matias-Cruz, Feliciano Barrón, Andrés F. Cardona, Luis E. Raez, Eduardo Rios-Garcia, Oscar Arrieta
Frontiers in Oncology.2023;[Epub] CrossRef
Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer
Gian Marco Leone, Saverio Candido, Alessandro Lavoro, Silvia Vivarelli, Giuseppe Gattuso, Daniela Calina, Massimo Libra, Luca Falzone
Pharmaceutics.2023; 15(4): 1252. CrossRef
Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 Retrospective Cohort Study
Vineeth Tatineni, Patrick J. O’Shea, Shreya Saxena, Atulya A. Khosla, Ahmad Ozair, Rupesh R. Kotecha, Xuefei Jia, Yasmeen Rauf, Erin S. Murphy, Samuel T. Chao, John H. Suh, David M. Peereboom, Manmeet S. Ahluwalia
Cancers.2023; 15(11): 3015. CrossRef
Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma
Daniela Cárdenas-Fernández, Pamela Soberanis Pina, Jenny G. Turcott, Norberto Chávez-Tapia, Emilio Conde-Flores, Andrés F. Cardona, Oscar Arrieta
Therapeutic Advances in Medical Oncology.2023;[Epub] CrossRef
Design and Synthesis of Novel Pyrazolopyrimidine Candidates As Promising EGFR-T790M Inhibitors and Apoptosis Inducers
Ahmed A Gaber, Marwa Sharaky, Ayman Abo Elmaaty, Mohamed M Hammouda, Ahmed AE Mourad, Samy Y Elkhawaga, Mahmoud Mohamed Mokhtar, Amr S Abouzied, Mai AE Mourad, Ahmed A Al-Karmalawy
Future Medicinal Chemistry.2023; 15(19): 1773. CrossRef
Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs
Huang‐Chih Chang, Chin‐Chou Wang, Chia‐Cheng Tseng, Kuo‐Tung Huang, Yu‐Mu Chen, Yu‐Ping Chang, Chien‐Hao Lai, Wen‐Feng Fang, Meng‐Chih Lin, Hung‐Yi Chuang
Thoracic Cancer.2023; 14(32): 3208. CrossRef
Survival outcomes of east Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR tyrosine kinase inhibitors: A network meta‐analysis of real‐world evidence
Huang‐Chih Chang, Kuo‐Tung Huang, Chia‐Cheng Tseng, Yu‐Mu Chen, Chien‐Hao Lai, Yu‐Ping Chang, Yung‐Che Chen, Hung‐Yi Chuang, Chin‐Chou Wang
Thoracic Cancer.2023; 14(32): 3217. CrossRef
Pyrrolo[2,1-f][1,2,4]triazine: a promising fused heterocycle to target kinases in cancer therapy
Sarbjit Singh, Divya Utreja, Vimal Kumar
Medicinal Chemistry Research.2022; 31(1): 1. CrossRef
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J.W. Chen, Gee-Chen Chang
Cancer Research and Treatment.2022; 54(2): 434. CrossRef
Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma
Chiao-En Wu, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Kuo, Ping-Chih Hsu, John Chang
Cancers.2022; 14(3): 674. CrossRef
Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu
Cancers.2022; 14(4): 977. CrossRef
Two Unusual Mutations in the Epidermal Growth Factor Receptor Gene in a Patient With Lung Adenocarcinoma
Martin Zapata Laguado, Andrea Zuluaga, Rafael Parra Medina, Ricardo Bruges
Cureus.2022;[Epub] CrossRef
Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands
Hong-Yi Zhao, Hai-Peng Wang, Yu-Ze Mao, Hao Zhang, Minhang Xin, Xiao-Xiao Xi, Hao Lei, Shuai Mao, Dong-Hui Li, San-Qi Zhang
Journal of Medicinal Chemistry.2022; 65(6): 4709. CrossRef
Cost-Effectiveness Analysis of Afatinib versus Gefitinib in Non-small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Mutation in Indonesia: Observational studies with Retrospectives
Seftika Sari, Tri Murti Andayani, Dwi Endarti, Kartika Widayati
Research Journal of Pharmacy and Technology.2022; : 1598. CrossRef
Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
Rong Liu, Jianying Zhou, Xia Ling
Clinical Medicine Insights: Oncology.2022;[Epub] CrossRef
Pharmacokinetic and Safety Comparison of 2 Afatinib Dimaleate Tablets in Healthy Chinese Volunteers Under Fasted Conditions: A Randomized, Open‐Label, 2‐Period, Single‐Dose Crossover Study
Ping Shi, Xin Jiang, Ye Tao, Ting Li, Xin Li, Chenjing Wang, Yanping Liu, Yaping Ma, Xiaomeng Gao, Yu Cao
Clinical Pharmacology in Drug Development.2022; 11(10): 1177. CrossRef
Grb2 interacts with necrosome components and is involved in rasfonin-induced necroptosis
Bolin Hou, Haiwen Huang, Yueqian Li, Jingnan Liang, Zhijun Xi, Xuejun Jiang, Ling Liu, Erwei Li
Cell Death Discovery.2022;[Epub] CrossRef
Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs
Hong-Yi Zhao, Xiao-Xiao Xi, Minhang Xin, San-Qi Zhang
Bioorganic Chemistry.2022; 128: 106057. CrossRef
Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity
Amr Sonousi, Rasha A. Hassan, Eman O. Osman, Amr M. Abdou, Soha H. Emam
Journal of Enzyme Inhibition and Medicinal Chemistry.2022; 37(1): 2644. CrossRef
Analysis of non-small cell lung cancer with miliary lung metastasis in patients harboring epidermal growth factor receptor mutations
Ming-Hung Chang, Kuo-Hwa Chiang, Jiunn-Min Shieh, Kuo-Chen Cheng, Chung-Han Ho
Scientific Reports.2022;[Epub] CrossRef
Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations
Kartik Sehgal, Deepa Rangachari, Paul A. VanderLaan, Susumu S. Kobayashi, Daniel B. Costa
The Oncologist.2021; 26(4): 281. CrossRef
Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A
Cheol‐Kyu Park, Sung‐Yong Lee, Jae Cheol Lee, Chang‐Min Choi, Shin Yup Lee, Tae‐Won Jang, In‐Jae Oh, Young‐Chul Kim
Thoracic Cancer.2021; 12(4): 444. CrossRef
Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells
Boonyakorn Boonsri, Kiren Yacqub-Usman, Pakpoom Thintharua, Kyaw Zwar Myint, Thannicha Sae-Lao, Pam Collier, Chinnawut Suriyonplengsaeng, Noppadol Larbcharoensub, Brinda Balasubramanian, Simran Venkatraman, Isioma U. Egbuniwe, Dhanwant Gomez, Abhik Mukher
Cancer Research and Treatment.2021; 53(2): 457. CrossRef
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
Sheng-Kai Liang, Li-Ta Keng, Chia-Hao Chang, Yueh-Feng Wen, Meng-Rui Lee, Ching-Yao Yang, Jann-Yuan Wang, Jen-Chung Ko, Jin-Yuan Shih, Chong-Jen Yu
Frontiers in Oncology.2021;[Epub] CrossRef
Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
Sojung Park, Sung Yong Lee, Dojin Kim, Yun Su Sim, Jeong-Seon Ryu, Juwhan Choi, Su Hwan Lee, Yon Ju Ryu, Jin Hwa Lee, Jung Hyun Chang
BMC Cancer.2021;[Epub] CrossRef
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study
Burak Bilgin, Mehmet Ali Nahit Sendur, Sebnem Yucel, Emir Celik, Deniz Tataroglu Ozyukseler, Murat Ayhan, Tugba Basoglu, Aysegul Ilhan, Nadiye Akdeniz, Ahmet Gulmez, Izzet Dogan, Burak Yasin Aktas, Mustafa Gurbuz, Sinan Koca, Semra Paydas, Ali Murat Tatli
Journal of Cancer Research and Clinical Oncology.2021; 147(7): 2145. CrossRef
Gefitinib reduces oocyte quality by disturbing meiotic progression
Hong-Yong Zhang, Ying-Chun Ouyang, Jian Li, Chun-Hui Zhang, Wei Yue, Tie-Gang Meng, Heide Schatten, Qing-Yuan Sun, Wei-Ping Qian
Toxicology.2021; 452: 152705. CrossRef
Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study
Kristof Cuppens, Liesbet Lodewyckx, Ingel Demedts, Lore Decoster, Benoît Colinet, Koen Deschepper, Annelies Janssens, Daniella Galdermans, Thierry Pieters
Drugs - Real World Outcomes.2021; 8(2): 141. CrossRef
Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
Shun Lu, Jin-Yuan Shih, Tae-Won Jang, Chong-Kin Liam, Yongfeng Yu
Advances in Therapy.2021; 38(5): 2038. CrossRef
PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment
Cheng-Yu Chang, Yi-Chun Lai, Yu-Feng Wei, Chung-Yu Chen, Shih-Chieh Chang
OncoTargets and Therapy.2021; Volume 14: 2301. CrossRef
Egfr Tyrosine Kinase Inhibitors for EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Outcomes in Asian Populations
Edward S Kim, Barbara Melosky, Keunchil Park, Nobuyuki Yamamoto, James C - H Yang
Future Oncology.2021; 17(18): 2395. CrossRef
The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Tsung-Ying Yang, Gee-Chen Chang
Scientific Reports.2021;[Epub] CrossRef
Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
Antonio Passaro, Filippo de Marinis, Hai-Yan Tu, Konstantin K. Laktionov, Jifeng Feng, Artem Poltoratskiy, Jun Zhao, Eng Huat Tan, Maya Gottfried, Victor Lee, Dariusz Kowalski, Cheng Ta Yang, BJ Srinivasa, Laura Clementi, Tejaswini Jalikop, Dennis Chin Lu
Frontiers in Oncology.2021;[Epub] CrossRef
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
Keunchil Park, Jin-Soo Kim, Joo-Hang Kim, Young-Chul Kim, Hoon-Gu Kim, Eun Kyung Cho, Jong-Youl Jin, Miyoung Kim, Angela Märten, Jin-Hyoung Kang
BMC Cancer.2021;[Epub] CrossRef
Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non‐small‐cell lung cancer harboring EGFR mutations: Results from a real‐world study in South Korea
Taeyun Kim, Tae Won Jang, Chang Min Choi, Mi‐Hyun Kim, Sung Yong Lee, Cheol‐Kyu Park, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong Seon Ryu, Jeong Eun Lee, Shin Yup Lee, Chan Kwon Park, Sang Hoon Lee, Seung Hun Jang, Seong Hoon Yoon
Cancer Medicine.2021; 10(17): 5809. CrossRef
Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
Chiao-En Wu, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, John Wen-Cheng Chang
BMC Cancer.2021;[Epub] CrossRef
Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
Po-Yen Chen, Chin-Chou Wang, Chien-Ning Hsu, Chung-Yu Chen
Frontiers in Pharmacology.2021;[Epub] CrossRef
Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?
Filippo Papini, Janani Sundaresan, Alessandro Leonetti, Marcello Tiseo, Christian Rolfo, Godefridus J. Peters, Elisa Giovannetti
Critical Reviews in Oncology/Hematology.2021; 166: 103454. CrossRef
Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer
Hayato Yokota, Kazuhiro Sato, Sho Sakamoto, Yuji Okuda, Mariko Asano, Masahide Takeda, Katsutoshi Nakayama, Masatomo Miura
Biology.2021; 10(10): 1054. CrossRef
Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
Yamin Shu, Qilin Zhang, Xucheng He, Li Chen
Cancer Management and Research.2021; Volume 13: 8297. CrossRef
Impact of Dose Reduction of Afatinib Used in Patients With Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Ziyu Wang, Xin Du, Ken Chen, Shanshan Li, Zhiheng Yu, Ziyang Wu, Li Yang, Dingding Chen, Wei Liu
Frontiers in Pharmacology.2021;[Epub] CrossRef
EFIKASI TERAPI EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (EGFR-TKIs) PADA KANKER PARU
Fitri Wulandari, Widyaningrum Utami, Evieta Rohana, Wimzy Rizqy Prabhata
Generics: Journal of Research in Pharmacy.2021;[Epub] CrossRef
Comparing the effectiveness of different EGFR‐TKIs in patients with EGFR mutant non–small‐cell lung cancer: A retrospective cohort study in Taiwan
Yao‐Yu Hsieh, Wei‐Tse Fang, Yu‐Wen Lo, Yi‐Han Chen, Li‐Nien Chien
International Journal of Cancer.2020; 147(4): 1107. CrossRef
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases
James Chih-Hsin Yang, Martin Schuler, Sanjay Popat, Satoru Miura, Simon Heeke, Keunchil Park, Angela Märten, Edward S. Kim
Journal of Thoracic Oncology.2020; 15(5): 803. CrossRef
Anticancer activity evaluation of indazolyl-substituted piperidin-4-yl-aminopyrimidines
Chao Wang, Xiao-Wen Liu, Ting Xiao, Zhi-Qiang Xu, Shuang Cao, Hai-Feng Wang, Qiong-Jiao Yan, Shuang-Xi Gu, Yuan-Yuan Zhu
Medicinal Chemistry Research.2020; 29(5): 910. CrossRef
Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer
Xiao-yun Liu, Zi-tao Guo, Zhen-dong Chen, Yi-fan Zhang, Jia-lan Zhou, Yong Jiang, Qian-yu Zhao, Xing-xing Diao, Da-fang Zhong
Acta Pharmacologica Sinica.2020; 41(10): 1366. CrossRef
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives
Giulia Sartori, Lorenzo Belluomini, Fiorella Lombardo, Alice Avancini, Ilaria Trestini, Emanuele Vita, Daniela Tregnago, Jessica Menis, Emilio Bria, Michele Milella, Sara Pilotto
Expert Review of Anticancer Therapy.2020; 20(7): 531. CrossRef
Survival analysis of afatinib versus erlotinib for individuals with advanced del19 lung adenocarcinoma with asymptomatic brain metastasis after pemetrexed-cisplatin chemotherapy: a retrospective study
Ye Jiang, Wenli Chen, Weiguang Yu, Ning Shi, Guowei Han, Shuai Mao, Xinlei Zhang, Meiji Chen
Journal of International Medical Research.2020;[Epub] CrossRef
Real‐life effectiveness of first‐line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry
Kristian Brat, Monika Bratova, Jana Skrickova, Magda Barinova, Karolina Hurdalkova, Milos Pesek, Libor Havel, Leona Koubkova, Michal Hrnciarik, Jana Krejci, Ondrej Fischer, Milada Zemanova, Helena Coupkova, Martin Svaton
Thoracic Cancer.2020; 11(11): 3346. CrossRef
Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations
Shouzheng Wang, Puyuan Xing, Ke Yang, Xuezhi Hao, Di Ma, Yuxin Mu, Junling Li
Thoracic Cancer.2019; 10(6): 1461. CrossRef
Afatinib/gefitinib

Reactions Weekly.2019; 1753(1): 17. CrossRef
Current Approaches in NSCLC Targeting K-RAS and EGFR
Veronica Aran, Jasminka Omerovic
International Journal of Molecular Sciences.2019; 20(22): 5701. CrossRef
Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA
Jonathan Lim, Carl Samuelsen, Amanda Golembesky, Sulena Shrestha, Li Wang, Ingolf Griebsch
Future Oncology.2019; 15(13): 1493. CrossRef
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study
Maximilian J Hochmair, Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Amanda Golembesky, Angela Märten, Tanja Cufer
Future Oncology.2018; 14(27): 2861. CrossRef

15,291 View
819 Download
79 Web of Science
68 Crossref

Tumor-Associated Macrophages Derived TGF-β‒Induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells through Smad2,3-4/Snail Signaling Pathway: Jianhui Cai, Limin Xia, Jinlei Li, Shichang Ni, Huayu Song, Xiangbin Wu; Cancer Res Treat. 2019;51(1):252-266. Published online April 25, 2018; DOI: https://doi.org/10.4143/crt.2017.613

Abstract PDF Supplementary Material PubReader ePub

Purpose
We investigated the role of tumor-associated macrophages (TAMs) on the epithelial to mesenchymal transition (EMT) of colorectal cancer cells and determined the potential mechanism involved in the metastatic process.
Materials and Methods
In this study, flow cytometry was used to detect the expression of target proteins. We used transwell assay to evaluate the migration of cancer cells under specific conditions. Using real-time polymerase chain reaction, we examined the expressions of cytokines and EMT-related markers in mRNA level. Animal assay was performed for analysis in vivo and hematoxylin and eosin was used to visualize the effect of TAMs on tumor metastasis. We also used immunohistochemistry and Western blotting to detect the expression of target proteins.
Results
Here, we observed enrichment of TAMs in colorectal tumor tissues, resulting in high metastasis in clinical therapy. Moreover, those TAMs could facilitate the EMT progression of colorectal cancer cells, which is induced by the transforming growth factor-β (TGF-β) derived from TAMs, leading to the invasion and migration of cancer cells.
Conclusion
Our results demonstrated that TAMs contributed the EMT progression through a TGF-β/Smad2,3-4/Snail signaling pathway, and disrupting this pathway with TGF-β receptor inhibitor could suppress metastasis, readjusting our focus to the connection of TAMs and cancer metastasis.

Citations

Citations to this article as recorded by

SMAD signaling in cancer: integrative roles in tumor progression, immune evasion, and therapeutic resistance
Hai Zhao, Fan Yang, Jiaxin Yang, Sheng Yang
Cytokine.2026; 198: 157090. CrossRef
GA inhibits CA9-mediated SMAD pathway to attenuate colon cancer metastasis and progression
Zhixin Zhang, Gang Cao, Lili Liang, Jinxuan Guo, Dandan Cheng, Zijian Zhao
Letters in Drug Design & Discovery.2026; : 100273. CrossRef
A paracrine-to-autocrine shunt of GREM1 fuels colorectal cancer metastasis via ACVR1C
Huaixiang Zhou, Qunlong Jin, Zhang Fu, Yanming Yang, Yunfei Gao, Niu Wang, Bo Zhao, Long Gui, Jiang Li, Zijing Zhu, Ying Zhang, Yulong He, Ying Zhang, Shouqing Luo, Li Fu, Xudong Wu, Guihua Wang, Zhiming Xu, Huiliang Li, Junjing Zhang, Xuetong Shen, Tao W
Molecular Cancer.2026;[Epub] CrossRef
Exploring the Role of the TGF-β Signaling Pathway in Colorectal Precancerous Polyps Biochemical Genetics
Shadi Sadri, Ali Aghajani, Hiva Soleimani, Sourena Ghorbani Kalkhajeh, Haniyeh Nazari, Peiman Brouki Milan, Noshad Peyravian, Zahra Pezeshkian, Maziar Malekzadeh Kebria, Fatemeh Shirazi, Elahe Shams, Fatemeh Naderi Noukabadi, Ehsan Nazemalhosseini-Mojarad
Biochemical Genetics.2025; 63(2): 1116. CrossRef
The multifaceted roles of macrophages in the transition from hepatitis to hepatocellular carcinoma: From mechanisms to therapeutic strategies
Shuairan Zhang, Hang Dong, Xiuli Jin, Jing Sun, Yiling Li
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2025; 1871(3): 167676. CrossRef
Cancer stem cells and tumor-associated macrophages as mates in tumor progression: mechanisms of crosstalk and advanced bioinformatic tools to dissect their phenotypes and interaction
Francesco Verona, Sebastiano Di Bella, Roberto Schirano, Camilla Manfredi, Francesca Angeloro, Giulia Bozzari, Matilde Todaro, Giuseppe Giannini, Giorgio Stassi, Veronica Veschi
Frontiers in Immunology.2025;[Epub] CrossRef
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Fan Guan, Ruixuan Wang, Zhenjie Yi, Peng Luo, Wanyao Liu, Yao Xie, Zaoqu Liu, Zhiwei Xia, Hao Zhang, Quan Cheng
Signal Transduction and Targeted Therapy.2025;[Epub] CrossRef
The tumor microenvironment is an ecosystem sustained by metabolic interactions
Emily Jane Kay, Sara Zanivan
Cell Reports.2025; 44(3): 115432. CrossRef
Nucleic acid coated photothermal nanoregulator for multiple therapy of drug-resistant breast cancer
Yuxin Shen, Yixin Wen, Sen Li, Xuefeng Ding, Yanfei Cai, Jian Jin, Zhaoqi Yang
International Journal of Biological Macromolecules.2025; 308: 142592. CrossRef
Immunoinformatic analysis of role of tumor microenvironment constituents secreted ligands in breast cancer progression, metastasis, prognosis, survival and development of effective tumor microenvironment directed therapeutic strategy
Pallabi Mondal, Krishna Mahanti, Sankar Bhattacharyya
In Silico Research in Biomedicine.2025; 1: 100017. CrossRef
Liver metastasis of colorectal cancer: Mechanism and clinical therapy (Review)
Changjiang Yang, Long Zhao, Caihong Wang, Yingjiang Ye, Zhanlong Shen
Oncology Reports.2025; 54(4): 1. CrossRef
A framework for the rational design of oncolytic viruses: A holistic perspective considering the tumour microenvironment
Dylan Thomas, Priya Bharadwa, Timothy Lee, Carolina S. Ilkow
Seminars in Immunology.2025; 79: 101977. CrossRef
Cholangiocarcinoma-derived SPP1 drives tumor progression by inducing macrophage chemotaxis and M2 polarization
Tianze Wang, Pinsheng Han, Chuanliang Cheng, Xingpeng Yang, Tong Wen, Dapeng Chen, Jinming Li, Xiangyu Liu, Xiyue Deng, Bai Yi, Yamin Zhang
International Immunopharmacology.2025; 167: 115650. CrossRef
Progress in research of premetastatic niche in colorectal cancer liver metastasis
Zhao-Chun Chi
World Chinese Journal of Digestology.2025; 33(11): 847. CrossRef
The role of matrix metalloproteinase-2 in the metastatic cascade: a review
Nigel P. Murray
Oncologie.2024; 26(1): 27. CrossRef
Tumor-associated macrophages in colorectal cancer metastasis: molecular insights and translational perspectives
Siyu Hou, Yuanchun Zhao, Jiajia Chen, Yuxin Lin, Xin Qi
Journal of Translational Medicine.2024;[Epub] CrossRef
The role of stromal cells in epithelial–mesenchymal plasticity and its therapeutic potential
Juanjing Wang, Junmei Peng, Yonglin Chen, M. I. Nasser, Hui Qin
Discover Oncology.2024;[Epub] CrossRef
Isolation and purification of polysaccharides from Bupleurum marginatum Wall.ex DC and their anti-liver fibrosis activities
Li Xiao, Hafsa Sunniya, Jingyi Li, Mohib Ullah Kakar, Rongji Dai, Bo Li
Frontiers in Pharmacology.2024;[Epub] CrossRef
Key players of immunosuppression in epithelial malignancies: Tumor‐infiltrating myeloid cells and γδ T cells
Baishali Tamuli, Sakshi Sharma, Meena Patkar, Subir Biswas
Cancer Reports.2024;[Epub] CrossRef
Correlation of tumor-associated macrophage density and proportion of M2 subtypes with the pathological stage of colorectal cancer
Fouzia Fazal, Muhammad Arsalan Khan, Sumayya Shawana, Rahma Rashid, Muhammed Mubarak
World Journal of Gastrointestinal Oncology.2024; 16(5): 1878. CrossRef
Reprogramming Tumor-Associated Macrophage Using Nanocarriers: New Perspectives to Halt Cancer Progression
Alyona B. Kuznetsova, Ekaterina P. Kolesova, Alessandro Parodi, Andrey A. Zamyatnin, Vera S. Egorova
Pharmaceutics.2024; 16(5): 636. CrossRef
Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy
Belén Toledo, Linrui Zhu Chen, María Paniagua-Sancho, Juan Antonio Marchal, Macarena Perán, Elisa Giovannetti
Journal of Hematology & Oncology.2024;[Epub] CrossRef
Unveiling the contribution of tumor-associated macrophages in driving epithelial-mesenchymal transition: a review of mechanisms and therapeutic Strategies
Yijia Zhang, Xiaofei Ding, Xue Zhang, Ye Li, Rui Xu, Hai-Jun Li, Daiying Zuo, Guang Chen
Frontiers in Pharmacology.2024;[Epub] CrossRef
The Role of Adipocytes Recruited as Part of Tumor Microenvironment in Promoting Colorectal Cancer Metastases
Yunxia Ma, Miljana Nenkov, Yuan Chen, Nikolaus Gaßler
International Journal of Molecular Sciences.2024; 25(15): 8352. CrossRef
Polarization of M2 Tumor-Associated Macrophages (TAMs) in Cancer Immunotherapy
Indy Bui, Benjamin Bonavida
Critical Reviews™ in Oncogenesis.2024; 29(4): 75. CrossRef
PPAR-γ/NF-kB/AQP3 axis in M2 macrophage orchestrates lung adenocarcinoma progression by upregulating IL-6
Guofu Lin, Lanlan Lin, Xiaohui Chen, Luyang Chen, Jiansheng Yang, Yanling Chen, Danwen Qian, Yiming Zeng, Yuan Xu
Cell Death & Disease.2024;[Epub] CrossRef
Mapping cellular interactions from spatially resolved transcriptomics data
James Zhu, Yunguan Wang, Woo Yong Chang, Alicia Malewska, Fabiana Napolitano, Jeffrey C. Gahan, Nisha Unni, Min Zhao, Rongqing Yuan, Fangjiang Wu, Lauren Yue, Lei Guo, Zhuo Zhao, Danny Z. Chen, Raquibul Hannan, Siyuan Zhang, Guanghua Xiao, Ping Mu, Ariell
Nature Methods.2024; 21(10): 1830. CrossRef
Elevated BEAN1 expression correlates with poor prognosis, immune evasion, and chemotherapy resistance in rectal adenocarcinoma
Tiannake Shapaer, Yi Chen, Yipeng Pan, Zhimin Wu, Tuoxian Tang, Zeliang Zhao, Xiangyue Zeng
Discover Oncology.2024;[Epub] CrossRef
MicroRNA-382 as a tumor suppressor during tumor progression
Yalda Samsami, Iman Akhlaghipour, Negin Taghehchian, Mahsa Palizkaran Yazdi, Saba Farrokhi, Hamid Reza Rahimi, Meysam Moghbeli
Bioorganic & Medicinal Chemistry Letters.2024; 113: 129967. CrossRef
Research progress of tumor-associated macrophages in immune checkpoint inhibitor tolerance in colorectal cancer
Qi Fan, Zheng-Wei Fu, Ming Xu, Feng Lv, Jia-Song Shi, Qi-Qi Zeng, De-Hai Xiong
World Journal of Gastrointestinal Oncology.2024; 16(10): 4064. CrossRef
Lidocaine combined with general anesthetics impedes metastasis of breast cancer cells via inhibition of TGF-β/Smad-mediated EMT signaling by reprogramming tumor-associated macrophages
Beom Seok Han, Soyeon Ko, Min Seok Park, Yun Ji Lee, Sang Eun Kim, Pureunchowon Lee, Ye Jin Cho, Han Gyeol Go, Sehan Kwak, Eunji Park, Ayoung Lim, Suji Lee, Seungjong Yoo, Hyunzu Kim, Kyung Hee Jung, Soon-Sun Hong
International Immunopharmacology.2024; 142: 113207. CrossRef
Targeted nanomedicine for reprogramming the tumor innate immune system: From bench to bedside
Kunal Pednekar, Julia Minnee, I. Jolanda M. de Vries, Jai Prakash
European Journal of Pharmaceutics and Biopharmaceutics.2024; 204: 114510. CrossRef
Natural compounds modulate the mechanism of action of tumour-associated macrophages against colorectal cancer: a review
Weichen Yuan, Jiexiang Zhang, Haibin Chen, Yupei Zhuang, Hongli Zhou, Wenting Li, Wenli Qiu, Hongguang Zhou
Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef
Retinoic acid-loaded PLGA nanocarriers targeting cell cholesterol potentialize the antitumour effect of PD-L1 antibody by preventing epithelial-mesenchymal transition mediated by M2-TAM in colorectal cancer
Raimundo Fernandes de Araújo Júnior, George A Lira, Timo Schomann, Rômulo S Cavalcante, Natalia Feitosa Vilar, Regina Célia Monteiro de Paula, Raelle Ferreira Gomes, Chih Kit Chung, Carla Jorquera-Cordero, Olena Vepris, Alan B Chan, Luis J. Cruz
Translational Oncology.2023; 31: 101647. CrossRef
The ceRNA network regulates epithelial-mesenchymal transition in colorectal cancer
Ruina Li, Hui Xu, Xiaoling Gao
Heliyon.2023; 9(3): e14143. CrossRef
Do Elevated YKL-40 Levels Drive the Immunosuppressive Tumor Microenvironment in Colorectal Cancer? Assessment of the Association of the Expression of YKL-40, MMP-8, IL17A, and PD-L1 with Coexisting Type 2 Diabetes, Obesity, and Active Smoking
Błażej Ochman, Sylwia Mielcarska, Agnieszka Kula, Miriam Dawidowicz, Julia Robotycka, Jerzy Piecuch, Monika Szrot, Sylwia Dzięgielewska-Gęsiak, Małgorzata Muc-Wierzgoń, Dariusz Waniczek, Elżbieta Świętochowska
Current Issues in Molecular Biology.2023; 45(4): 2781. CrossRef
TGFβ and the Tumor Microenvironment in Colorectal Cancer
Maximilian J. Waldner, Markus F. Neurath
Cells.2023; 12(8): 1139. CrossRef
Exosomes in metastasis of colorectal cancers: Friends or foes?
Zheng Wu, Ze-Xuan Fang, Yan-Yu Hou, Bing-Xuan Wu, Yu Deng, Hua-Tao Wu, Jing Liu
World Journal of Gastrointestinal Oncology.2023; 15(5): 731. CrossRef
Dynamic polarization of tumor-associated macrophages and their interaction with intratumoral T cells in an inflamed tumor microenvironment: from mechanistic insights to therapeutic opportunities
Jiashu Han, Luochu Dong, Mengwei Wu, Fei Ma
Frontiers in Immunology.2023;[Epub] CrossRef
MicroRNA functional metal-organic framework nanocomposite for efficient inhibition of drug-resistant breast cancer cells
Yuxin Shen, Yao Zhang, Xiyue Gao, Mengdi Shang, Yanfei Cai, Zhaoqi Yang
Emergent Materials.2023; 6(5): 1537. CrossRef
Impact of Opioids on Cellular Metabolism: Implications for Metabolic Pathways Involved in Cancer
Doorsa Tarazi, Jason T. Maynes
Pharmaceutics.2023; 15(9): 2225. CrossRef
Suppressing epithelial‐mesenchymal‐transition blue light therapy for reducing macrophage‐mediated cancerous pulmonary fibrosis: An in‐vitro study
Wenjun Zhang, Jianfei Dong
Journal of Biophotonics.2023;[Epub] CrossRef
Metastasis organotropism in colorectal cancer: advancing toward innovative therapies
Kai He, Zhihan Wang, Maochao Luo, Bowen Li, Ning Ding, Lei Li, Bo He, Han Wang, Jiangjun Cao, Canhua Huang, Jun Yang, Hai-Ning Chen
Journal of Translational Medicine.2023;[Epub] CrossRef
Thermal/ultrasound-triggered release of liposomes loaded with Ganoderma applanatum polysaccharide from microbubbles for enhanced tumour ablation
Jiani Yuan, Lei Ding, Lu Han, Lina Pang, Peidi Zhang, Xiao Yang, Haijing Liu, Minjuan Zheng, Yunfei Zhang, Wen Luo
Journal of Controlled Release.2023; 363: 84. CrossRef
MicroRNAs and their vital role in apoptosis in hepatocellular carcinoma: miRNA-based diagnostic and treatment methods
Masoumeh Hajizadeh, Farnaz Hajizadeh, Sevil Ghaffarei, Mohammad Amin Doustvandi, Khadijeh Hajizadeh, Seyyed Mohammad Yaghoubi, Fateme Mohammadnejad, Nadia Allahyarzadeh Khiabani, Pegah Mousavi, Behzad Baradaran
Gene.2023; 888: 147803. CrossRef
Tumour-associated macrophages: versatile players in the tumour microenvironment
Zoey Zeyuan Ji, Max Kam-Kwan Chan, Alex Siu-Wing Chan, Kam-Tong Leung, Xiaohua Jiang, Ka-Fai To, Yi Wu, Patrick Ming-Kuen Tang
Frontiers in Cell and Developmental Biology.2023;[Epub] CrossRef
Exploiting innate immunity for cancer immunotherapy
Ming Yi, Tianye Li, Mengke Niu, Qi Mei, Bin Zhao, Qian Chu, Zhijun Dai, Kongming Wu
Molecular Cancer.2023;[Epub] CrossRef
Functional and Therapeutic Significance of Tumor-Associated Macrophages in Colorectal Cancer
Yitong Li, Zhenmei Chen, Jiahao Han, Xiaochen Ma, Xin Zheng, Jinhong Chen
Frontiers in Oncology.2022;[Epub] CrossRef
Targeting Epithelial-to-Mesenchymal Transition in Radioresistance: Crosslinked Mechanisms and Strategies
Lili Qiao, Yanfei Chen, Ning Liang, Jian Xie, Guodong Deng, Fangjie Chen, Xiaojuan Wang, Fengjun Liu, Yupeng Li, Jiandong Zhang
Frontiers in Oncology.2022;[Epub] CrossRef
SNAIL driven by a feed forward loop motif promotes TGFβ induced epithelial to mesenchymal transition
Gottumukkala Sai Bhavani, Anbumathi Palanisamy
Biomedical Physics & Engineering Express.2022; 8(4): 045012. CrossRef
Comparative analysis of tumor control gene and microRNA expression profiles in tumor and adjacent tissues in patients with colorectal cancer
M. I. Sluzhev, M. I. Zaraisky, V. V. Semiglazov, T. Yu. Semiglazova, E. V. Tkachenko, S. V. Kondratev, N. A. Brish, Yu. V. Alekseeva, Iu. V. Petrik, A. N. Sidorova
Siberian journal of oncology.2022; 21(2): 55. CrossRef
D-tryptophan triggered epithelial-mesenchymal transition by activating TGF-β signaling pathway
Chong Wang, Fangting Wang, Yanbo Wang, Linglin Fu
Food Science and Human Wellness.2022; 11(5): 1215. CrossRef
AST·MLR index and operation injury condition are novel prognostic predictor for the prediction of survival in patients with colorectal cancer liver metastases undergoing surgical resection
Qichen Chen, Mingxia Li, Jinghua Chen, Zhen Huang, Xiao Chen, Hong Zhao, Jianqiang Cai
BMC Cancer.2022;[Epub] CrossRef
Molecular Characterizations of Gynecologic Carcinosarcomas: A Focus on the Immune Microenvironment
Sanaa Nakad Borrego, Ernst Lengyel, Katherine C. Kurnit
Cancers.2022; 14(18): 4465. CrossRef
miR‑382 inhibits breast cancer progression and metastasis by affecting the M2 polarization of tumor‑associated macrophages by targeting PGC‑1α
Hua Zhou, Mingyu Gan, Xin Jin, Meng Dai, Yuanyuan Wang, Youyang Lei, Zijing Lin, Jia Ming
International Journal of Oncology.2022;[Epub] CrossRef
TGF-β Signaling in Metastatic Colorectal Cancer (mCRC): From Underlying Mechanism to Potential Applications in Clinical Development
Xiaoshuang Li, Yanmin Wu, Tian Tian
International Journal of Molecular Sciences.2022; 23(22): 14436. CrossRef
Naringenin in the Prevention of Colon Cancer: An Updated Review
Vemula Sarojamma, Ramakrishna Vadde
Onco Therapeutics.2022; 9(2): 25. CrossRef
Relationship between Epithelial-to-Mesenchymal Transition and Tumor-Associated Macrophages in Colorectal Liver Metastases
Aurora Gazzillo, Michela Anna Polidoro, Cristiana Soldani, Barbara Franceschini, Ana Lleo, Matteo Donadon
International Journal of Molecular Sciences.2022; 23(24): 16197. CrossRef
CD147 deficiency in T cells prevents thymic involution by inhibiting the EMT process in TECs in the presence of TGFβ
Ruo Chen, Ke Wang, Zhuan Feng, Ming-Yang Zhang, Jiao Wu, Jie-Jie Geng, Zhi-Nan Chen
Cellular & Molecular Immunology.2021; 18(1): 171. CrossRef
TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer
Karen Slattery, Elena Woods, Vanessa Zaiatz-Bittencourt, Sam Marks, Sonya Chew, Michael Conroy, Caitriona Goggin, Colm MacEochagain, John Kennedy, Sophie Lucas, David K Finlay, Clair M Gardiner
Journal for ImmunoTherapy of Cancer.2021; 9(2): e002044. CrossRef
Long non-coding RNA ZFAS1 is a major regulator of epithelial-mesenchymal transition through miR-200/ZEB1/E-cadherin, vimentin signaling in colon adenocarcinoma
Stephen J. O’Brien, Casey Fiechter, James Burton, Jacob Hallion, Mason Paas, Ankur Patel, Ajay Patel, Andre Rochet, Katharina Scheurlen, Sarah Gardner, Maurice Eichenberger, Harshini Sarojini, Sudhir Srivastava, Shesh Rai, Theodore Kalbfleisch, Hiram C. P
Cell Death Discovery.2021;[Epub] CrossRef
Creatine promotes cancer metastasis through activation of Smad2/3
Liwen Zhang, Zijing Zhu, Huiwen Yan, Wen Wang, Zhenzhen Wu, Fei Zhang, Qixiang Zhang, Guizhi Shi, Junfeng Du, Huiyun Cai, Xuanxuan Zhang, David Hsu, Pu Gao, Hai-long Piao, Gang Chen, Pengcheng Bu
Cell Metabolism.2021; 33(6): 1111. CrossRef
Creatine promotes metastatic dissemination
Damien Lagarde, Lawrence Kazak
Cell Metabolism.2021; 33(6): 1065. CrossRef
Lactate Dehydrogenase-A (LDH-A) Preserves Cancer Stemness and Recruitment of Tumor-Associated Macrophages to Promote Breast Cancer Progression
Shengnan Wang, Lingyu Ma, Ziyuan Wang, Huiwen He, Huilin Chen, Zhaojun Duan, Yuyang Li, Qin Si, Tsung-Hsien Chuang, Chong Chen, Yunping Luo
Frontiers in Oncology.2021;[Epub] CrossRef
Partial EMT in head and neck cancer biology: a spectrum instead of a switch
Ananya Pal, Thomas F. Barrett, Rachel Paolini, Anuraag Parikh, Sidharth V. Puram
Oncogene.2021; 40(32): 5049. CrossRef
Macrophages, as a Promising Strategy to Targeted Treatment for Colorectal Cancer Metastasis in Tumor Immune Microenvironment
Yingru Zhang, Yiyang Zhao, Qi Li, Yan Wang
Frontiers in Immunology.2021;[Epub] CrossRef
Tumor‐associated macrophage‐derived CCL5 promotes chemotherapy resistance and metastasis in prostatic cancer
Jian Ma, Fuerhaiti Shayiti, Jing Ma, Meng Wei, Tingting Hua, Rong Zhang, Junyan Su, Peng Chen
Cell Biology International.2021; 45(10): 2054. CrossRef
Tumor Microenvironment: Involved Factors and Signaling Pathways in Epithelial-Mesenchymal Transition
Madeh Ghaderi, Azadeh Niknejad
International Journal of Cancer Management.2021;[Epub] CrossRef
The Multifaceted Role of TGF-β in Gastrointestinal Tumors
Fabio Sabbadini, Monica Bertolini, Serena De Matteis, Domenico Mangiameli, Serena Contarelli, Silvia Pietrobono, Davide Melisi
Cancers.2021; 13(16): 3960. CrossRef
TMEM100 Modulates TGF-β Signaling Pathway to Inhibit Colorectal Cancer Progression
Huixia Li, Chuan Cheng, Weibo You, Jiujian Zheng, Jie Xu, Peng Gao, Jianping Wang, Tatsuya Toyokawa
Gastroenterology Research and Practice.2021; 2021: 1. CrossRef
Green Synthesized Honokiol Transfersomes Relieve the Immunosuppressive and Stem-Like Cell Characteristics of the Aggressive B16F10 Melanoma
Yasmeen Ezzeldeen, Shady Swidan, Aliaa ElMeshad, Aya Sebak
International Journal of Nanomedicine.2021; Volume 16: 5693. CrossRef
Copper content in ascitic fluid is associated with angiogenesis and progression in ovarian cancer
Toshimichi Onuma, Tetsuya Mizutani, Yuko Fujita, Shizuka Yamada, Yoshio Yoshida
Journal of Trace Elements in Medicine and Biology.2021; 68: 126865. CrossRef
KLK8 promotes the proliferation and metastasis of colorectal cancer via the activation of EMT associated with PAR1
Qing Hua, Zhirong Sun, Yi Liu, Xuefang Shen, Weiwei Zhao, Xiaoyan Zhu, Pingbo Xu
Cell Death & Disease.2021;[Epub] CrossRef
Tumor-Released Products Promote Bone Marrow-Derived Macrophage Survival and Proliferation
Juliana Maria Motta, Vivian Mary Rumjanek, Alberto Mantovani, Massimo Locati
Biomedicines.2021; 9(10): 1387. CrossRef
Potential role of tumor-infiltrating T-, B-lymphocytes, tumor-associated macrophages and IgA-secreting plasma cells in long-term survival in the rectal adenocarcinoma patients
Dmitry A. Zinovkin, Suheyla Y. Kose, Eldar A. Nadyrov, Sergey L. Achinovich, Dmitry M. Los', Tatyana E. Gavrilenko, Dmitry I. Gavrilenko, Jale Yuzugulen, Md Zahidul Islam Pranjol
Life Sciences.2021; 286: 120052. CrossRef
Targeting Tumor-Associated Macrophages in Cancer Immunotherapy
Amy J. Petty, Dwight H. Owen, Yiping Yang, Xiaopei Huang
Cancers.2021; 13(21): 5318. CrossRef
Tumour microenvironment: a non-negligible driver for epithelial−mesenchymal transition in colorectal cancer
Lei Han, Shuyi Wang, Chen Wei, Yan Fang, Sihao Huang, Tailang Yin, Bin Xiong, Chaogang Yang
Expert Reviews in Molecular Medicine.2021;[Epub] CrossRef
Anti-Cancer Activity Profiling of Chemotherapeutic Agents in 3D Co-Cultures of Pancreatic Tumor Spheroids with Cancer-Associated Fibroblasts and Macrophages
So-Dam Jang, Jeeyeun Song, Hyun-Ah Kim, Chang-Nim Im, Iftikhar Ali Khawar, Jong Kook Park, Hyo-Jeong Kuh
Cancers.2021; 13(23): 5955. CrossRef
M2-Type Macrophages Induce Tregs Generation by Activating the TGF-β/Smad Signalling Pathway to Promote Colorectal Cancer Development
Xueqian Ma, Yu Gao, Yanlei Chen, Jinhao Liu, Chunyu Yang, Cuifen Bao, Yanping Wang, Yang Feng, Xiaoyu Song, Shifeng Qiao
OncoTargets and Therapy.2021; Volume 14: 5391. CrossRef
Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion
Yuanyuan Jiang, Hanxiang Zhan
Cancer Letters.2020; 468: 72. CrossRef
Signaling of Macrophages that Contours the Tumor Microenvironment for Promoting Cancer Development
Justin K. Messex, Crystal J. Byrd, Geou-Yarh Liou
Cells.2020; 9(4): 919. CrossRef
The roles of tumor-associated macrophages in tumor angiogenesis and metastasis
Luo-Qin Fu, Wen-Lin Du, Mao-Hua Cai, Jia-Yu Yao, Yuan-Yuan Zhao, Xiao-Zhou Mou
Cellular Immunology.2020; 353: 104119. CrossRef
Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site
Elaheh Nasrollahzadeh, Sepideh Razi, Mahsa Keshavarz-Fathi, Massimiliano Mazzone, Nima Rezaei
Cancer Immunology, Immunotherapy.2020; 69(9): 1673. CrossRef
Clinical Implication of Concordant or Discordant Genomic Profiling between Primary and Matched Metastatic Tissues in Patients with Colorectal Cancer
Jung Yoon Choi, Sunho Choi, Minhyeok Lee, Young Soo Park, Jae Sook Sung, Won Jin Chang, Ju Won Kim, Yoon Ji Choi, Jin Kim, Dong-Sik Kim, Sung-Ho Lee, Junhee Seok, Kyong Hwa Park, Seon Hahn Kim, Yeul Hong Kim
Cancer Research and Treatment.2020; 52(3): 764. CrossRef
Caspase Recruitment Domain Containing Protein 9 Suppresses Non-Small Cell Lung Cancer Proliferation and Invasion via Inhibiting MAPK/p38 Pathway
Linyue Pan, Yuting Tan, Bin Wang, Wenjia Qiu, Yulei Yin, Haiyan Ge, Huili Zhu
Cancer Research and Treatment.2020; 52(3): 867. CrossRef
RUNX1 regulates TGF-β induced migration and EMT in colorectal cancer
Chenghao Lu, Zheyu Yang, Dingye Yu, Jianwei Lin, Wei Cai
Pathology - Research and Practice.2020; 216(11): 153142. CrossRef
Targeting Tumor-Associated Macrophages in Anti-Cancer Therapies: Convincing the Traitors to Do the Right Thing
Cristina Belgiovine, Elisabeth Digifico, Clément Anfray, Aldo Ummarino, Fernando Torres Andón
Journal of Clinical Medicine.2020; 9(10): 3226. CrossRef
Mapping a Circular RNA–microRNA–mRNA-Signaling Regulatory Axis that Modulates Stemness Properties of Cancer Stem Cell Populations in Colorectal Cancer Spheroid Cells
Vimalan Rengganaten, Chiu-Jung Huang, Ping-Hsing Tsai, Mong-Lien Wang, Yi-Ping Yang, Yuan-Tzu Lan, Wen-Liang Fang, Shelly Soo, Hooi Tin Ong, Soon Keng Cheong, Kong Bung Choo, Shih-Hwa Chiou
International Journal of Molecular Sciences.2020; 21(21): 7864. CrossRef
A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy
Gizem Duru, Marjolein van Egmond, Niels Heemskerk
Frontiers in Immunology.2020;[Epub] CrossRef
Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance
Łukasz Zadka, Damian J. Grybowski, Piotr Dzięgiel
Cellular Oncology.2020; 43(4): 539. CrossRef
Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights
Ammad Ahmad Farooqi, Marc de la Roche, Mustafa B.A. Djamgoz, Zahid H. Siddik
Seminars in Cancer Biology.2019;[Epub] CrossRef
Transcriptome Sequencing Investigated the Tumor-Related Factors Changes After T. gondii Infection
Gang Lu, Jian Zhou, Ying hui Zhao, Qiao ling Li, Yun yun Gao, Lin Wang
Frontiers in Microbiology.2019;[Epub] CrossRef
Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer
Serena De Matteis, Matteo Canale, Alberto Verlicchi, Giuseppe Bronte, Angelo Delmonte, Lucio Crinò, Giovanni Martinelli, Paola Ulivi
Journal of Oncology.2019; 2019: 1. CrossRef
Tumor-associated macrophages: an accomplice in solid tumor progression
Yibing Chen, Yucen Song, Wei Du, Longlong Gong, Haocai Chang, Zhengzhi Zou
Journal of Biomedical Science.2019;[Epub] CrossRef
Transforming Growth Factor-β Signaling Pathway in Colorectal Cancer and Its Tumor Microenvironment
Yoshiro Itatani, Kenji Kawada, Yoshiharu Sakai
International Journal of Molecular Sciences.2019; 20(23): 5822. CrossRef
Gastric cancer-derived mesenchymal stromal cells trigger M2 macrophage polarization that promotes metastasis and EMT in gastric cancer
Wei Li, Xu Zhang, Fenglei Wu, Ying Zhou, Zengtao Bao, Haining Li, Ping Zheng, Shaolin Zhao
Cell Death & Disease.2019;[Epub] CrossRef
Pimozide suppresses colorectal cancer via inhibition of Wnt/β-catenin signaling pathway
Yonggang Ren, Jia Tao, Zhen Jiang, Dongmei Guo, Jiancai Tang
Life Sciences.2018; 209: 267. CrossRef

16,938 View
458 Download
95 Web of Science
97 Crossref

The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy: Ji Young Choi, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Seong Jin Jo; Cancer Res Treat. 2019;51(1):169-177. Published online April 5, 2018; DOI: https://doi.org/10.4143/crt.2017.491

Abstract PDF PubReader ePub

Purpose
Despite the successful use of tyrosine kinase inhibitors (TKIs) in cancer patients, their effect on herpes zoster development has not been studied. The aim of this study was to evaluate and compare the effects of epidermal growth factor receptor (EGFR) TKI and cytotoxic chemotherapy on the risk of herpes zoster development in non-small cell lung cancer (NSCLC) patients.
Materials and Methods
We conducted a medical review of all eligible NSCLC patients in Seoul National University hospital between 2002 and 2015. We classified patients based on whether they previously underwent EGFR TKI therapy into either the TKI group or the cytotoxic group. We compared the incidence rates of herpes zoster during TKI therapy and cytotoxic chemotherapy. Additionally, the longitudinal risk of herpes zoster from TKIs was analyzed using the incidence rate ratio (IRR) of the TKI group to the cytotoxic group and the log-rank test of the Kaplan-Meier method.
Results
Of the 2,981 NSCLC patients, 54 patients (1.54%) developed herpes zoster. In the TKI group (2,002 patients), the IRR of herpes zoster during TKI therapy compared to that during cytotoxic chemotherapy was 1.05 (95% confidence interval [CI], 0.53 to 2.09). The IRR of the TKI group compared to the cytotoxic group was 1.33 (95% CI, 0.64 to 2.76). The Kaplan-Meier cumulative risk of both groups was not significantly different.
Conclusion
Our results show that the incidence rate of herpes zoster in the TKI group was not statistically different from the incidence in the cytotoxic group during and after chemotherapy in NSCLC patients.

Citations

Citations to this article as recorded by

The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects
Bei Cao, Tingting Ma, Yuqiang Zhang, Lei Huang, Hui Lin, Huanhuan Jiang, Yu Zhao, Yan Geng, Yuanxun Yang, Sumin Cao, Juan Li
Investigational New Drugs.2024; 42(3): 289. CrossRef
Reactivation of Varicella-Zoster Virus in Patients with Lung Cancer Receiving Immune Checkpoint Inhibitors: Retrospective Nationwide Population-Based Cohort Study from South Korea
Jiyun Jung, Seong-Yeon Park, Jae-Yoon Park, Dalyong Kim, Kyoungmin Lee, Sungim Choi
Cancers.2024; 16(8): 1499. CrossRef
Herpes Zoster in Patients with Lung Cancer Treated with PD-1/PD-L1 Antibodies
Yoshiaki Nagai, Masafumi Sata, Hiromitsu Ohta, Tsugitoshi Onuki, Tatsuya Saito, Ayumi Uchiyama, Ayako Kurosaki, Naoko Yoshizumi, Ayako Takigami, Shoko Nakazawa, Masayuki Nakayama, Hironori Yamaguchi, Koichi Hagiwara
Immunotherapy.2022; 14(15): 1211. CrossRef
Generalized herpes zoster and cutaneous metastasis during chemotherapy for non‐small cell lung cancer: A case report
Naoya Yasokawa, Yuri Yasuda, Houhi Chin, Koji Kurose, Yumi Aoyama, Toru Oga
Thoracic Cancer.2021; 12(1): 117. CrossRef
The risk of herpes zoster among patients with ankylosing spondylitis: A population‐based cohort study in Taiwan
Shuya Wang, James Cheng‐Chung Wei, Jing‐Yang Huang, Wuu‐Tsun Perng, Zhiyi Zhang
International Journal of Rheumatic Diseases.2020; 23(2): 181. CrossRef

10,240 View
245 Download
6 Web of Science
5 Crossref

Impact of Pulmonary Tuberculosis on the EGFR Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma: In Kyoung Hwang, Seung Sook Paik, Seung Hyeun Lee; Cancer Res Treat. 2019;51(1):158-168. Published online April 2, 2018; DOI: https://doi.org/10.4143/crt.2018.084

Abstract PDF Supplementary Material PubReader ePub

Purpose
Although it has been suggested that pulmonary tuberculosis (TB) is associated with increased risk of lung cancer, the exact mechanism is not clearly identified. We investigated the effect of pulmonary TB on the epidermal growth factor receptor (EGFR) mutational status and clinical outcome in patients with pulmonary adenocarcinoma.
Materials and Methods
We reviewed data of patients diagnosed with pulmonary adenocarcinoma harboring EGFR mutations and treated at our institution from 2008 to 2015. We divided our population into two groups: patients with pre-existing TB lesions on chest computed tomography scan (TB group) and those without the lesions (non-TB group). We compared the differences in EGFR mutational status, response to tyrosine kinase inhibitors (TKIs) and survival between the two groups.
Results
A total of 477 patients with pulmonary adenocarcinoma were analyzed. One hundred eighty-three patients (39%) had EGFR-mutated tumors and 100 (21%) patients had pre-existing TB lesions. The frequency of EGFR mutation was significantly higher in the TB group compared with the non-TB group (56% vs. 34%, p=0.038). Pre-existing TB lesions were independently associated with more frequent EGFR mutations in multivariate analysis (odds ratio, 1.43). In addition, both the progression-free survival (9.1 months vs. 11.6 months, p=0.020) and the overall survival (19.4 months vs. 24.5 months, p=0.014) after first-line EGFR-TKIs were significantly shorter in the TB group than in the non-TB group.
Conclusion
Previous pulmonary TB may be associated with more frequent EGFR mutations and poorer treatment response to EGFR-TKIs in patients with pulmonary adenocarcinoma.

Citations

Citations to this article as recorded by

A DNA Methylation Signature From Buccal Swabs to Identify Tuberculosis Infection
Lovisa Karlsson, Isabelle Öhrnberg, Shumaila Sayyab, David Martínez-Enguita, Mika Gustafsson, Patricia Espinoza, Melissa Méndez-Aranda, Cesar Ugarte-Gil, Lameck Diero, Ronald Tonui, Jakob Paues, Maria Lerm
The Journal of Infectious Diseases.2025; 231(1): e47. CrossRef
Contagious illness of tuberculosis and correlation with various types of cancer
Karthikeyan Sundaram, Venkataraman Prabhu
Medicine in Microecology.2025; 24: 100123. CrossRef
Coexistent Pulmonary Tuberculosis and Lung Cancer: An Analysis of Incidence Trends, Financial Burdens and Influencing Factors
Fei Qi, Hongjie Yang, Yi Han, Yujie Dong, Fan Zhang, Yishuo Wang, Juan Du, Yuan Gao, Xueguang Hu, Liqun Zhang, Tongmei Zhang
Cancer Innovation.2025;[Epub] CrossRef
Coexisting Lung Cancer and Pulmonary Tuberculosis: A Comprehensive Review From Incidence to Management
Wendi Zhou, Hongxu Lu, Jiamin Lin, Jialou Zhu, Jizhen Liang, Yalin Xie, Jinxing Hu, Ning Su
Cancer Reports.2025;[Epub] CrossRef
New Vistas in Mycobacterium tuberculosis Infection and Its Association with Lung Cancer Development
Kostas A. Papavassiliou, Amalia A. Sofianidi, Fotios G. Spiliopoulos, Alice G. Vassiliou, Athanasios G. Papavassiliou
Cancers.2025; 17(13): 2224. CrossRef
Real-world progression-free survival of first line afatinib patients with EGFR-mutant advanced lung adenocarcinoma: A multicentre study in Indonesia
Noni Novisari Soeroso, Elisna Syahruddin, Chaliza Soliha, Laksmi Wulandari, Ana Rima Setijadi, Sabrina Ermayanti, Suryanti Dwi Pratiwi, Andreas Infianto, Novita Andayani, Sri Melati Munir, Avissena Dutha Pratama, Ida Ayu Jasminarti Dwi Kusumawardani, Hary
Cancer Treatment and Research Communications.2025; 44: 100979. CrossRef
Tuberculosis Coinciding With Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma: A Diagnostic Conundrum
Nithiyanandan Ravi
Cureus.2025;[Epub] CrossRef
Reprogramming the host: Mycobacterium tuberculosis as a silent architect of the immuno-tumoral
Rodolfo L. Chávez-Domínguez, Martha Torres, Atziri A. Acevedo-Domínguez, Jesús A. Ibarra-Inocente, Claudia Carranza
Frontiers in Cellular and Infection Microbiology.2025;[Epub] CrossRef
Progress in mechanism-based diagnosis and treatment of tuberculosis comorbid with tumor
Chuan Wang, Rong-Qi Zou, Guo-Zhong He
Frontiers in Immunology.2024;[Epub] CrossRef
Lung cancer and pulmonary tuberculosis: key features of molecular mechanisms of concomitant disease
G. M. Agafonov, G. G. Kudriashov, U. S. Krylova, T. S. Zubareva, I. M. Kvetnoy, P. K. Yablonskiy
Uspehi fiziologičeskih nauk.2024; 55(3): 58. CrossRef
Antimicrobial peptides as drugs with double response against Mycobacterium tuberculosis coinfections in lung cancer
Giulia Polinário, Laura Maria Duran Gleriani Primo, Maiara Alane Baraldi Cerquetani Rosa, Freddy Humberto Marin Dett, Paula Aboud Barbugli, Cesar Augusto Roque-Borda, Fernando Rogério Pavan
Frontiers in Microbiology.2023;[Epub] CrossRef
Mycobacterium Tubercular Mediated Inflammation and Lung Carcinogenesis: Connecting Links
Abhay Vashishth, Mohd Shuaib, Tanya Bansal, Shashank Kumar
OBM Genetics.2023; 07(02): 1. CrossRef
Prevalence of Lung Cancer with a History of Tuberculosis
Nadira Putri Nastiti, Laksmi Wulandari, Sulistiawati Sulistiawati, Anna Febriani, Wiwin Is Effendi
Jurnal Respirasi.2023; 9(2): 87. CrossRef
Previous pulmonary tuberculosis enhances the risk of lung cancer: systematic reviews and meta-analysis
Hossein Abdeahad, Maryam Salehi, Atieh Yaghoubi, Amir Hossein Aalami, Farnoosh Aalami, Saman Soleimanpour
Infectious Diseases.2022; 54(4): 255. CrossRef
Pulmonary Tuberculosis and Risk of Lung Cancer: A Systematic Review and Meta-Analysis
Soo Young Hwang, Jong Yeob Kim, Hye Sun Lee, Sujee Lee, Dayeong Kim, Subin Kim, Jong Hoon Hyun, Jae Il Shin, Kyoung Hwa Lee, Sang Hoon Han, Young Goo Song
Journal of Clinical Medicine.2022; 11(3): 765. CrossRef
Clinical and pathological characteristics associated with the presence of the IS6110 Mycobacterim tuberculosis transposon in neoplastic cells from non-small cell lung cancer patients
Oscar Arrieta, Camilo Molina-Romero, Fernanda Cornejo-Granados, Brenda Marquina-Castillo, Alejandro Avilés-Salas, Gamaliel López-Leal, Andrés F. Cardona, Alette Ortega-Gómez, Mario Orozco-Morales, Adrián Ochoa-Leyva, Rogelio Hernandez-Pando
Scientific Reports.2022;[Epub] CrossRef
Lung cancer occurrence after an episode of tuberculosis: a systematic review and meta-analysis
Javier Cabrera-Sanchez, Vicente Cuba, Victor Vega, Patrick Van der Stuyft, Larissa Otero
European Respiratory Review.2022; 31(165): 220025. CrossRef
Proteomic profile of vitreous in patients with tubercular uveitis
Reema Bansal, Mohd M. Khan, Surendra Dasari, Indu Verma, David R. Goodlett, Nathan P. Manes, Aleksandra Nita-Lazar, Surya P. Sharma, Aman Kumar, Nirbhai Singh, Anuradha Chakraborti, Vishali Gupta, M.R. Dogra, Jagat Ram, Amod Gupta
Tuberculosis.2021; 126: 102036. CrossRef
Epidermal growth factor receptor-mutant pulmonary adenocarcinoma coexisting with tuberculosis
Ning Liu, Lingnan Zheng, Min Yu, Shuang Zhang
Medicine.2021; 100(8): e24569. CrossRef
Quantitative analysis of cell-free DNA by droplet digital PCR reveals the presence of EGFR mutations in non-malignant lung pathologies
Rajesh Venkataram, Srividya Arjuna, Giridhar Belur Hosmane, Anirban Chakraborty
Monaldi Archives for Chest Disease.2021;[Epub] CrossRef
Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
Yalin Xie, Ning Su, Wei Zhou, An Lei, Xiang Li, Weiwei Li, Zhan Huang, Wenchang Cen, Jinxing Hu
Cancer Management and Research.2021; Volume 13: 7517. CrossRef
A Case of Delayed Diagnostic Pulmonary Tuberculosis during Targeted Therapy in an EGFR Mutant Non-Small Cell Lung Cancer Patient
Caibao Jin, Bin Yang
Case Reports in Oncology.2021; 14(1): 659. CrossRef
Follow‐up of an occult tuberculosis scar cancer after resection of metastatic lesions
Mengyao Sun, Yinghui Xu, Xu Wang, Chao Sun, Ye Guo, Guoguang Shao, Zhiguang Yang, Yunpeng Liu, Peng Zhang, Shi Qiu, Kewei Ma
Thoracic Cancer.2020; 11(8): 2347. CrossRef

11,303 View
284 Download
20 Web of Science
23 Crossref

Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer: Sumi Yun, Yoonjin Kwak, Soo Kyung Nam, An Na Seo, Heung-Kwon Oh, Duck-Woo Kim, Sung-Bum Kang, Hye Seung Lee; Cancer Res Treat. 2018;50(4):1351-1361. Published online January 17, 2018; DOI: https://doi.org/10.4143/crt.2017.487

Abstract PDF Supplementary Material PubReader ePub

Purpose
Molecular treatments targeting epidermal growth factor receptors (EGFRs) are important strategies for advanced colorectal cancer (CRC). However, clinicopathologic implications of EGFRs and EGFR ligand signaling have not been fully evaluated. We evaluated the expression of EGFR ligands and correlation with their receptors, clinicopathologic factors, and patients’ survival with CRC.
Materials and Methods
The expression of EGFR ligands, including heparin binding epidermal growth factor-like growth factor (HBEGF), transforming growth factor (TGF), betacellulin, and epidermal growth factor (EGF), were evaluated in 331 consecutive CRC samples using mRNA in situ hybridization (ISH). We also evaluated the expression status of EGFR, human epidermal growth factor receptor 2 (HER2), HER3, and HER4 using immunohistochemistry and/or silver ISH.
Results
Unlike low incidences of TGF (38.1%), betacellulin (7.9%), and EGF (2.1%), HBEGF expression was noted in 62.2% of CRC samples. However, the expression of each EGFR ligand did not reveal significant correlations with survival. The combined analyses of EGFR ligands and EGFR expression indicated that the ligands‒/EGFR+ group showed a significant association with the worst disease-free survival (DFS; p=0.018) and overall survival (OS; p=0.005). It was also an independent, unfavorable prognostic factor for DFS (p=0.026) and OS (p=0.007). Additionally, HER4 nuclear expression, regardless of ligand expression, was an independent, favorable prognostic factor for DFS (p=0.034) and OS (p=0.049), by multivariate analysis.
Conclusion
Ligand-independent EGFR overexpression was suggested to have a significant prognostic impact; thus, the expression status of EGFR ligands, in addition to EGFR, might be necessary for predicting patients' outcome in CRC.

Citations

Citations to this article as recorded by

Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions
Said A. Khelwatty, Soozana Puvanenthiran, Alan M. Seddon, Izhar Bagwan, Sharadah Essapen, Helmout Modjtahedi
Cancers.2025; 17(17): 2810. CrossRef
Gastrin-Releasing Peptide Receptors Stimulate MAPK-Mediated Growth of Lung Cancer Cells by Transactivating HER4 in a Neuregulin-1, MAP Kinase-Dependent Manner Requiring Activation of the ROS-System
Terry W. Moody, Irene Ramos-Alvarez, Tatiana Iordanskaia, Samuel A. Mantey, Robert T. Jensen
Biology.2025; 14(9): 1225. CrossRef
Systematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancer
Harshabad Singh, Ashley Kang, Lisa Bloudek, Ling-I Hsu, Maria Corinna Palanca-Wessels, Michael Stecher, Muriel Siadak, Kimmie Ng
JNCI Cancer Spectrum.2024;[Epub] CrossRef
Molecular characterization of colorectal mucinous adenocarcinoma and adenocarcinoma, not otherwise specified, identified by multiomic data analysis
Kailun Xu, Shu Zheng, Baosheng Li, Yingkuan Shao, Xiaoyang Yin
Frontiers in Molecular Biosciences.2023;[Epub] CrossRef
Mechanism of 5-fluorouracil nanoparticles on releasing skin squamous cell carcinoma through regulation of Wnt/β-catenin expression
Lixin Peng, Xinping Zhang, Bin Du, Liangliang Sun, Yuguang Zhao
Materials Express.2022; 12(2): 220. CrossRef
Research on Anti-Tumor Nano-Particle with New Type 5-Fluorouracil on the Peritoneal Metastasis of Breast Cancer
Yujie Xiao, Guilin Huang, Yibo Xiang
Journal of Biomaterials and Tissue Engineering.2021; 11(7): 1277. CrossRef
Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?
Constantin Stefani, Daniela Miricescu, Iulia-Ioana Stanescu-Spinu, Remus Iulian Nica, Maria Greabu, Alexandra Ripszky Totan, Mariana Jinga
International Journal of Molecular Sciences.2021; 22(19): 10260. CrossRef
SOX2 Promotes Brain Metastasis of Breast Cancer by Upregulating the Expression of FSCN1 and HBEGF
Weikai Xiao, Shaoquan Zheng, Xinhua Xie, Xing Li, Lijuan Zhang, Anli Yang, Jian Wang, Hailin Tang, Xiaoming Xie
Molecular Therapy - Oncolytics.2020; 17: 118. CrossRef
Combined Therapeutic Effects of ¹³¹I-Labeled and 5Fu-Loaded Multifunctional Nanoparticles in Colorectal Cancer

Pingping Wu, Huayun Zhu, Yan Zhuang, Xiaofeng Sun, Ning Gu
International Journal of Nanomedicine.2020; Volume 15: 2777. CrossRef
Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon
Pingping Wu, Qing Zhou, Huayun Zhu, Yan Zhuang, Jun Bao
BMC Cancer.2020;[Epub] CrossRef
HER4 promotes the progression of colorectal cancer by promoting epithelial‑mesenchymal transition
Xiaojing Jia, Huien Wang, Zhongxin Li, Jing Yan, Yan Guo, Wujie Zhao, Lixia Gao, Bin Wang, Yitao Jia
Molecular Medicine Reports.2020;[Epub] CrossRef
Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery
A. A. Rosenkranz, T. A. Slastnikova
Biochemistry (Moscow).2020; 85(9): 967. CrossRef
Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer
Said Abdullah Khelwatty, Sharadah Essapen, Izhar Bagwan, Margaret Green, Alan M. Seddon, Helmout Modjtahedi
Oncotarget.2019; 10(18): 1704. CrossRef

11,544 View
220 Download
14 Web of Science
13 Crossref

The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma: Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Kun-Chieh Chen, Chia-Hung Hsu, Kang-Yi Su, Jeremy J. W. Chen, Huei-Wen Chen, Sung-Liang Yu, Tsung-Ying Yang, Gee-Chen Chang; Cancer Res Treat. 2018;50(4):1294-1303. Published online January 4, 2018; DOI: https://doi.org/10.4143/crt.2017.512

Abstract PDF Supplementary Material PubReader ePub

Purpose
The main objective of this study was to investigate the relationship among the clinical characteristics and the frequency of T790M mutation in advanced epidermal growth factor receptor (EGFR)‒mutant lung adenocarcinoma patients with acquired resistance after firstline EGFR‒tyrosine kinase inhibitor (TKI) treatment.
Materials and Methods
We enrolled EGFR-mutant stage IIIB-IV lung adenocarcinoma patients, who had progressed to prior EGFR-TKI therapy, and evaluated their rebiopsy EGFR mutation status.
Results
A total of 205 patients were enrolled for analysis. The overall T790M mutation rate of rebiopsy was 46.3%. The T790M mutation rates among patients with exon 19 deletion mutation, exon 21 L858R point mutation, and other mutations were 55.0%, 37.3%, and 27.3%, respectively. Baseline exon 19 deletion was associated with a significantly higher frequency of T790M mutation (adjusted odds ratio, 2.14; 95% confidence interval [CI], 1.20 to 3.83; p=0.010). In the exon 19 deletion subgroup, there was a greater prevalence of T790M mutation than other exon 19 deletion subtypes in patients with the Del E746-A750 mutation (61.6% vs. 40.6%; odds ratio, 2.35; 95% CI, 1.01 to 5.49; p=0.049). The progression-free survival (PFS) of first-line TKI treatment > 11 months was also associated with a higher T790M mutation rate (54.1% vs. 39.3%; adjusted odds ratio, 1.82; 95% CI, 1.02 to 3.25; p=0.044). Patients who underwent rebiopsy at metastatic sites had more chance to harbor T790M mutation (52.6% vs. 33.8%; adjusted odds ratio, 1.97; 95% CI, 1.06 to 3.67; p=0.032).
Conclusion
PFS of first-line EGFR-TKI, rebiopsy site, EGFR exon 19 deletion and its subtype Del E746- A750 mutation are associated with the frequency of T790M mutation.

Citations

Citations to this article as recorded by

Drug Resistance in Late-Stage Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Patients After First-Line Treatment with Tyrosine Kinase Inhibitors
Ching-Yi Lee, Shih-Wei Lee, Yi-Chiung Hsu
International Journal of Molecular Sciences.2025; 26(5): 2042. CrossRef
Next-Generation Sequencing: A Review of Its Transformative Impact on Cancer Diagnosis, Treatment, and Resistance Management
Alexandru Isaic, Nadica Motofelea, Teodora Hoinoiu, Alexandru Catalin Motofelea, Ioan Cristian Leancu, Emanuela Stan, Simona R. Gheorghe, Alina Gabriela Dutu, Andreea Crintea
Diagnostics.2025; 15(19): 2425. CrossRef
Novel Resistance Mechanisms to Second‐Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC
Fengwu Lin, Miaoqing Zhao, Qiang Wu, Wenqi Wu, Xiaoying Wu, Ya Ma, Jiani C. Yin, Meng Yang, Min Gao
Genes, Chromosomes and Cancer.2025;[Epub] CrossRef
Patients with Advanced Non-Small Cell Lung Cancer and the EGFR Exon 19 Deletion p.L747 Benefit from Chemotherapy and First-Generation Tyrosine Kinase Inhibitors Compared with Patients with p.E746
Maojing Guan, Qingming Shi, Wei Ye, Kangsheng Gu
OncoTargets and Therapy.2025; Volume 18: 1227. CrossRef
MRI-based radiomics for noninvasive prediction of T790M resistance mutation in lung cancer spinal metastases: an exploratory study
Xiaoya Zhou, Jiashi Zheng, Hua Ai, Chunna Yang, Jiahui Wang, Yiyao Sun, Lijun Jin
Frontiers in Cell and Developmental Biology.2025;[Epub] CrossRef
RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants
Kazumi Nishino, Jin-Yuan Shih, Kazuhiko Nakagawa, Martin Reck, Edward B. Garon, Michelle Carlsen, Tomoko Matsui, Carla Visseren-Grul, Ernest Nadal
JTO Clinical and Research Reports.2024; 5(2): 100624. CrossRef
Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Advanced Nonsmall Cell Lung Cancer Patients
Yan-Jei Tang, John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu
Journal of Cancer Research and Practice.2024; 11(1): 28. CrossRef
CRISPR-Based Fluorescent Reporter (CBFR) Assay for Sensitive, Specific, Inexpensive, and Visual Detection of a Specific EGFR Exon 19 Deletion in NSCLC
Pouya Salehipour, Mojdeh Mahdiannasser, Ghazal Sedaghat Shayegan, Kimia Shankaie, Mina Tabrizi, Majid Mojarrad, Mohammad Hossein Modarressi
Molecular Biotechnology.2023; 65(5): 807. CrossRef
Endobronchial ultrasound‐guided re‐biopsy of non–small cell lung cancer with acquired resistance after EGFR tyrosine kinase inhibitor treatment
Kyung Soo Hong, Jinmo Cho, Jong Geol Jang, Min Hye Jang, June Hong Ahn
Thoracic Cancer.2023; 14(4): 363. CrossRef
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
Chun-Ta Huang, Chih-An Lin, Te-Jen Su, Ching-Yao Yang, Tzu-Hsiu Tsai, Chia-Lin Hsu, Wei-Yu Liao, Kuan-Yu Chen, Chao-Chi Ho, Chong-Jen Yu
BMC Cancer.2023;[Epub] CrossRef
Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations
Jinfei Si, Yue Hao, Jingwen Wei, Jing Xiang, Chunwei Xu, Qiuping Shen, Zhengbo Song
BMC Pulmonary Medicine.2023;[Epub] CrossRef
FRET probe for detecting two mutations in one EGFR mRNA
Myat Thu, Kouta Yanai, Hajime Shigeto, Shohei Yamamura, Kazunori Watanabe, Takashi Ohtsuki
The Analyst.2023; 148(11): 2626. CrossRef
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
Michael J. Grant, Jacqueline V. Aredo, Jacqueline H. Starrett, Paul Stockhammer, Iris K. van Alderwerelt van Rosenburgh, Anna Wurtz, Andrew J. Piper-Valillo, Zofia Piotrowska, Christina Falcon, Helena A. Yu, Charu Aggarwal, Dylan Scholes, Tejas Patil, Chr
Clinical Cancer Research.2023; 29(11): 2123. CrossRef
NSCLC presents metabolic heterogeneity, and there is still some leeway for EGF stimuli in EGFR-mutated NSCLC
Cindy Mendes, Isabel Lemos, Inês Francisco, Teresa Almodôvar, Fernando Cunha, Cristina Albuquerque, Luís G. Gonçalves, Jacinta Serpa
Lung Cancer.2023; 182: 107283. CrossRef
Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first‐line tyrosine kinase inhibitors: A single‐center ambispective cohort study
Yangchun Gu, Jinyu Yu, Haifeng Hu, Hua Zhang, Baoshan Cao, Li Liang
Thoracic Cancer.2023; 14(31): 3147. CrossRef
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
Jia-Shiuan Ju, Allen Chung-Cheng Huang, Pi-Hung Tung, Chi-Hsien Huang, Tzu-Hsuan Chiu, Chin-Chou Wang, How-Wen Ko, Fu-Tsai Chung, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Scientific Reports.2023;[Epub] CrossRef
Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation
Chi‐Hsien Huang, Jia‐Shiuan Ju, Tzu‐Hsuan Chiu, Allen Chung‐Cheng Huang, Pi‐Hung Tung, Chin‐Chou Wang, Chien‐Ying Liu, Fu‐Tsai Chung, Yueh‐Fu Fang, Yi‐Ke Guo, Chih‐Hsi Scott Kuo, Cheng‐Ta Yang
International Journal of Cancer.2022; 150(4): 626. CrossRef
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J.W. Chen, Gee-Chen Chang
Cancer Research and Treatment.2022; 54(2): 434. CrossRef
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer
Le-Tian Huang, Shu-Ling Zhang, Cheng-Bo Han, Jie-Tao Ma
Lung Cancer.2022; 166: 9. CrossRef
Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu
Cancers.2022; 14(4): 977. CrossRef
Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer
Minehiko Inomata, Masahiro Matsumoto, Isami Mizushima, Kana Hayashi, Zenta Seto, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe
The Egyptian Journal of Bronchology.2022;[Epub] CrossRef
Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Non–Small Cell Lung Cancer Patients Treated with Osimertinib
Ji Young Park, Seung Hun Jang, Chang Youl Lee, Taehee Kim, Soo Jie Chung, Ye Jin Lee, Hwan Il Kim, Joo-Hee Kim, Sunghoon Park, Yong Il Hwang, Ki-Suck Jung
Tuberculosis and Respiratory Diseases.2022; 85(2): 155. CrossRef
Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
Rong Liu, Jianying Zhou, Xia Ling
Clinical Medicine Insights: Oncology.2022;[Epub] CrossRef
State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan
Yung-Hung Luo, Kung-Hao Liang, Hsu-Ching Huang, Chia-I Shen, Chi-Lu Chiang, Mong-Lien Wang, Shih-Hwa Chiou, Yuh-Min Chen
International Journal of Molecular Sciences.2022; 23(13): 7037. CrossRef
Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT)
Urška Janžič, Nina Turnšek, Mircea Dediu, Ivan Shterev Donev, Roxana Lupu, Gabriela Teodorescu, Tudor E. Ciuleanu, Adam Pluzanski
Current Oncology.2022; 29(8): 5833. CrossRef
Efficacy and Failure Patterns of Early SBRT to the Primary Tumor in Advanced EGFR-Mutation-Positive Lung Cancer with EFGR-TKI Treatment: A Prospective, Single Arm, Phase II Study
Yangyang Shi, Hailing Xu, William Y. Raynor, Jiapei Ding, Ling Lin, Chao Zhou, Wei Wang, Yinnan Meng, Xiaomai Wu, Xiaofeng Chen, Dongqing Lv, Haihua Yang
Life.2022; 12(12): 1954. CrossRef
Association of hOGG1‐Cys variants with occurrence of p53 and EGFR deletion mutations in non‐small cell lung cancer
Ming‐Jenn Chen, Ching‐Ju Shen, Lee Wang, Po‐Ming Chen, Chih‐Yi Chen, Huei Lee
Thoracic Cancer.2021; 12(4): 534. CrossRef
The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
Wen-Chien Cheng, Te-Chun Hsia, Chih-Yen Tu, Hung-Jen Chen
OncoTargets and Therapy.2021; Volume 13: 13425. CrossRef
EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis
Jeng-Shiuan Tsai, Po-Lan Su, Szu-Chun Yang, Chao-Chun Chang, Chia-Ying Lin, Yi-Ting Yen, Yau-Lin Tseng, Wu-Wei Lai, Chien-Chung Lin, Wu-Chou Su
Journal of the Formosan Medical Association.2021; 120(9): 1729. CrossRef
The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Tsung-Ying Yang, Gee-Chen Chang
Scientific Reports.2021;[Epub] CrossRef
First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
Allen Chung-Cheng Huang, Chi-Hsien Huang, Jia-Shiuan Ju, Tzu-Hsuan Chiu, Pi-Hung Tung, Chin-Chou Wang, Chien-Ying Liu, Fu-Tsai Chung, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Therapeutic Advances in Medical Oncology.2021;[Epub] CrossRef
Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
Po-Yen Chen, Chin-Chou Wang, Chien-Ning Hsu, Chung-Yu Chen
Frontiers in Pharmacology.2021;[Epub] CrossRef
Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer
Xinying Li, Cen Chen, Zimu Wang, Jiaxin Liu, Wei Sun, Kaikai Shen, Yanling Lv, Suhua Zhu, Ping Zhan, Tangfeng Lv, Yong Song
Cancer Cell International.2021;[Epub] CrossRef
Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
Paola Ulivi, Elisabetta Petracci, Matteo Canale, Ilaria Priano, Laura Capelli, Daniele Calistri, Elisa Chiadini, Paola Cravero, Alice Rossi, Angelo Delmonte, Lucio Crinò, Giuseppe Bronte
Biomedicines.2021; 9(10): 1299. CrossRef
Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non–small cell lung cancer patients
Po-Hsin Lee, Kun-Chieh Chen, Kuo-Hsuan Hsu, Yen-Hsiang Huang, Jeng-Sen Tseng, Tsung-Ying Yang, Gee-Chen Chang
Anti-Cancer Drugs.2021; 32(10): 1099. CrossRef
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy
Alessandro Dal Maso, Martina Lorenzi, Elisa Roca, Sara Pilotto, Marianna Macerelli, Valentina Polo, Fabiana Letizia Cecere, Alessandro Del Conte, Giorgia Nardo, Vanessa Buoro, Daniela Scattolin, Sara Monteverdi, Loredana Urso, Elisabetta Zulato, Stefano F
Clinical Lung Cancer.2020; 21(1): 1. CrossRef
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
Ching-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, Kuan-Yu Chen, Tzu-Hsiu Tsai, Chia-Lin Hsu, Kang-Yi Su, Yih-Leong Chang, Chen-Tu Wu, Chia-Chi Hsu, Bin-Chi Liao, Wei-Hsun Hsu, Jih-Hsiang Lee, Chia-Chi Lin, Jin-Yuan Shih, James C.-H. Yang, Chong-Jen Yu
European Journal of Cancer.2020; 124: 110. CrossRef
Comparison detection methods for EGFR in formalin-fixed paraffin-embedded tissues of patients with NSCLC
Xiaojie Fan, Xiaoxiao Wang, Meng Zhang, Huiyan Deng, Yueping Liu
Pathology - Research and Practice.2020; 216(1): 152783. CrossRef
Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation
Sang Hoon Lee, Eun Young Kim, Arum Kim, Yoon Soo Chang
Cancer Biology & Therapy.2020; 21(8): 741. CrossRef
Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI
Chi-Lu Chiang, Hsu-Ching Huang, Chia-I Shen, Yung-Hung Luo, Yuh-Min Chen, Chao-Hua Chiu
Targeted Oncology.2020; 15(4): 503. CrossRef
An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
Shang-Gin Wu, Chi-Lu Chiang, Chien-Ying Liu, Chin-Chou Wang, Po-Lan Su, Te-Chun Hsia, Jin-Yuan Shih, Gee-Chen Chang
Frontiers in Oncology.2020;[Epub] CrossRef
Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment
Jianchun Duan, JiaChen Xu, Zhijie Wang, Hua Bai, Ying Cheng, Tongtong An, Hongjun Gao, Kai Wang, Qing Zhou, Yanping Hu, Yong Song, Cuimin Ding, Feng Peng, Li Liang, Yi Hu, Cheng Huang, Caicun Zhou, Yuankai Shi, Jiefei Han, Di Wang, Yanhua Tian, Zhenlin Ya
Journal of Thoracic Oncology.2020; 15(12): 1857. CrossRef
A Highly Sensitive Next-Generation Sequencing-Based Genotyping Platform for EGFR Mutations in Plasma from Non-Small Cell Lung Cancer Patients
Jung-Young Shin, Jeong-Oh Kim, Mi-Ran Lee, Seo Ree Kim, Kyongmin Sarah Beck, Jin Hyoung Kang
Cancers.2020; 12(12): 3579. CrossRef
Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy
Minehiko Inomata, Kenji Azechi, Naoki Takata, Kana Hayashi, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe
Diagnostics.2020; 10(12): 1006. CrossRef
Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
Jiyun Lee, Joon Ho Shim, Woong-Yang Park, Hee Kyung Kim, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Research and Treatment.2019; 51(1): 408. CrossRef
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations
Yen‐Ting Lin, Jin‐Shing Chen, Wei‐Yu Liao, Chao‐Chi Ho, Chia‐Lin Hsu, Ching‐Yao Yang, Kuan‐Yu Chen, Jih‐Hsiang Lee, Zhong‐Zhe Lin, Jin‐Yuan Shih, James Chih‐Hsin Yang, Chong‐Jen Yu
International Journal of Cancer.2019; 144(11): 2887. CrossRef
Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib
Chih-Hsi Scott Kuo, Chi-Hsien Huang, Chien-Ying Liu, Stelios Pavlidis, Ho-Wen Ko, Fu-Tsai Chung, Tin-Yu Lin, Chih-Liang Wang, Yi-Ke Guo, Cheng-Ta Yang
Targeted Oncology.2019; 14(4): 433. CrossRef
Frecuencia de mutación T790M determinada por biopsia líquida en pacientes con cáncer pulmonar de células no pequeñas después de la progresión a inhibidores de tirosina cinasa contra EGFR en primera línea
Jorge Arturo Alatorre-Alexander, Patricio Santillán-Doherty, María del Rosario Flores-Soto, Luis Manuel Martínez-Barrera, Jerónimo Rafael Rodríguez-Cid, Carla Paola Sánchez-Ríos
NCT Neumología y Cirugía de Tórax.2019; 78(4): 348. CrossRef

14,557 View
605 Download
53 Web of Science
48 Crossref

Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment: Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kuo-Hsuan Hsu, Yen-Hsiang Huang, Kang-Yi Su, Sung-Liang Yu, Gee-Chen Chang; Cancer Res Treat. 2018;50(4):1164-1174. Published online December 11, 2017; DOI: https://doi.org/10.4143/crt.2017.460

Abstract PDF Supplementary Material PubReader ePub

Purpose
Epidermal growth factor receptor (EGFR) T790M mutation serves as an important predictor of osimertinib efficacy. However, little is known about how it works among patients with various timings of T790M emergence and treatment.
Materials and Methods
Advanced EGFR-mutant lung adenocarcinoma patients with positive T790M mutation in tumor were retrospectively enrolled and observed to determine the outcomes of osimertinib treatment. We evaluated the association between patients’ characteristics and the efficacy of osimertinib treatment, particularly with respect to the timing of T790M emergence and osimertinib prescription.
Results
A total of 91 patients were enrolled, including 14 (15.4%) with primary and 77 (84.6%) with acquired T790M mutation. The objective response rate and disease controlratewere 60.9% and 85.1%, respectively. The median progression-free survival (PFS) and overall survival were 11.5 months (95% confidence interval [CI], 9.0 to 14.0) and 30.4 months (95% CI, 11.3 to 49.5), respectively. There was no significant difference in response rate and PFS between primary and acquired T790M populations. In the acquired T790M subgroup, patientswho received osimertinib after T790M had been confirmed by rebiopsy had a longer PFS than those with intercalated treatments between rebiopsy and osimertinib prescription (14.0 months [95% CI, 9.0 to 18.9] vs. 7.2 months [95% CI, 3.7 to 10.8]; adjusted hazard ratio, 0.48 [95% CI, 0.24 to 0.98; p=0.043]). Rebiopsy timing did not influence the outcome.
Conclusion
Osimertinib prescription with intercalated treatment following rebiopsy but not the timing of T790M emergence influenced the treatment outcome. We suggest that it is better to start osimertinib treatment once T790M mutation has been confirmed by biopsy.

Citations

Citations to this article as recorded by

Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer
Gee-Chen Chang, Jin-Yuan Shih, Chong-Jen Yu, Heng-Sheng Chao, Cheng-Ta Yang, Chien-Chung Lin, Jen-Yu Hung, Sheng-Yen Hsiao, Chin-Chou Wang, Chih-Feng Chian, Te-Chun Hsia, Yuh-Min Chen, Chien-Feng Li
PLOS ONE.2024; 19(5): e0303046. CrossRef
Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment
Jeng-Sen Tseng, Kuo-Hsuan Hsu, Zhe-Rong Zheng, Tsung-Ying Yang, Kun-Chieh Chen, Yen-Hsiang Huang, Kang-Yi Su, Sung-Liang Yu, Gee-Chen Chang
Oncology.2021; 99(1): 32. CrossRef
Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI
Chi-Lu Chiang, Hsu-Ching Huang, Chia-I Shen, Yung-Hung Luo, Yuh-Min Chen, Chao-Hua Chiu
Targeted Oncology.2020; 15(4): 503. CrossRef
Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib
Chih-Hsi Scott Kuo, Chi-Hsien Huang, Chien-Ying Liu, Stelios Pavlidis, Ho-Wen Ko, Fu-Tsai Chung, Tin-Yu Lin, Chih-Liang Wang, Yi-Ke Guo, Cheng-Ta Yang
Targeted Oncology.2019; 14(4): 433. CrossRef

11,055 View
270 Download
6 Web of Science
4 Crossref

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors: Jiyoul Yang, Ok-Jun Lee, Seung-Myoung Son, Chang Gok Woo, Yusook Jeong, Yaewon Yang, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han; Cancer Res Treat. 2018;50(3):908-916. Published online September 19, 2017; DOI: https://doi.org/10.4143/crt.2017.378

Abstract PDF PubReader ePub

Purpose
Malignant pleural effusions (MPEs) are often observed in lung cancer, particularly adenocarcinoma. The aim of this study was to investigate epidermal growth factor receptor (EGFR) mutation status in lung adenocarcinoma-associated MPEs (LA-MPEs) and its correlation with efficacy of EGFR tyrosine kinase inhibitor (TKI) therapy.
Materials and Methods
Samples comprised 40 cell blocks of pathologically-confirmed LA-MPEs collected before the start of EGFR TKI therapy. EGFR mutation status was re-evaluated by peptide nucleic acid clamping and the clinical outcomes of EGFR TKI‒treated patients were analyzed retrospectively.
Results
EGFR mutations were detected in 72.5% of LA-MPE cell blocks (29/40). The median progression-free survival for patients with EGFR mutations in LA-MPEs was better than that for patients with wild-type EGFR (7.33 months vs. 2.07 months; hazard ratio, 0.486; 95% confidence interval, 0.206 to 1.144; p=0.032). The objective response rate (ORR) of 26 patients with EGFR mutations in LA-MPEs among the 36 patients with measurable lesions was 80.8%, while the ORR of the 10 patients with wild-type EGFR in LA-MPEs was 10% (p < 0.001). Among the 26 patients with EGFR mutations in LA-MPEs, the ORR of target lesions and LA-MPEs were 88.5% and 61.5%, respectively (p=0.026).
Conclusion
EGFR mutation status in cell blocks of LA-MPEs confirmed by pathologic diagnosis is highly predictive of EGFR TKI efficacy. For patients with EGFR mutations in LA-MPEs, the response to EGFR TKIs seems to be worse for pleural effusions than for solid tumors.

Citations

Citations to this article as recorded by

Pathobiology and clinical significance of malignant pleural effusions
Allison T Woods, Abner A Murray, Benjamin G Vincent, Jason Akulian, Chad V Pecot
EMBO Molecular Medicine.2026;[Epub] CrossRef
Cancer‐associated fibroblast‐derived colony‐stimulating factor 2 confers acquired osimertinib resistance in lung adenocarcinoma via promoting ribosome biosynthesis
Yutang Huang, Xiaoqing Wang, Chunjie Wen, Jingchan Wang, Honghao Zhou, Lanxiang Wu
MedComm.2024;[Epub] CrossRef
Effect of chemotherapy, immunotherapy, and targeted therapies on removal of indwelling pleural catheters in non-small cell lung cancer patients with malignant pleural effusions
Melissa Wang, Kaitlin Sparrow, Chrystal Chan, Ashley Gillson, Daniel Stollery, Pen Li
Respiratory Medicine.2023; 206: 107093. CrossRef
Malignant pleural effusion diagnosis and therapy
Liangliang Yang, Yue Wang
Open Life Sciences.2023;[Epub] CrossRef
Failure pattern and radiotherapy exploration in malignant pleural effusion non-small cell lung cancer treated with targeted therapy
Qingsong Li, Cheng Hu, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Huiqin Li, Bing Lu
Frontiers in Oncology.2023;[Epub] CrossRef
Impact of thoracic tumor radiotherapy on survival in non‐small‐cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study
Qingsong Li, Cheng Hu, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Haijie Jin, Huiqin Li, Bing Lu
Cancer Medicine.2023; 12(14): 14949. CrossRef
EGFR Mutation is a Prognostic Factor in Lung Cancer Patients with Pleural Dissemination Detected During or After Surgery
Toshiya Fujiwara, Kazuhiko Shien, Motoki Matsuura, Junichi Soh, Hiromasa Yamamoto, Soshi Takao, Yuho Maki, Tsuyoshi Ueno, Ryujiro Sugimoto, Ken Suzawa, Mikio Okazaki, Hiroyuki Tao, Makio Hayama, Masafumi Kataoka, Yoshifumi Sano, Hidetoshi Inokawa, Motohir
Annals of Surgical Oncology.2023; 30(11): 6697. CrossRef
Efficacy of hyperthermic intrathoracic chemotherapy for initially diagnosed lung cancer with symptomatic malignant pleural effusion
Zihui Li, Jie Deng, Fei Yan, Li Liu, Yanling Ma, Jianhai Sun
Scientific Reports.2023;[Epub] CrossRef
Establishment of prognostic nomograms for predicting the progression free survival of EGFR‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs
Xinyang Du, Hua Bai, Zhijie Wang, Jianchun Daun, Zheng Liu, Jiachen Xu, Geyun Chang, Yixiang Zhu, Jie Wang
Thoracic Cancer.2022; 13(9): 1289. CrossRef
Clinical features and prognosis according to genomic mutations in primary and metastatic lesions of non‐small‐cell lung cancer
Wei Zhang, Wenjuan Han, Bo Yu, Xin Zhao, Gaojun Lu, Wendy Wu, Yi Zhang
Thoracic Cancer.2022; 13(11): 1642. CrossRef
Management of Malignant Pleural Effusion: Where Are We Now?
Julien Guinde, Hervé Dutau, Philippe Astoul
Seminars in Respiratory and Critical Care Medicine.2022; 43(04): 559. CrossRef
Non-Small Cell Lung Cancer with Malignant Pleural Effusion May Require Primary Tumor Radiotherapy in Addition to Drug Treatment
Qingsong Li, Cheng Hu, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Huiqin Li, Bing Lu
Cancer Management and Research.2022; Volume 14: 3347. CrossRef
The impact of smoking status on the progression‐free survival of non‐small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta‐analysis
Xinyi Li, Cong Huang, Xiaohui Xie, Ziyang Wu, Xia Tian, Yibo Wu, Xin Du, Luwen Shi
Journal of Clinical Pharmacy and Therapeutics.2021; 46(2): 256. CrossRef
Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations
Audra J. Schwalk, David E. Ost, Sahara N. Saltijeral, Henriette De La Garza, Roberto F. Casal, Carlos A. Jimenez, Georgie A. Eapen, Jeff Lewis, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Jack Lee, Yasir Elamin, Jianjun Zhang, Jack A. Roth, Stephen S
Chest.2021; 159(3): 1256. CrossRef
Advances in pleural infection and malignancy
Eihab O. Bedawi, Julien Guinde, Najiib M. Rahman, Philippe Astoul
European Respiratory Review.2021; 30(159): 200002. CrossRef
Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions
Maria Alba Sorolla, Anabel Sorolla, Eva Parisi, Antonieta Salud, José M. Porcel
Cancers.2021; 13(11): 2798. CrossRef
Clinical Characteristics and Therapeutic Outcomes of Metastatic Peritoneal Carcinomatosis in Non-Small-Cell Lung Cancer
Tetsuo Tani, Ichiro Nakachi, Shinnosuke Ikemura, Shigenari Nukaga, Keiko Ohgino, Aoi Kuroda, Hideki Terai, Keita Masuzawa, Taro Shinozaki, Kota Ishioka, Yohei Funatsu, Hidefumi Koh, Koichi Fukunaga, Kenzo Soejima
Cancer Management and Research.2021; Volume 13: 7497. CrossRef
LENT Score: Predicting the Survival of Malignant Pleural Effusion – A Prospective Study of Three Years
Sara Raimundo, Ana Isabel Loureiro, Fortunato Vieira, Ana Fernandes
Archivos de Bronconeumología.2020; 56(7): 465. CrossRef
Current applications of molecular testing on body cavity fluids
Daniel Pinto, Fernando Schmitt
Diagnostic Cytopathology.2020; 48(9): 840. CrossRef
Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer
Jianqiang Li, Xingliang Li, Wenxian Wang, Yang Shao, Yiping Zhang, Zhengbo Song
Translational Oncology.2020; 13(8): 100784. CrossRef
Progression of malignant pleural effusion during the early stage of gefitinib treatment in advanced EGFR-mutant lung adenocarcinoma involving complex driver gene mutations
Ning Liu, Min Yu, Tao Yin, Yong Jiang, Xuelian Liao, Jie Tang, Yanying Li, Diyuan Qin, Dan Li, Yongsheng Wang
Signal Transduction and Targeted Therapy.2020;[Epub] CrossRef
LENT Score: Predicting the Survival of Malignant Pleural Effusion – A Prospective Study of Three Years
Sara Raimundo, Ana Isabel Loureiro, Fortunato Vieira, Ana Fernandes
Archivos de Bronconeumología (English Edition).2020; 56(7): 465. CrossRef
Recent Developments in the Management of Malignant Pleural Effusions: a Narrative Review
Clifford E. Coile, Jessie G. Harvey, Michal Senitko
Current Pulmonology Reports.2020; 9(4): 164. CrossRef
Detecting EGFR mutations and ALK/ROS1 rearrangements in non‐small cell lung cancer using malignant pleural effusion samples
Yi Yao, Min Peng, Qinglin Shen, Qinyong Hu, Hongyun Gong, Qingqing Li, Zhongliang Zheng, Bin Xu, Yingge Li, Yi Dong
Thoracic Cancer.2019; 10(2): 193. CrossRef
Making cold malignant pleural effusions hot: driving novel immunotherapies
Pranav Murthy, Chigozirim N. Ekeke, Kira L. Russell, Samuel C. Butler, Yue Wang, James D. Luketich, Adam C. Soloff, Rajeev Dhupar, Michael T. Lotze
OncoImmunology.2019; 8(4): e1554969. CrossRef
Novel insights into the systemic treatment of lung cancer malignant pleural effusion
Claire Tissot, Pierre Gay, Clément Brun, Marios E. Froudarakis
The Clinical Respiratory Journal.2019; 13(3): 131. CrossRef
Proceedings of the American Society of Cytopathology companion session at the 2019 United States and Canadian Academy of Pathology Annual meeting, part 2: effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma
Momin T. Siddiqui, Fernando Schmitt, Andrew Churg
Journal of the American Society of Cytopathology.2019; 8(6): 352. CrossRef

12,200 View
280 Download
36 Web of Science
27 Crossref

Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer: Jong Ho Cho, Wei Zhou, Yoon-La Choi, Jong-Mu Sun, Hyejoo Choi, Tae-Eun Kim, Marisa Dolled-Filhart, Kenneth Emancipator, Mary Anne Rutkowski, Jhingook Kim; Cancer Res Treat. 2018;50(1):95-102. Published online March 17, 2017; DOI: https://doi.org/10.4143/crt.2016.591

Abstract PDF PubReader ePub

Purpose
Data are limited on programmed death ligand 1 (PD-L1) expression in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC).
Materials and Methods
We retrospectively evaluated the relationship between PD-L1 expression and recurrence-free survival (RFS) and overall survival in 319 patients with EGFR-mutant NSCLC who were treated at Samsung Medical Center from 2006 to 2014. Membranous PD-L1 expression on tumor cells was measured using the PD-L1 IHC 22C3 pharmDx antibody and reported as tumor proportion score (TPS). Kaplan-Meier methods, log-rank test, and Cox proportional hazards models were used for survival analysis.
Results
All patients had ≥ 1 EGFR mutation—54% in exon 19 and 39% in exon 21. Overall, 51% of patients had PD-L1–positive tumors. The prevalence of PD-L1 positivity was higher among patients with stages II-IV versus stage I disease (64% vs. 44%) and among patients with other EGFR mutations (75%) than with L858R mutation (39%) or exon 19 deletion (52%). PD-L1 positivity was associated with shorter RFS, with an adjusted hazard ratio of 1.52 (95% confidence interval [CI], 0.81 to 2.84; median, 18 months) for the PD-L1 TPS ≥ 50% group, 1.51 (95% CI, 1.02 to 2.21; median, 31 months) for the PD-L1 TPS 1%-49% group, and 1.51 (95% CI, 1.05 to 2.18) for the combined PD-L1–positive groups (TPS ≥ 1%) compared with the PD-L1–negative group (median, 35 months).
Conclusion
PD-L1 expression is associated with disease stage and type of EGFR mutation. PD-L1 positivity might be associated with worse RFS among patients with surgically treated EGFR-mutant NSCLC.

Citations

Citations to this article as recorded by

Spatial Heterogeneity of PD‐L1 Expression as a Biomarker for Third‐Generation EGFR‐TKI Response in Advanced EGFR‐Mutant NSCLC
Yidan Zhang, Yingqi Xu, Hongping Jin, Tengfei Liu, Hua Zhong, Jianlin Xu, Yuqing Lou, Runbo Zhong
Cancer Science.2025; 116(6): 1648. CrossRef
The role of PD-L1 in EGFR-mutant non-small cell lung cancer
Wentao Gao, Lingling Wang, Yanyan Zhao, Lucheng Zhu
Discover Oncology.2025;[Epub] CrossRef
Visualizing pulmonary pathologies using smart molecular fluorescent probes
Zhijin Ruan, Lizhou Yue, Bin Liu, Eunji Kim, Xiaoqiang Chen, Jun Li, Hoyeon Jang, Zhiqiang Lin, Mingle Li, Xiaojun Peng, Jong Seung Kim
Coordination Chemistry Reviews.2025; 545: 217025. CrossRef
Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review
Yi Dong, Liaqat Khan, Yi Yao
Journal of the National Cancer Center.2024; 4(4): 289. CrossRef
Activatable near-infrared fluorescence probe for real-time imaging of PD-L1 expression in tumors
Hyunjin Kim, Maixian Liu, Chan Hyeok Park, Byung Il Lee, Hyonchol Jang, Yongdoo Choi
Journal of Materials Chemistry B.2024; 12(42): 10877. CrossRef
Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR‐mutant non‐small cell lung cancer
Si‐Yu Lei, Hai‐Yan Xu, Hong‐Shuai Li, Ya‐Ning Yang, Fei Xu, Jun‐Ling Li, Zhi‐Jie Wang, Pu‐Yuan Xing, Xue‐Zhi Hao, Yan Wang
Thoracic Cancer.2023; 14(24): 2327. CrossRef
Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR‐mutated NSCLC
Yusuke Hamakawa, Yoko Agemi, Aya Shiba, Toshiki Ikeda, Yuko Higashi, Masaharu Aga, Kazuhito Miyazaki, Yuri Taniguchi, Yuki Misumi, Yukiko Nakamura, Tsuneo Shimokawa, Yusuke Saigusa, Nobuaki Kobayashi, Hiroaki Okamoto, Takeshi Kaneko
Cancer Medicine.2023; 12(17): 17788. CrossRef
Determining Risk Factors Associated with Depression and Anxiety in Young Lung Cancer Patients: A Novel Optimization Algorithm
Yu-Wei Fang, Chieh-Yu Liu
Medicina.2021; 57(4): 340. CrossRef
Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
Edouard Dantoing, Nicolas Piton, Mathieu Salaün, Luc Thiberville, Florian Guisier
International Journal of Molecular Sciences.2021; 22(12): 6288. CrossRef
Programmed Death Ligand 1 Expression and Related Markers in Pleuropulmonary Blastoma
Zahra Alipour, Kris Ann P Schultz, Ling Chen, Anne K Harris, Ivan A Gonzalez, John Pfeifer, D Ashley Hill, Mai He, Louis P Dehner
Pediatric and Developmental Pathology.2021; 24(6): 523. CrossRef
The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC
Bo Lan, Yongfang Wang, Jingni Wu, Kai Wang, Pingli Wang
Medicine.2021; 100(34): e27038. CrossRef
The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay
Matthew Evans, Brendan O’Sullivan, Frances Hughes, Tina Mullis, Matthew Smith, Nicola Trim, Philippe Taniere
Pathology & Oncology Research.2020; 26(1): 79. CrossRef
PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer
Eriko Miyawaki, Haruyasu Murakami, Keita Mori, Nobuaki Mamesaya, Takahisa Kawamura, Haruki Kobayashi, Shota Omori, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Toshiaki Takahashi
Japanese Journal of Clinical Oncology.2020; 50(5): 617. CrossRef
Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma
Mai He, Brooj Abro, Madhurima Kaushal, Ling Chen, Tiffany Chen, Mercia Gondim, Weisi Yan, Julie Neidich, Louis P. Dehner, John D. Pfeifer
Human Pathology.2020; 100: 15. CrossRef
Clinicopathological characteristics of primary lung nuclear protein in testis carcinoma: A single‐institute experience of 10 cases
Yoon Ah Cho, Yoon‐La Choi, Inwoo Hwang, Kyungjong Lee, Jong Ho Cho, Joungho Han
Thoracic Cancer.2020; 11(11): 3205. CrossRef
Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma
Jang Ho Cho, Hyun Ae Jung, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jong-Mu Sun
Journal of Cancer Research and Clinical Oncology.2019; 145(5): 1341. CrossRef
The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer
Yang Zhang, Yuanyuan Zeng, Ting Liu, Wenwen Du, Jianjie Zhu, Zeyi Liu, Jian-an Huang
Respiratory Research.2019;[Epub] CrossRef
Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation
Lee, Kim, Sung, Lee, Han, Kim, Choi
International Journal of Molecular Sciences.2019; 20(19): 4794. CrossRef
Addictions oncogéniques et immunothérapie : quelle séquence?
L. Mhanna, J. Mazières
Revue des Maladies Respiratoires Actualités.2019; 11(4): S476. CrossRef
Clinical and Molecular Predictors of PD-L1 Expression in Non–Small-Cell Lung Cancer: Systematic Review and Meta-analysis
Fausto Petrelli, Mariangela Maltese, Gianluca Tomasello, Barbara Conti, Karen Borgonovo, Mary Cabiddu, Mara Ghilardi, Michele Ghidini, Rodolfo Passalacqua, Sandro Barni, Matteo Brighenti
Clinical Lung Cancer.2018; 19(4): 315. CrossRef
Status of programmed death-ligand 1 expression in sarcomas
Hyung Kyu Park, Mingi Kim, Minjung Sung, Seung Eun Lee, Yu Jin Kim, Yoon-La Choi
Journal of Translational Medicine.2018;[Epub] CrossRef
Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis
Bo Lan, Chengxi Ma, Chengyan Zhang, Shoujie Chai, Pingli Wang, Liren Ding, Kai Wang
Oncotarget.2018; 9(7): 7684. CrossRef
Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma
Byung Soo Lee, Dong Il Park, Da Hye Lee, Jeong Eun Lee, Min-kyung Yeo, Yeon Hee Park, Dae Sik Lim, Wonyoung Choi, Da Hye Lee, Geon Yoo, Han-byul Kim, Dahyun Kang, Jae Young Moon, Sung Soo Jung, Ju Ock Kim, Sang Yeon Cho, Hee Sun Park, Chaeuk Chung
Biochemical and Biophysical Research Communications.2017; 491(2): 493. CrossRef

14,841 View
661 Download
26 Web of Science
23 Crossref

Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study: Keunchil Park, Eun Kyung Cho, Maximino Bello, Myung-Ju Ahn, Sumitra Thongprasert, Eun-Kee Song, Victoria Soldatenkova, Henrik Depenbrock, Tarun Puri, Mauro Orlando; Cancer Res Treat. 2017;49(4):937-946. Published online January 6, 2017; DOI: https://doi.org/10.4143/crt.2016.423

Abstract PDF PubReader ePub

Purpose
The phase 3 randomized SQUIRE study revealed significantly longer overall survival (OS) and progression-free survival (PFS) for necitumumab plus gemcitabine and cisplatin (neci+GC) than for gemcitabine and cisplatin alone (GC) in 1,093 patients with previously untreated advanced squamous non-small cell lung cancer (NSCLC). This post hoc subgroup analysis assessed the efficacy and safety of neci+GC among East Asian (EA) patients enrolled in the study.
Materials and Methods
All patients received up to six 3-week cycles of gemcitabine (days 1 and 8, 1,250 mg/m²) and cisplatin (day 1, 75 mg/m²). Patients in the neci+GC arm also received necitumumab (days 1 and 8, 800 mg) until disease progression or unacceptable toxicity. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated from stratified Cox proportional hazards models.
Results
In EA patients, there were improvements for neci+GC (n=43) versus GC (n=41) in OS (HR, 0.805; 95% CI, 0.484 to 1.341) and PFS (HR, 0.720; 95% CI, 0.439 to 1.180), consistent with the results for non-EA patients observed in the present study. The overall safety data were consistent between EA and non-EA patients. A numerically higher proportion of patients experienced serious adverse events (AEs), grade ≥ 3 AEs, and AEs with an outcome of death for neci+GC versus GC in EA patients and EA patients versus non-EA patients for neci+GC.
Conclusion
Although limited by the small sample size and post hoc nature of the analysis, these findings are consistent with those of the overall study and suggest that neci+GC offers a survival advantage and favorable benefit/risk for EA patients with advanced squamous NSCLC.

Citations

Citations to this article as recorded by

Phytochemicals intended for anticancer effects at preclinical levels to clinical practice: Assessment of formulations at nanoscale for non-small cell lung cancer (NSCLC) therapy
The Hong Phong Nguyen, V. Bharath Kumar, Vinoth Kumar Ponnusamy, Thi Thu Thao Mai, Phuong Tran Nhat, Kathirvel Brindhadevi, Arivalagan Pugazhendhi
Process Biochemistry.2021; 104: 55. CrossRef
Effects of adding necitumumab to first-line chemotherapy in patients with stage IV non-small-cell lung cancer: Meta-analysis
Irena Ilic, Sandra Sipetic, Jovan Grujicic, Milena Ilic
Journal of Oncology Pharmacy Practice.2020; 26(6): 1331. CrossRef
Recent progress in systemic treatment for lung cancer
Jeffrey W. Clark, Dan L. Longo
Current Opinion in Pulmonary Medicine.2018; 24(4): 355. CrossRef
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies
Vincenzo di Noia, Ettore D’Argento, Sara Pilotto, Giulia Grizzi, Mario Caccese, Roberto Iacovelli, Giampaolo Tortora, Emilio Bria
Expert Opinion on Biological Therapy.2018; 18(9): 937. CrossRef
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting
Alastair Greystoke, Nicola Steele, Hendrik-Tobias Arkenau, Fiona Blackhall, Noor Md Haris, Colin R Lindsay, Raffaele Califano, Mark Voskoboynik, Yvonne Summers, Karen So, Dana Ghiorghiu, Angela W Dymond, Stuart Hossack, Ruth Plummer, Emma Dean
British Journal of Cancer.2017; 117(7): 938. CrossRef

12,738 View
408 Download
8 Web of Science
5 Crossref

Review Article

Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review: Li-Tzong Chen, Do-Youn Oh, Min-Hee Ryu, Kun-Huei Yeh, Winnie Yeo, Roberto Carlesi, Rebecca Cheng, Jongseok Kim, Mauro Orlando, Yoon-Koo Kang; Cancer Res Treat. 2017;49(4):851-868. Published online January 3, 2017; DOI: https://doi.org/10.4143/crt.2016.176

Abstract PDF Supplementary Material PubReader ePub

Despite advancements in therapy for advanced gastric and gastroesophageal junction cancers, their prognosis remains dismal. Tumor angiogenesis plays a key role in cancer growth and metastasis, and recent studies indicate that pharmacologic blockade of angiogenesis is a promising approach to therapy. In this systematic review, we summarize current literature on the clinical benefit of anti-angiogenic agents in advanced gastric cancer. We conducted a systematic search of PubMed and conference proceedings including the American Society of Clinical Oncology, the European Society for Medical Oncology, and the European Cancer Congress. Included studies aimed to prospectively evaluate the efficacy and safety of anti-angiogenic agents in advanced gastric or gastroesophageal junction cancer. Each trial investigated at least one of the following endpoints: overall survival, progression-free survival/time to progression, and/or objective response rate. Our search yielded 139 publications. Forty-two met the predefined inclusion criteria. Included studies reported outcomes with apatinib, axitinib, bevacizumab, orantinib, pazopanib, ramucirumab, regorafenib, sorafenib, sunitinib, telatinib, and vandetanib. Second-line therapy with ramucirumab and third-line therapy with apatinib are the only anti-angiogenic agents so far shown to significantly improve survival of patients with advanced gastric cancer. Overall, agents that specifically target the vascular endothelial growth factor ligand or receptor have better safety profile compared to multi-target tyrosine kinase inhibitors.

Citations

Citations to this article as recorded by

The Potential Impact of Renin–Angiotensin System Inhibitors on Cancer Survival and Recurrence: A Systemic Review and Meta-Analysis
Kaneez Fatima, Aayat Ellahi, Mariam Adil, Haider Kashif, Muhammad Uzair, Naela Ashraf, Mehak Barolia, Mujtaba Hyder, Areeba Nakhuda, Michelle Ayub, Sofia Jamil Butt, Ahmed Mustafa Rashid
Journal of Cardiovascular Pharmacology.2025; 85(1): 35. CrossRef
Deciphering the anticancer potential of thymoquinone: in-depth exploration of the potent flavonoid from Nigella sativa
Bunty Sharma, Himanshu Shekhar, Anidrisha Sahu, Shafiul Haque, Damandeep Kaur, Hardeep Singh Tuli, Ujjawal Sharma
Molecular Biology Reports.2025;[Epub] CrossRef
Human Epidermal Growth Factor Receptor 2 [HER‐2/neu] Amplification and Microsatellite Stable Status in Gastric and Gastroesophageal Adenocarcinoma: Assessing Frequency and Prognostic Implications at the Cancer Institute of Iran
Samaneh Salarvand, Abbas Mohammadi, Reza Shahsiah, Farzaneh Bagheri, Mahsa Gholizadeh, Somayeh Jolany‐Vangah, Ebrahim Esmati, Marzieh Lashkari, Vahid Soleymani, Seraj Zareh‐Dehabadi, Vahid Mehrtash, Amirmohsen Jalaeefar, Mohammad Shirkhoda, Moones Toosang
Cancer Reports.2025;[Epub] CrossRef
Modulation of the Tumour Microenvironment by HER2 in Oesophagogastric Adenocarcinoma: Implications for Tumour Progression, Therapeutic Resistance, and Clinicopathological Outcomes
Nicola B. Raftery, Mark Ward, Narayanasamy Ravi, John V. Reynolds, Jessie A. Elliott, Claire L. Donohoe
Cancers.2025; 17(24): 3987. CrossRef
Efficacy and Safety of Low-Dose Apatinib Combined with Chemotherapy as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis
Liang Wang, Juyuan Li, Huamin Chen
Chemotherapy.2024; 69(1): 11. CrossRef
Ononin: A comprehensive review of anticancer potential of natural isoflavone glycoside
Ujjawal Sharma, Bunty Sharma, Ambrish Mishra, Anidrisha Sahu, Darin M. Mathkor, Shafiul Haque, Deepika Raina, Seema Ramniwas, Madhu Gupta, Hardeep S. Tuli
Journal of Biochemical and Molecular Toxicology.2024;[Epub] CrossRef
Dihydroartemisinin inhibited vasculogenic mimicry in gastric cancer through the FGF2/FGFR1 signaling pathway
Huina Wang, Qingzhu Ding, Haihua zhou, Chuanjiang Huang, Guiyuan Liu, Xiaojun Zhao, Zhiyi Cheng, Xiaolan You
Phytomedicine.2024; 134: 155962. CrossRef
Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE)
Min‐Hee Ryu, Kyung Hee Lee, Lin Shen, Kun‐Huei Yeh, Changhoon Yoo, Young Seon Hong, Young Iee Park, Sung Hyun Yang, Dong Bok Shin, Dae Young Zang, Won Ki Kang, Ik‐Joo Chung, Yeul Hong Kim, Baek‐Yeol Ryoo, Byung‐Ho Nam, Young Soo Park, Yoon‐Koo Kang
Cancer Medicine.2023; 12(7): 7784. CrossRef
Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma
Naoya Kanogawa, Sadahisa Ogasawara, Susumu Maruta, Yotaro Iino, Masamichi Obu, Takamasa Ishino, Keita Ogawa, Sae Yumita, Terunao Iwanaga, Hidemi Unozawa, Miyuki Nakagawa, Kisako Fujiwara, Takafumi Sakuma, Naoto Fujita, Ryuta Kojima, Hiroaki Kanzaki, Keisu
BMC Gastroenterology.2023;[Epub] CrossRef
Imidazopyridine-based kinase inhibitors as potential anticancer agents: A review
Fariba Peytam, Zahra Emamgholipour, Alireza Mousavi, Mahfam Moradi, Roham Foroumadi, Loghman Firoozpour, Fatemeh Divsalar, Maliheh Safavi, Alireza Foroumadi
Bioorganic Chemistry.2023; 140: 106831. CrossRef
Pazopanib with 5‐FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase‐II study—The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO‐STO‐0510
Anica Högner, Salah‐Eddin Al‐Batran, Jens T. Siveke, Mario Lorenz, Prisca Bartels, Kirstin Breithaupt, Peter Malfertheiner, Nils Homann, Alexander Stein, Dietrich Gläser, Ingo Tamm, Axel Hinke, Arndt Vogel, Peter Thuss‐Patience
International Journal of Cancer.2022; 150(6): 1007. CrossRef
Diagnostic value of combined prealbumin-to-fibrinogen and albumin-to-fibrinogen ratios in Hp-negative gastric cancer
Linyan Zhang, Simeng Qin, Liuyi Lu, Li Huang, Shan Li
The International Journal of Biological Markers.2022; 37(1): 66. CrossRef
Tumor vessel normalization and immunotherapy in gastric cancer
Xianzhe Yu, Shan He, Jian Shen, Qiushi Huang, Peng Yang, Lin Huang, Dan Pu, Li Wang, Lu Li, Jinghua Liu, Zelong Liu, Lingling Zhu
Therapeutic Advances in Medical Oncology.2022;[Epub] CrossRef
Pull the plug: Anti‐angiogenesis potential of natural products in gastrointestinal cancer therapy
Yanling Ai, Ziyi Zhao, Hengyi Wang, Xiaomei Zhang, Weihan Qin, Yanlei Guo, Maoyuan Zhao, Jianyuan Tang, Xiao Ma, Jinhao Zeng
Phytotherapy Research.2022; 36(9): 3371. CrossRef
Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity
Ying Fu, Rengui Saxu, Kadir Ahmad Ridwan, Cai Zhao, Xiangshun Kong, Yao Rong, Weida Zheng, Peng Yu, Yuou Teng
RSC Advances.2022; 12(34): 21821. CrossRef
Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling
Hardeep Singh Tuli, Ajay Kumar, Seema Ramniwas, Renuka Coudhary, Diwakar Aggarwal, Manoj Kumar, Ujjawal Sharma, Nidarshana Chaturvedi Parashar, Shafiul Haque, Katrin Sak
Molecules.2022; 27(21): 7653. CrossRef
Upregulation of Linc-ROR Promotes the Proliferation, Migration, and Invasion of Gastric Cancer Cells Through miR-212-3p/FGF7 Axis
Yanjun Mi, Yongwen Li, Zhuo He, Donghan Chen, Qingqi Hong, Jun You
Cancer Management and Research.2021; Volume 13: 899. CrossRef
Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway
Shucheng Chen, Lan Yao
Cancer Chemotherapy and Pharmacology.2021; 88(2): 323. CrossRef
Combined detection of peripheral blood VEGF and inflammation biomarkers to evaluate the clinical response and prognostic prediction of non-operative ESCC
Yuanyuan Ma, Xinyu Su, Xin Li, Xiaohui Zhi, Kan Jiang, Jianhong Xia, Hongliang Li, Chen Yan, Liqing Zhou
Scientific Reports.2021;[Epub] CrossRef
Tenascin-c knockdown suppresses vasculogenic mimicry of gastric cancer by inhibiting ERK- triggered EMT
Xing Kang, En Xu, Xingzhou Wang, Lulu Qian, Zhi Yang, Heng Yu, Chao Wang, Chuanfu Ren, Yizhou Wang, Xiaofeng Lu, Xuefeng Xia, Wenxian Guan, Tong Qiao
Cell Death & Disease.2021;[Epub] CrossRef
A novel role for apatinib in enhancing radiosensitivity in non-small cell lung cancer cells by suppressing the AKT and ERK pathways
Lin Li, Yuexian Li, Huawei Zou
PeerJ.2021; 9: e12356. CrossRef
Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
Masatoshi Kudo, Takuji Okusaka, Kenta Motomura, Izumi Ohno, Manabu Morimoto, Satoru Seo, Yoshiyuki Wada, Shinpei Sato, Tatsuya Yamashita, Masayuki Furukawa, Takeshi Aramaki, Seijin Nadano, Kazuyoshi Ohkawa, Hirofumi Fujii, Toshihiro Kudo, Junji Furuse, Hi
Journal of Gastroenterology.2020; 55(6): 627. CrossRef
The Correlation between EGFR and Androgen Receptor Pathways: A Novel Potential Prognostic Marker in Gastric Cancer
Shahrzad S. Fard, Kioomars Saliminejad, Masoud Sotoudeh, Niloofar Soleimanifard, Shaghayegh Kouchaki, Mansour Yazdanbod, Habibollah Mahmoodzadeh, Ardeshir Ghavamzadeh, Reza Malekzadeh, Bahram Chahardouli, Kamran Alimoghaddam, Seyed H. Ghaffari
Anti-Cancer Agents in Medicinal Chemistry.2020; 19(17): 2097. CrossRef
Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis
Alessandro Rizzo, Veronica Mollica, Angela Dalia Ricci, Ilaria Maggio, Maria Massucci, Fabiola Lorena Rojas Limpe, Francesca Di Fabio, Andrea Ardizzoni
Future Oncology.2020; 16(2): 4409. CrossRef
S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma
Chu Zhang, Guang-Mao Yu, Miao Zhang, Dong Liu
Medicine.2020; 99(1): e18691. CrossRef
An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)
Xiang Wang, Ruixing Zhang, Nan Du, Mudan Yang, Aimin Zang, Likun Liu, Junyan Yu, Jinghua Gao, Junping Zhang, Zhanzhao Fu, Yuchuan Ren, Liwen Ma, Jun Guo, Qingshan Li, Xiaomei Li, Zaiwen Fan, Xiang Song, Zheng Liu, Yan Zhang, Guozhong Li, Zhonghe Yu, Jianf
Therapeutic Advances in Medical Oncology.2020;[Epub] CrossRef
The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis
Jia-Yong Liu, Bao-Rang Zhu, Yu-Dong Wang, Xin Sun
International Journal of Clinical Oncology.2020; 25(6): 1195. CrossRef
Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced esophageal squamous cell carcinoma
Guohui Liu, Yanbo Wang, Chunbo Wang, Yunlong He, Mingyan E
Expert Review of Clinical Pharmacology.2020; 13(12): 1423. CrossRef
Effective Treatment of Cytotoxic Agent Refractory Alpha-Fetoprotein-Producing Gastric Cancer with Ramucirumab: a Case Report and Review of the Literature
Jun Takada, Hiroshi Araki, Noritaka Ozawa, Tomohiko Sugiyama, Masaya Kubota, Takashi Ibuka, Masahito Shimizu
Journal of Gastrointestinal Cancer.2019; 50(3): 556. CrossRef
Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response
Vineet Govinda Gupta, Ranga Rao Rangaraju, Rajat Saha, Peush Bajpai
Journal of Gastrointestinal Cancer.2019; 50(4): 943. CrossRef
Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies
Letizia Procaccio, Vera Damuzzo, Francesca Di Sarra, Alberto Russi, Federica Todino, Vincenzo Dadduzio, Francesca Bergamo, Alessandra Anna Prete, Sara Lonardi, Hans Prenen, Angelo Claudio Palozzo, Fotios Loupakis
Drug Safety.2019; 42(2): 159. CrossRef
VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer
Lian Lian, Xiang-Li Li, Meng-Dan Xu, Xian-Min Li, Meng-Yao Wu, Yan Zhang, Min Tao, Wei Li, Xiao-Ming Shen, Chong Zhou, Min Jiang
BMC Cancer.2019;[Epub] CrossRef
STUDY OF VEGF-A AND TGF-Β LEVELS IN BIOPTATES OF SQUAMOUS CELL CARCINOMA OF THE TONGUE AND MOUTH FLOOR MUCOSA IN POLYCHEMOTHERAPY WITH MONOCLONAL ANTIBODIES – CETUXIMAB
O. I. Kit, E. M. Frantsiyants, I. V. Neskubina, L. Yu. Vladimirova, A. A. Lyanova, Yu. A. Pogorelova, E. V. Shalashnaya, M. A. Еngibaryan, Yu. S. Sidorenko
Research and Practical Medicine Journal.2019; 6(3): 20. CrossRef
Tumor progression-dependent angiogenesis in gastric cancer and its potential application
Hsi-Lung Hsieh, Ming-Ming Tsai
World Journal of Gastrointestinal Oncology.2019; 11(9): 686. CrossRef
Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours
Guohui Liu, Chunbo Wang, Yunlong He, Mingyan E
BMC Pharmacology and Toxicology.2019;[Epub] CrossRef
N-methyl-N-nitro-N-nitrosoguanidine-mediated ING4 downregulation contributed to the angiogenesis of transformed human gastric epithelial cells
Yansu Chen, Rui Fu, Mengdie Xu, Yefei Huang, Guixiang Sun, Lichun Xu
Life Sciences.2018; 199: 179. CrossRef
GSE1 predicts poor survival outcome in gastric cancer patients by SLC7A5 enhancement of tumor growth and metastasis
Keshuo Ding, Sheng Tan, Xing Huang, Xiaonan Wang, Xiaocan Li, Rong Fan, Yong Zhu, Peter E. Lobie, Wenbin Wang, Zhengsheng Wu
Journal of Biological Chemistry.2018; 293(11): 3949. CrossRef
Nanoparticles designed to regulate tumor microenvironment for cancer therapy
Min Li, Fangrong Zhang, Yujie Su, Jianping Zhou, Wei Wang
Life Sciences.2018; 201: 37. CrossRef
Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
Xiaodong Wang, Yu Liu, Yuwen Diao, Ningning Gao, Yanyan Wan, Jingjing Zhong, Huali Zheng, Zhulin Wang, Guangyi Jin
Journal of Translational Medicine.2018;[Epub] CrossRef
ASO Author Reflections: Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Gastric Cancer
In-Hwan Kim
Annals of Surgical Oncology.2018; 25(S3): 749. CrossRef
Identification of Bone Metastasis-associated Genes of Gastric Cancer by Genome-wide Transcriptional Profiling
Mingzhe Lin, Xin Li, Haizhou Guo, Faxiang Ji, Linhan Ye, Xuemei Ma, Wen Cheng
Current Bioinformatics.2018; 14(1): 62. CrossRef
Antiangiogenic effects of oridonin
Lili Tian, Kangjie Xie, Donglai Sheng, Xiaoqing Wan, Guofu Zhu
BMC Complementary and Alternative Medicine.2017;[Epub] CrossRef
The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer
Dimakatso Alice Senthebane, Arielle Rowe, Nicholas Ekow Thomford, Hendrina Shipanga, Daniella Munro, Mohammad A. M. Al Mazeedi, Hashim A. M. Almazyadi, Karlien Kallmeyer, Collet Dandara, Michael S. Pepper, M. Iqbal Parker, Kevin Dzobo
International Journal of Molecular Sciences.2017; 18(7): 1586. CrossRef
Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study
Yong Zhang, Chun Han, Juan Li, Li Zhang, Lijie Wang, Sisi Ye, Yi Hu, Li Bai
Scientific Reports.2017;[Epub] CrossRef
Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer
Henrik Nienhüser, Thomas Schmidt
International Journal of Molecular Sciences.2017; 19(1): 43. CrossRef

19,829 View
928 Download
50 Web of Science
45 Crossref

Original Article

A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors: Ji-Youn Han, Ki Hyeong Lee, Sang-We Kim, Young Joo Min, Eunkyung Cho, Youngjoo Lee, Soo-Hyun Lee, Hyae Young Kim, Geon Kook Lee, Byung Ho Nam, Hyesun Han, Jina Jung, Jin Soo Lee; Cancer Res Treat. 2017;49(1):10-19. Published online May 3, 2016; DOI: https://doi.org/10.4143/crt.2016.058

Abstract PDF Supplementary Material PubReader ePub

Purpose
We examined the efficacy of poziotinib, a second-generation epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) in patients with lung adenocarcinoma with activating EGFR mutations, who developed acquired resistance (AR) to EGFR-TKIs.
Materials and Methods
This single-arm phase II study included EGFR-mutant lung adenocarcinoma with AR to erlotinib or gefitinib based on the Jackman criteria. Patients received poziotinib 16 mg orally once daily in a 28-day cycle. The primary endpoint was progression-free survival (PFS). Prestudy tumor biopsies and blood samples were obtained to determine resistance mechanisms.
Results
Thirty-nine patients were treated. Tumor genotyping was determined in 37 patients; 19 EGFR T790M mutations and two PIK3CAmutations were detected in the prestudy tumors, and seven T790M mutations were detected in the plasma assay. Three (8%; 95% confidence interval [CI], 2 to 21) and 17 (44%; 95% CI, 28 to 60) patients had partial response and stable disease, respectively. The median PFS and overall survival were 2.7 months (95% CI, 1.8 to 3.7) and 15.0 months (95% CI, 9.5 to not estimable), respectively. A longer PFS was observed for patients without T790M or PIK3CA mutations in tumor or plasma compared to those with these mutations (5.5 months vs. 1.8 months, p=0.003). The most frequent grade 3 adverse events were rash (59%), mucosal inflammation (26%), and stomatitis (18%). Most patients required one (n=15) or two (n=15) dose reductions.
Conclusion
Low activity of poziotinib was detected in patients with EGFR-mutant non-small cell lung cancer who developed AR to gefitinib or erlotinib, potentially because of severe-toxicityimposed dose limitation.

Citations

Citations to this article as recorded by

Repeat biopsy versus initial biopsy in terms of complication risk factors and clinical outcomes for patients with non-small cell lung cancer: a comparative study of 113 CT-guided needle biopsy of lung lesions
Yangyang Wang, Yongyuan Zhang, Nana Ren, Fangting Li, Lin Lu, Xin Zhao, Zhigang Zhou, Mengyu Gao, Meng Wang
Frontiers in Oncology.2024;[Epub] CrossRef
EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis
Isabella Michelon, Maysa Vilbert, Caio Ernesto do Rego Castro, Carlos Stecca, Maria Inez Dacoregio, Manglio Rizzo, Vladmir Cláudio Cordeiro de Lima, Ludimila Cavalcante
Journal of Personalized Medicine.2024; 14(7): 752. CrossRef
3D bioprinted vascularized lung cancer organoid models with underlying disease capable of more precise drug evaluation
Yoo-mi Choi, Haram Lee, Minjun Ann, Minyeong Song, Jinguen Rheey, Jinah Jang
Biofabrication.2023; 15(3): 034104. CrossRef
Association of Hypokalemia Incidence and Better Treatment Response in NSCLC Patients: A Meta-Analysis and Systematic Review on Anti-EGFR Targeted Therapy Clinical Trials
Jiawei Zhou, Jianling Bai, Yuanping Yue, Xin Chen, Theis Lange, Dongfang You, Yang Zhao
Frontiers in Oncology.2022;[Epub] CrossRef
Anlotinib plus chemotherapy for T790M‐negative EGFR‐mutant non‐sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial
Juan Li, Yuke Tian, Min Zheng, Jun Ge, Jiliang Zhang, Dejun Kong, Mei Chen, Ping Yu
Thoracic Cancer.2022; 13(24): 3496. CrossRef
Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers
Vidhi Malik, Vipul Kumar, Sunil C. Kaul, Renu Wadhwa, Durai Sundar
Biomolecules.2021; 11(2): 160. CrossRef
Validation of a multicellular tumor microenvironment system for modeling patient tumor biology and drug response
Devin G. Roller, Stephen A. Hoang, Kristopher D. Rawls, Katherine A. Owen, Michael B. Simmers, Robert A. Figler, Julia D. Wulfkuhle, Emanuel F. Petricoin, Brian R. Wamhoff, Daniel Gioeli
Scientific Reports.2021;[Epub] CrossRef
Epidermal growth factor receptor inhibitor-induced diarrhea: clinical incidence, toxicological mechanism, and management
Gabriel Tao, Pavan Kumar Chityala
Toxicology Research.2021; 10(3): 476. CrossRef
Geriatric Nutritional Risk Index as a Prognostic Factor for Mortality in Elderly Patients with Moderate to Severe Traumatic Brain Injuries
Wei-Ti Su, Ching-Hua Tsai, Chun-Ying Huang, Sheng-En Chou, Chi Li, Shiun-Yuan Hsu, Ching-Hua Hsieh
Risk Management and Healthcare Policy.2021; Volume 14: 2465. CrossRef
Geriatric nutritional risk index in screening malnutrition among young adult and elderly trauma patients
Yueh-Wei Liu, Ching-Hua Tsai, Sheng-En Chou, Wei-Ti Su, Chi Li, Shiun-Yuan Hsu, Ching-Hua Hsieh
Formosan Journal of Surgery.2021; 54(5): 183. CrossRef
In silico studies on p21-activated kinase 4 inhibitors: comprehensive application of 3D-QSAR analysis, molecular docking, molecular dynamics simulations, and MM-GBSA calculation
Yinli Gao, Hanxun Wang, Jian Wang, Maosheng Cheng
Journal of Biomolecular Structure and Dynamics.2020; 38(14): 4119. CrossRef
Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
Iosune Baraibar, Laura Mezquita, Ignacio Gil-Bazo, David Planchard
Critical Reviews in Oncology/Hematology.2020; 148: 102906. CrossRef
Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy
Afshin Derakhshani, Zohreh Rezaei, Hossein Safarpour, Morteza Sabri, Atefeh Mir, Mohammad Amin Sanati, Fatemeh Vahidian, Ali Gholamiyan Moghadam, Ali Aghadoukht, Khalil Hajiasgharzadeh, Behzad Baradaran
Journal of Cellular Physiology.2020; 235(4): 3142. CrossRef
Toward a More Precise Future for Oncology
Yonina R. Murciano-Goroff, Barry S. Taylor, David M. Hyman, Alison M. Schram
Cancer Cell.2020; 37(4): 431. CrossRef
Nanocarrier centered therapeutic approaches: Recent developments with insight towards the future in the management of lung cancer
Jigar D. Vanza, Rashmin B. Patel, Mrunali R. Patel
Journal of Drug Delivery Science and Technology.2020; 60: 102070. CrossRef
Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
Yongchao Zhang, Zhuo-Xun Wu, Yuqi Yang, Jing-Quan Wang, Jun Li, Zoey Sun, Qiu-Xu Teng, Charles R. Ashby, Dong-Hua Yang
Cancers.2020; 12(11): 3249. CrossRef
Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib
Nishan Tchekmedyian, Bill Paxton, Francois Lebel, Lena Keossayan, John V. Heymach
JTO Clinical and Research Reports.2020; 1(4): 100081. CrossRef
Geriatric Nutritional Risk Index as a Screening Tool to Identify Patients with Malnutrition at a High Risk of In-Hospital Mortality among Elderly Patients with Femoral Fractures—A Retrospective Study in a Level I Trauma Center
Wei-Ti Su, Shao-Chun Wu, Chun-Ying Huang, Sheng-En Chou, Ching-Hua Tsai, Chi Li, Shiun-Yuan Hsu, Ching-Hua Hsieh
International Journal of Environmental Research and Public Health.2020; 17(23): 8920. CrossRef
Geriatric Nutritional Risk Index as a Tool to Evaluate Impact of Malnutrition Risk on Mortality in Adult Patients with Polytrauma
Cheng-Hsi Yeh, Shao-Chun Wu, Sheng-En Chou, Wei-Ti Su, Ching-Hua Tsai, Chi Li, Shiun-Yuan Hsu, Ching-Hua Hsieh
International Journal of Environmental Research and Public Health.2020; 17(24): 9233. CrossRef
Association between Geriatric Nutritional Risk Index and Mortality in Older Trauma Patients in the Intensive Care Unit
Hang-Tsung Liu, Shao-Chun Wu, Ching-Hua Tsai, Chi Li, Sheng-En Chou, Wei-Ti Su, Shiun-Yuan Hsu, Ching-Hua Hsieh
Nutrients.2020; 12(12): 3861. CrossRef
Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology
Rashmi R. Shah, Devron R. Shah
Drug Safety.2019; 42(2): 181. CrossRef
Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
Wei Jiang, Meiju Ji
Seminars in Cancer Biology.2019; 59: 3. CrossRef
Clinical Impact of Rare and Compound Mutations of Epidermal Growth Factor Receptor in Patients With Non–Small-Cell Lung Cancer
Juliane Martin, Annika Lehmann, Frederick Klauschen, Michael Hummel, Dido Lenze, Christian Grohé, Antje Tessmer, Joachim Gottschalk, Berndt Schmidt, Hans-Wilhelm Pau, Christian Witt, Stefan Moegling, Robert Kromminga, Korinna Jöhrens
Clinical Lung Cancer.2019; 20(5): 350. CrossRef
Metastasiertes Lungenkarzinom – therapierbare molekulare Alterationen
W. M. Brückl, J. H. Ficker
Der Pneumologe.2019; 16(6): 343. CrossRef
Successful Treatment of a Miliary Metastatic NSCLC Patient With Activating EGFR Exon 20 Insertion Mutation with Response to Poziotinib
Juyin Yang, Jian Yang, Shao Ban, Xinmin Li, Xingde Chen, Jihua Yang, Jun Qian
Journal of Thoracic Oncology.2019; 14(9): e198. CrossRef
Targeting Epidermal Growth Factor Receptor in Non-Small-Cell-Lung Cancer: Current State and Future Perspective
Shui-Ming Bao, Qing-Hui Hu, Wen-Ting Yang, Yao Wang, Yin-Ping Tong, Wen-Dai Bao
Anti-Cancer Agents in Medicinal Chemistry.2019; 19(8): 984. CrossRef
Maximum allele frequency observed in plasma: A potential indicator of liquid biopsy sensitivity
Yong Tang, Xianling Liu, Zhu'an Ou, Zhe He, Qihang Zhu, Ye Wang, Mei Yang, Junyi Ye, Han Han‑Zhang, Guibin Qiao
Oncology Letters.2019;[Epub] CrossRef
TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
Hibiki Udagawa, Shinichi Hasako, Akihiro Ohashi, Rumi Fujioka, Yumi Hakozaki, Mikiko Shibuya, Naomi Abe, Toshiharu Komori, Tomonori Haruma, Miki Terasaka, Ryoto Fujita, Akihiro Hashimoto, Kaoru Funabashi, Hiroyuki Yasuda, Kazutaka Miyadera, Koichi Goto, D
Molecular Cancer Research.2019; 17(11): 2233. CrossRef
Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor
Chengying Xie, Xiaozhe Wan, Haitian Quan, Mingyue Zheng, Li Fu, Yun Li, Liguang Lou
Cancer Science.2018; 109(4): 1207. CrossRef
Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
Jacqulyne P. Robichaux, Yasir Y. Elamin, Zhi Tan, Brett W. Carter, Shuxing Zhang, Shengwu Liu, Shuai Li, Ting Chen, Alissa Poteete, Adriana Estrada-Bernal, Anh T. Le, Anna Truini, Monique B. Nilsson, Huiying Sun, Emily Roarty, Sarah B. Goldberg, Julie R.
Nature Medicine.2018; 24(5): 638. CrossRef
Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma
In-Jae Oh, Jae Young Hur, Cheol-Kyu Park, Young-Chul Kim, Seung Joon Kim, Min Ki Lee, Hee Joung Kim, Kye Young Lee, Jae Cheol Lee, Chang-Min Choi
Clinical Lung Cancer.2018; 19(5): e775. CrossRef
Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors
Yanmei Peng, Qiang Li, Jingyi Zhang, Wen Shen, Xu Zhang, Chenyao Sun, Huijuan Cui
BioScience Trends.2018; 12(6): 537. CrossRef
EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa
Clinical Cancer Research.2018; 24(24): 6548. CrossRef
EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs
Zhiyong Liang, Ying Cheng, Yuan Chen, Yanping Hu, Wei-Ping Liu, You Lu, Jie Wang, Ye Wang, Gang Wu, Jian-Ming Ying, He-Long Zhang, Xu-Chao Zhang, Yi-Long Wu
Cancer Letters.2017; 403: 186. CrossRef
Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer
Xuefei Li, Caicun Zhou
Oncotarget.2017; 8(59): 100801. CrossRef

16,458 View
568 Download
37 Web of Science
35 Crossref

First
Prev
Page of 3
Next
Last

Search